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Systemic inflammation is thought to be an important driver in chronic 
neurodegeneration. During systemic infection, the inflammatory status of the 
periphery is communicated to the brain and conserved sickness behaviours initiated. 
However, in the context of dementia the same inflammatory stimulus might trigger 
delirium. 
Delirium is a severe, transient neuropsychiatric condition characterised by altered 
levels of arousal, inattention, cognitive deficits and psychoses. Delirium and systemic 
inflammation exacerbate the trajectory of pre-existing dementia, and are associated 
with increased risk of future dementia.  
Accumulating experimental studies suggest microglia are “primed” by chronic 
neurodegeneration, such that a subsequent inflammatory insult – central or systemic 
– induces an increased inflammatory response which manifests as exaggerated 
sickness behaviours. To date there have been no studies of microglial priming in the 
context of pure tau pathology, without amyloid pathology, and none investigating 
acute sickness behaviour in such a model. The overarching aim of this thesis is to 
address this gap in the literature and further our understanding of the interactions 
between systemic inflammation, neuroinflammation and neurodegeneration in the 
context of tauopathy. 
The P301S mouse over-expresses human mutant tau protein under the Thy1.2 
promoter. It develops hyperphosphorylated and insoluble tau accumulations and 
progressive neuronal loss. Consequently, P301S mice develop progressive hind limb 
paralysis. This study identified the horizontal bar task, a test of motor control and 
coordination, conducted at weekly intervals from 8-22 weeks of age, as a non-invasive 
measure of disease progression. In addition, a detailed temporal profile of 
pathological hallmarks at 8, 9, 10, 11, 12, 16 and 20 weeks of age was determined. Key 
results presented here demonstrate progressive, superficial neuronal loss in the 
cortex of P301S mice, with associated astrogliosis and surprisingly this occurs in the 
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absence of apparent cortical microgliosis. In stark contrast, there is progressive 
microgliosis in the spinal cord of P301S mice.  
On this background, lipopolysaccharide (LPS), a chemical moiety found on the outer 
surface of gram-negative bacteria, was used to mimic a systemic bacterial infection. 
P301S mice and C57BL/6 control mice were injected, at 10 or 16 weeks of age, 
intraperitoneally with 500 µg/kg LPS or saline and were monitored in the following 
hours and weeks.  
Acutely, P301S mice showed signs of an exaggerated, longer lasting sickness 
response. Importantly, exaggerated acute symptoms extended beyond those typically 
associated with sickness behaviour; LPS induced an exaggerated acute impairment 
of horizontal bar performance in P301S mice and not C57BL/6 mice –  a function 
which is known to be impaired in P301S mice later in disease. Impairments were age-
dependent in terms of timing of injection. These data suggest an interaction between 
acute infection and existing CNS vulnerability leading to acute neurological 
dysfunction that is not a feature observed in sickness in a normal animal. LPS-injected 
P301S mice also showed, again age-dependent, increased rate of decline in motor 
performance compared with controls.  
There was no evidence of microglial priming in P301S mice. LPS caused an acute 
increase in AT8-positive phospho-tau however this did not persist until end stage. At 
22 weeks of age there was significant disease-associated cortical neuronal loss in the 
vehicle-injected P301S mice, and additional superficial cortical neuronal loss in LPS-
injected P301S mice and control mice. There was significant IBA1-positive 
microgliosis in the spinal cord of P301S mice at end stage which was further increased 
in LPS-injected P301S mice. 
Taken together these data indicate a clear and clinically relevant interaction between 
systemic inflammation and tau-associated neuropathology with acute and long-
term functional consequences. In the absence of evidence of microglial priming, 




You will recognise from personal experience that common symptoms of illness or 
infection include feeling antisocial, lethargic, and feverish. This is because when you 
get an infection, it is detected by immune cells, which are like soldiers patrolling the 
body looking for foreign invaders, and these “soldiers” send chemical and electrical 
signals to the brain which tell it about the infection. The brain then initiates the 
“sickness behaviours”, including those described above. These behaviours have 
evolved over time to aid our recovery and reduce the risk of further spread of the 
infection.  
However, when somebody who has dementia suffers from a similar infection they 
might experience delirium. Delirium is a disturbed state of mind where the sufferer 
may feel confused and unable to focus their attention; they might hallucinate and 
often fluctuate between being hyperactive and unresponsive. Delirium usually only 
lasts a matter of days but it can be very distressing and it can have long-term impacts 
on the brain; it can make the dementia worse, and increase the rate of cognitive 
decline of dementia patients. 
How does this happen? It is thought that, in someone with dementia, when the 
chemical and electrical signals reach the brain, it over-reacts. The predominant theory 
in the field is that the immune “soldier” cells stationed in the brain – called 
“microglia” – which are normally very tightly controlled, can detect that something 
is awry in a brain with dementia and become “primed”. This might be akin to turning 
off their weapons’ safety catches, so that when they later receive the signals from the 
patrolling cells that there is an infection in the body, they over-react with negative 
consequences. This over-reaction is thought to underpin delirium and might also 
cause permanent damage leading to the observed long-term impacts. 
This work aimed to test this theory using genetically modified mice with dementia-
like features and injecting them with a compound which mimics a bacterial infection.  
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A genetic mutation that caused dementia in humans was identified in the gene that 
encodes a protein called “tau” and this faulty gene was turned on in the nerve cells 
of mice to create “mutant-tau” mice. As these genetically modified mice age the faulty 
tau protein accumulates in “tangles” in the nerve cells. The nerve cells in the brain 
and spinal cord are then no longer able to function properly and eventually those 
nerve cells die. Some of them are important for controlling movement and 
coordination so as those nerve cells die the mice develop movement problems. 
This thesis demonstrated that a behavioural task, the horizontal bar task, that 
measures muscle control and coordination in mice, can be used as a non-invasive way 
to measure disease severity. Secondly, this thesis determined a detailed time course 
for nerve cell death in the brains of mutant-tau mice and investigated markers of 
inflammation in the brain and spinal cord.  
When the mice were still young, before they developed symptoms, they were injected 
with a chemical compound called lipopolysaccharide (LPS) which is recognised by 
the patrolling immune cells as a bacterial infection. These experiments demonstrated, 
for the first time, that in the hours following injection with LPS, mutant-tau mice were 
much sicker than normal mice and in the longer-term, mutant-tau mice that received 
LPS showed an increased rate of decline compared with those that were injected with 
a control solution. These experiments mimic the situation in dementia patients 
following an infection.  
Importantly, when the brain and spinal cord were studied there were no signs of 
“primed” microglia. Therefore, future work will explore potential mechanisms to 
explain how infection increases the rate of decline of dementia.  
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1 Chapter 1: Introduction 
1.1 Introduction Part 1: Dementia and Tauopathies 
1.1.1 Dementia 
 Dementia definition 
Dementia, is now referred to in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM)-5 as Major Neurocognitive Disorder and is diagnosed based on 
“Evidence of significant cognitive decline from a previous level of performance in one or more 
cognitive domains” which include learning and memory, language, executive function, 
complex attention, perceptual-motor and social cognition. In order to meet the 
diagnostic criteria the cognitive deficits must cause impairment in personal, social or 
occupational functioning, impact on independence in everyday activities, cannot be 
better explained by another mental disorder (e.g., major depressive disorder, 
schizophrenia) and must not occur exclusively in the context of delirium 
(American_Psychiatric_Association).  
Dementia is the clinical manifestation of neuronal damage and dysfunction hence 
symptoms include memory loss, emotional or mood changes and problems with 
communication and reasoning. Dementia is also often associated with impaired 
motor function. Together these deficits often make it impossible for sufferers to live 
independently, especially as the disease progresses (Buchman et al., 2011). 
 Dementia prevalence and cost 
In 2015 Dementia and Alzheimer’s disease replaced ischaemic heart disease as the 
leading cause of death registered in England and Wales, accounting for 11.6% of all 
deaths registered in 2015 according to the Office for National Statistics (ONS, 2016). 
Dementia accounted for 21.2% of deaths in 2015 among women aged 80 and over and 
13.7% of deaths in males of this age group (ONS, 2016). There are currently 
approximately 850,000 people living with dementia in the UK today and with the 
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rapidly expanding and ageing population that figure is predicted to reach 1 million 
by 2025 and over 2 million by 2050 (ARUK – Defeat Dementia Policy Report 2014).  
The cost to society in the UK was £26 billion per year, according to a 2014 report by 
Alzheimer’s Society, this includes social care (£10bn) and healthcare (£4bn). An 
estimated 670,000 people in the UK act as primary carers for people with dementia 
saving the state £11bn a year, but often have to leave work in order to care full-time; 
by 2030 the estimated cost to business is £3bn per year (ARUK – Defeat Dementia 
Policy Report 2014).  
Government funding for dementia research was approximately £66m in the year 
2014/2015 and in February 2015 then-Prime Minister David Cameron published The 
Prime Minister’s Challenge on Dementia 2020 which pledged to double research 
funding by 2025 (2015).  
The Prime Minister’s Challenge on Dementia states “it is estimated that if there was 
a disease-modifying treatment from 2020 that delayed the onset of Alzheimer’s 
disease by five years, by 2035 there would be 425,000 fewer people with dementia, 
with accumulated savings from 2020 of around £100 billion.”, there is a powerful 
argument for the economic benefit of even just delaying the onset of dementia by a few 
years, since there would be fewer dementia sufferers to treat, fewer sufferers in care 
homes or hospitals, fewer carers forced to leave work and vastly improved quality of 
life for would-be patients and carers. 
Dementia is a collective term describing a legion of diseases including Alzheimer’s 
disease (AD, 62%), vascular dementia (17%), and Frontotemporal Dementia (FTD, 
2%), Parkinson’s Disease (PD, 2%), Dementia with Lewy Bodies and Motor Neuron 
Disease to name a few. Dementia is a clinical syndrome caused by multiple 
pathologies which often overlap and interact; the heterogeneous clinical 
presentations are the result of variation in underlying disease pathology; which 
neuronal and/or glial populations are impacted and how. For example, AD is 
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associated with accumulation of amyloid-β (Aβ) protein deposits and tau protein in 
the form of neurofibrillary tangles (discussed below), and significant loss of 
cholinergic and glutamatergic neurons, and resulting early episodic memory 
impairments and later semantic memory impairments (Grand et al., 2011). Whereas 
frontotemporal dementia describes a variety of non-Alzheimer’s clinical syndromes, 
with behavioural, personality, language and sometimes motor 
disturbances associated with accumulation of tau protein, and degeneration of 
anterior hemispheres (Grand et al., 2011). Vascular dementia (VaD), on the other hand 
results from the effects of cerebrovascular disease. Multi-infarct dementia (post-
stroke dementia) occurs when multiple infarcts are caused by occlusion of large 
vessels e.g. by atherosclerotic thrombosis or cardiac embolization. Patients present 
with severe deficits in specific domains while other domains remain intact (Grand et 
al., 2011). Dementia is usually progressive, however with such distinct aetiologies 
there is marked heterogeneity in the speed of decline; occlusion of blood vessels in 
VaD causes a sudden decline, compared with the gradual decline of AD. 
Although distinct neurodegenerative diseases are characterised by accumulation of 
specific proteins, in actual fact it is more complicated. Mis-accumulation of proteins 
associated with neurodegeneration does not necessitate disease; plaques and tangles 
have been observed in non-demented cases at autopsy (Price et al., 1999, Bennett et 
al., 2006) and there is often overlap between pathologies among diseases. Aggregated 
proteins including Aβ, tau, TDP-43 and α-synuclein can interact with each other, 
causing mis-localisation, dysregulation of post-translational modifications and cross-
seeding of aggregates of other protein species. In a study of pathological cohorts at 
different ages Aβ deposits were found in 80% of all autopsy cases over 80 years of age 
and tau deposits were found in almost 100% of cases in the same age group (Spires-
Jones et al., 2017). 
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 Drug Treatments 
Drug treatment for dementia is currently limited to symptomatic treatment with 
acetylcholinesterase (AChE) inhibitors, including rivastigmine, donepezil and 
galantamine (Allgaier et al., 2013) and treatment of behavioural and psychological 
symptoms of dementia (BPSD) with antipsychotics and other agents (Zdanys et al., 
2016). Acetylcholine is a neurotransmitter in the CNS. Positron emission tomography 
(PET) studies indicate that increasing cortical acetylcholinesterase inhibition in AD 
correlates with an increase in cognitive rescue (Bohnen et al., 2005). Cholinergic 
dysfunction is a consequence rather than a cause of neurodegeneration however 
AChE blockers aim to rebalance cholinergic neurotransmission by prolonging the 
action of ACh at the synaptic cleft. Memantine is the only approved AD drug which 
targets the glutamatergic system instead. The glutamatergic system is affected by the 
impaired glutamate uptake by glial cells which results in elevated background 
glutamatergic “noise”. Memantine, an N-methyl-D-aspartate (NMDA) receptor 
antagonist is a fast, voltage dependent blocker (Francis et al., 2012). Currently 
available treatments are often ineffective and are not disease-modifying. 
 Dementias as proteinopathies 
Diagnoses of specific dementias are made based on clinical presentation; cognitive 
and motor tests have been designed to scrutinise the CNS regions affected by disease. 
However, it is not until post mortem that diagnoses can be confirmed. 
Insoluble protein deposits are consistent hallmarks of neurodegenerative conditions. 
Alois Alzheimer observed senile plaques, now known as amyloid-β (Aβ) plaques, 
aggregates composed of misfolded amyloid protein and neurofibrillary tangles 
(NFTs), aggregates composed of filamentous hyperphosphorylated tau protein in a 
patient with early onset Alzheimer’s disease over a century ago. Since then several 
additional mis-folded proteins have been identified in neurodegeneration (Table 1). 
some of which are implicated in multiple diseases, for example tau protein, which 
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will be discussed in more detail later. These proteins have proved useful indicators 
of the pathways implicated in disease aetiology. 
Discovery of mutations in hundreds of the genes encoding these pivotal proteins as 
well as the enzymes involved in their processing have continued to focus research 
attention towards this aspect of pathology and have enabled the development of 






Amyloid β (Aβ) • Alzheimer’s disease (AD)  
• Dementia with Lewy bodies 
Tau • AD,  
• Fronto-temporal dementia with parkinsonism 
(FTDP),  
• Progressive supranuclear palsy (PSP),  
• Corticobasal degeneration (CBD),  
Huntingtin • Huntington’s disease 
α-synuclein • Parkinson’s disease,  
• Multiple systems atrophy,   
• Dementia with Lewy bodies 
Prion protein (PrP) • Transmissible spongiform telencephalopathies 
Super-oxide 
dismutase (SOD1) 
• Familial Amyotrophic lateral sclerosis (fALS) 
TAR DNA binding 
protein 43 (TDP-43) 
• FTD 
• ALS 
Ubiquitin 2 • FTD 
• ALS 
Table 1 – Proteins commonly accumulated in neurodegenerative diseases  
1.1.2 Tau Protein and its Role in Dementia 
Tau protein is the main component of neurofibrillary tangles (NFTs) (Grundke-Iqbal 
et al., 1986) which are the defining feature of a myriad of neurodegenerative diseases 
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including Alzheimer’s disease and inherited frontotemporal dementias (Spillantini et 
al., 2013) (discussed further in section 1.1.4). 
Discovery of mutations in tau protein which are responsible for inherited tauopathies 
indicate that tau dysfunction is sufficient to cause dementia on its own (Clark et al., 
1998, Hutton et al., 1998, Poorkaj et al., 1998, Spillantini et al., 1998) however the 
mechanisms leading from mutation to neurodegeneration are not clearly defined.  
The following section will first introduce tau protein and its normal role in the healthy 
brain before discussing the role of tau protein in neurodegeneration, animal models 
of tauopathy and finally it will introduce the P301S tau mouse model used in my 
thesis. 
1.1.3 Tau Protein 
Tau is a microtubule-associated protein (MAP) which consists of an N-terminal 
projection domain and a C-terminal microtubule binding domain. In humans, there 
are 6 different isoforms of tau all encoded by one gene (MAPT) (Neve et al., 1986, 
Goedert et al., 1989a). Tau is 55–74 kDa in size (depending on splice variant and 
phosphorylation status). Multiple isoforms arise from a single gene via alternative 
splicing (see Figure 1) and they differ from each other by inclusion or not of exons 2 
(orange) and 3 (green) in the N-terminal half and exon 10 (dark yellow) at the C-
terminus. Exon 10 contains a Pro-Gly-Gly-Gly microtubule binding motif. Tau 
lacking this insert contains three microtubule binding motifs (yellow) and is referred 
to as three-repeat (3R) tau, and tau including this insert is referred to as 4R tau. The 
inclusion of this microtubule binding domain influences the microtubule binding 
affinity. Splicing of tau is developmentally regulated, only 3R tau is found in foetal 
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brain whereas adult brain contains a 1:1 ratio of 3R and 4R tau (Goedert et al., 1990). 
4R tau promotes microtubule assembly 2.5- to 3-fold faster than 3R tau.  
 Role of Tau protein in healthy CNS 
Tau binds reversibly to the microtubules of the cytoskeleton in order to stabilise them. 
Microtubules are a key component of the cytoskeleton – they are long hollow fibres 
made up of tubular subunits which can be added and removed dynamically to allow 
the cytoskeleton to grow and collapse in response to its environment (Lodish et al., 
2000).  
The cytoskeleton is important in all cells for cell division, maintaining cell structure, 
enabling cell migration and transport of nutrients and waste around the cell, hence 
the proper function of the cytoskeleton is important for cell survival (Fletcher et al., 
2010). The successful regulation of cytoskeletal stability by tau and other MAPs is 
even more critical in neurons than other cell types due to their specialised 
morphology and function.  
Tau binding is dynamic and its binding affinity is largely dependent on post-
translational modifications, including, importantly its phosphorylation state 
(Drechsel et al., 1992, Biernat et al., 1993). Hence it is subject to second messengers, 








Exon 3 MT binding motif of Exon 10 
MT binding motif 
Figure 1 – Tau Isoforms: Alternative splicing generates 6 isoforms of tau with or without Exons 2, 3, and 10. 
Exon 10 contains an additional microtubule binding domain hence alternative splicing influences MT-binding 
affinity. Isoforms excluding this domain are referred to as 3-repeat or 3R tau and isoforms including this domain 
are referred to as 4R tau. 
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protein kinases such as mitogen activated protein kinases (MAPKs), glycogen 
synthase kinase 3 (GSK3), cyclin dependent kinase 5 (CDK5) and phosphatases 
(phosphatase proteins 1, 2A and 2B). Tau protein is hyperphosphorylated during 
mitosis (Kanemaru et al., 1992, Brion et al., 1993, Pope et al., 1994, Illenberger et al., 
1998) and during hibernation (Zhou et al., 2001, Arendt et al., 2003) where it is 
associated with neuronal plasticity. It is important to recognise that tau 
hyperphosphorylation is not necessarily pathological but is a normal feature of tau 
regulation. 
1.1.4 Tau protein is implicated in Dementia  
Neuronal death and dysfunction underpin all dementias. Alzheimer’s disease is 
characterised by accumulation of amyloid-β protein into Aβ-plaques and 
hyperphosphorylated tau into NFTs. Multiple mutations have been identified in the 
Aβ processing pathway and although Aβ is thought to be the main initiator of AD 
(Hardy et al., 2002) , the extent of misfolded tau protein correlates more closely with 
neuronal loss and cognitive dysfunction (Arriagada, 1992, Bancher et al., 1993, Bierer 
et al., 1995, Gomez-Isla et al., 1997, Giannakopoulos et al., 2003, Guillozet et al., 2003, 
Ingelsson et al., 2004). NFTs are a consistent hallmark of AD and tau protein is 
recurrently implicated in sporadic neurodegenerative conditions.  
Tau pathology is not exclusively found in association with amyloid pathology. 
Dementias where tau is implicated as the main cause are known as tauopathies. 
Importantly several inherited tau mutations have been discovered which 
demonstrate that tau mutations are sufficient to cause dementia.  Rare genetic forms 
of tauopathy dementia share pathology with the more common sporadic forms of 
disease and have been pivotal in our understanding of the pathology of dementias. 
 Frontotemporal dementia 
Frontotemporal dementia (FTD) is the second most common dementia affecting 
people in middle age,  after AD and accounts for almost 20% of presenile dementias 
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(Snowden et al., 2002). Symptoms of FTD include social behavioural changes such as 
a lack of empathy, disinhibition, agitation and loss of social etiquette, as the disease 
progresses symptoms including cognitive decline, memory loss and in some cases 
motor symptoms develop. FTD is classified into different neuropathologic subtypes 
based on the predominance of: tau pathology, i.e., FTLD-tau; TDP43 pathology, i.e., 
FTLD-TDP; or other accumulated proteins including fused-in-sarcoma (FUS) protein, 
i.e., FTLD-FUS. FTLD-tau encompasses corticobasal degeneration (CBD), progressive 
supranuclear palsy (PSP), Pick’s disease (PiD) and argyrophilic grain disease (AGD). 
These diseases are all characterised by the accumulation of pathological tau protein 
in neurons, astrocytes and oligodendrocytes.  
 Disease associated tau mutations 
At the time of writing this thesis more than 100 tau mutations have been sequenced 
in 150 families worldwide (http://www.alzforum.org/mutations/). Mutations in the 
MAPT gene encoding tau protein account for approximately 5% of cases of FTD and 
tau protein is implicated in sporadic FTD.  
 Pathological Tau hyperphosphorylation 
Tau protein is normally unfolded, soluble and monomeric, however, in tauopathies 
it becomes hyperphosphorylated and forms insoluble filaments. There are seventy-
nine serine (Ser) or threonine (Thr) phosphorylation sites on the longest tau isoform 
in the brain. In the normal healthy brain for every mole of tau there is approximately 
1.9 moles of phosphate, however in AD the ratio shifts to 1 mole of tau to 6-8 moles 
of phosphate (Ksiezak-Reding et al., 1992). Abnormal hyperphosphorylation of tau 
results in both loss of normal function of tau and gain of toxic function of tau. 
As previously discussed (section 1.1.3.1) phosphorylation, and even 
hyperphosphorylation of tau protein can occur in the normal, healthy brain. In the 
diseased brain, however there is excessive hyperphosphorylation which renders tau 
unable to bind to microtubules.  
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Tau phosphorylation status depends on the relative activity of protein kinases and 
phosphatases, many of which have been implicated in neurodegenerative diseases. 
Most of the kinases involved in tau phosphorylation are proline-directed protein 
kinases (PDPKs). In vitro studies have suggested a potential role of several PDPKs in 
phosphorylation of tau in tauopathies, including MAPK (Drewes et al., 1992, Vulliet 
et al., 1992), GSK3 (Hanger et al., 1992, Zheng-Fischhöfer et al., 1998), cyclin-
dependent kinases cdc2 (which  was physically associated with paired helical 
filaments (PHF) from Alzheimer's disease brains), CDK5 (Baumann et al., 1993, Liu et 
al., 1995) and activated protein kinases ERK6 and SAPK4,  p38, p38β and JNK1 
(Goedert et al., 1997, Reynolds et al., 1997, Kumagae et al., 1999).  
Outside of the PDPK family, other protein kinases capable of phosphorylating tau 
include microtubule-affinity regulating kinase (MARK) (Drewes et al., 1997), 
Ca2+/calmodulin-dependent protein kinase II (CaMK II) (Baudier et al., 1987), cyclic-
AMP-dependent kinase (PKA) (Johnson, 1992)  and casein kinase II (Greenwood et 
al., 1994). 
The increased hyperphosphorylation of tau might also be the result of a shift in 
activity of phosphatases such as phosphatase proteins 2A and 2B (PP2A and PP2B) 
whose activity is decreased in AD  (Gong et al., 1995, Ladner et al., 1996). 
 Tau aggregation in disease 
While tau hyperphosphorylation may occur in the native developing brain as well as 
the pathological brain, aggregation of tau into filaments and then tangles does not 
occur during development. This suggests that further post-translational 
modifications are required for aggregation. These modifications may include further 
hyperphosphorylation at pathology-specific sites, glycosylation (Sasaki et al., 1998) 
ubiquitination (Mori et al., 1987) and truncation.  
Monomeric tau usually exists in a random coil conformation under normal 
physiological conditions. Tau may form dimers, trimers and small soluble oligomers 
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(Sahara et al., 2007). Granular tau oligomers (GTOs) are densely packed soluble tau 
polymers which have been isolated from AD brains and are composed of 
approximately 40 monomers of tau (Maeda et al., 2007). 
Healthy monomeric tau does not form filaments, hence a “prion-like” seeding event 
is required. Aggregation is concentration-dependent hence aberrant tau expression 
might be a sufficient trigger. Post-translational modifications including truncation 
and phosphorylation might also be sufficient to cause conformational changes 
required to seed aggregation.  
Tau can form different types of filaments depending on the isoforms recruited and 
these different tau filaments are associated with different tauopathies. Paired-helical 
filaments (PHFs) are twisted ribbons of 10–20 nm width, with aperiodicity of ~80 nm, 
associated with AD; all six tau isoforms are present in PHFs in the brains of patients 
with AD (Goedert et al., 1992) whereas in CBD and PSP tau tends to form straight 
filaments (SFs), 15-nm-wide filaments that lack periodicity and are composed of 4R 
tau only (Ksiezak-Reding et al., 1994, Delacourte et al., 1996). In Pick’s disease tau 
forms filamentous, non-fibrillar aggregates called Pick’s bodies which are 
approximately the size of the nucleus and are composed of disorganised bundles of 
3R tau filaments (Goedert, 1998). Argyrophilic grains of AGD are much smaller and 
are composed of bundles of 4R tau-containing SFs and smooth tubules. (Braak et al., 
1989). Tau filaments may also exist as twisted ribbons or rope-like filaments. PHFs 
and SFs form large fibres which bundle together into ‘flame-shaped’ neurofibrillary 
tangles (NFTs) in cell bodies, neuropil threads within neuronal processes, and 
neuritic plaques which are associated with dystrophic neurites (Buée et al., 2000). 
As well as being comprised from different isoforms, tau pathology is found in 
neurons and glial cells in different ratios depending on the disease (Kahlson et al., 
2015). Tau forms coiled cytoplasmic bodies in oligodendrocytes prominent in PSP, 
CBD, PiD and in fibrous and protoplasmic astrocytes in PiD (Kahlson et al., 2015). 
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The degree of tau pathology correlates with cognitive decline, however it remains 
unclear which is the toxic tau species – soluble tau, monomeric, small oligomeric, 
insoluble or fibrillary tau and whether tau toxicity is due to loss of function or gain of 
toxic function.   
 Tau Spread 
Once it has begun, tau aggregation is an energetically favourable, self-propagating 
process, with a “prion-like” recruitment of tau into pathological tau filaments. 
Hyperphosphorylated, truncated or mutated tau is recruited more rapidly than 
endogenous tau. Interestingly 3R tau can recruit 4R tau but 4R tau cannot recruit 3R 
tau (Dinkel et al., 2011); this might be an important consideration when designing 
animal models since the rodent brain contains only 4R tau.  
In AD tau pathology tends to spread according to the Braak progressive stages of tau 
pathology which range from I to VI (Braak et al., 2006):  
 “Stage I: Lesions develop in the transentorhinal region (locus coeruleus, 
magnocellular nuclei of the basal forebrain)...  
Stage II: Lesions extend into the entorhinal region…  
Stage III: Lesions extend into the neocortex of the fusiform and lingual gyri…  
Stage IV: The disease process progresses more widely into neocortical 
association areas…  
Stage V: The neocortical pathology extends fanlike in frontal, superolateral, 
and occipital directions, and reaches the peristriate region…  
Stage VI: The pathology reaches the secondary and primary neocortical areas 
and, in the occipital lobe, extends into the striate area…” 
22 
 
There have been several in vivo studies indicating a trans-synaptic spread of tau 
pathology through the brain. Stereotaxic injection of brain homogenate from mice 
over-expressing human mutant P301S pathological tau into mice expressing human 
wild-type tau induced recruitment of wild-type tau into filaments and propagation 
of tau pathology to neighbouring brain regions (Clavaguera et al., 2009). Multiple 
studies in transgenic mice over-expressing human mutant tau restricted to the 
entorhinal cortex (EC) showed progression of tau pathology from transgene-
expressing neurons of the EC to neighbouring cells, and then to synaptically 
connected neurons in the dentate gyrus, and CA1 of the hippocampus (de Calignon 
et al., 2012, Harris et al., 2012, Liu et al., 2012b). In vitro experiments have shown the 
release of intracellular tau into the medium and uptake by recipient cells thus 
demonstrating trans-synaptic spread of tau protein from cell to cell (Frost et al., 2009, 
Kfoury et al., 2012)  tau filaments were then able to induce fibrillization in naïve cells 
(Kfoury et al., 2012) offering a mechanism for the spread of tau pathology to distal 
but synaptically-connected regions. 
1.1.5 Rodent models of tauopathy 
The discovery of rare inherited mutations in tau protein capable of causing dementia 
has enabled the development of animal models to investigate the mechanisms of tau 
driven neurodegeneration. These are summarised in Table 2 and discussed below. 
The idiosyncrasies of specific models are dependent on the background strain of the 
animal model, the promoter used to drive tau expression, the isoform of tau 
expressed and the mutation introduced, if any.  Despite these variables several rodent 
models have been generated with robust and overlapping characteristics which 
recapitulate key hallmarks of tauopathies including hyperphosphorylation of tau and 
accumulation into filaments and NFTs, associated gliosis and upregulation of 
inflammatory markers, synaptic changes, neuronal loss and associated phenotypes 
include cognitive and motor changes (Table 2). 
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Transgene expression varies considerably between models, from 1 to 13-fold 
endogenous tau levels, dependent on the promoter, the copy number and location of 
integration (Table 2). 
Unlike humans, adult mice express only 3 isoforms of tau, all of which include 4 
microtubule repeats (4R tau) rather than the 6 isoforms (3R or 4R) expressed in the 
human brain. Over-expression of normal human wild-type tau can cause pathological 
tau changes (Ishihara et al., 1999, Spittaels et al., 1999, Probst et al., 2000, Andorfer et 
al., 2003) hence care must be taken when interpreting mechanistic data from 
transgenic mice since some tau pathology might be attributed to over-expression per 
se or a shift in isoform ratio rather than human dementia relevant tau pathology.  
Mice expressing a transgene for all 6 isoforms of human tau under the mouse tau 
promoter on top of the endogenous mouse tau (8c mice) showed no signs of tau 
pathology (Duff et al., 2000) (Table 2). However when the same mice were crossed 
with tau knock-out mice to produce hTau mice, expressing exclusively human tau, 
these mice demonstrated pathological tau phosphorylation and accumulation which 
authors attribute to a shift in tau isoforms (Andorfer et al., 2003). In line with this, 
rodents expressing only 3R isoforms of tau or pathological truncated tau found in AD 
both developed pathological tau filaments with associated hind limb paralysis 
(Ishihara et al., 1999, Zilka et al., 2006, Zilka et al., 2009). 
Tau mouse models often display a progressive motor phenotype (11 of the 26 lines 
described in Table 2); when lifted by the tail mutant tau mice clasp their hind limbs 
rather than splay them out and they show impaired performance on the rotarod task 
– a test of motor coordination where mice are placed on a rotating rod (with constant 
or increasing speed depending on the protocol) and time taken to fall from the rod is 
recorded (see Table 2 for multiple references). This progressive hind limb phenotype 
might reflect cell specific vulnerability of motor neurons of the spinal cord to tau 
pathology; different cell types express different isoforms of tau (Goedert et al., 1989b) 
which might influence the recruitment of endogenous tau into NFTs or perhaps the 
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long axonal projections of motor neurons make them more susceptible to disruption 
of microtubule stability. Alternatively, it might reflect cell specificity of the promoter 
driving transgene expression. 
In order to circumvent the problems associated with hind-limb deficits, researchers 
have developed models with region specific and inducible promoters (Table 2 – 
Column 1). Transgenic mice expressing the full length R406W mutant tau under the 
CaMK-II promoter showed very little human tau expression in the spinal cord and 
had no apparent motor deficits (Tatebayashi et al., 2002). However, another model 
expressing the P301L mutant tau under the same promoter still displayed the clasping 
reflex and weight loss typical of mutant tau mice (Ramsden et al., 2005) hence the 
phenotype cannot be attributed to the promoter driven expression alone. 
Because AD is the most common type of dementia, animal models which recapitulate 
AD-associated tau pathology are desirable and hence models have been engineered 
with promoters which drive predominantly hippocampal and cortical expression of 
tau. These models often display spatial impairments in the Morris water maze or 
radial arm maze which can be attributed to hippocampal pathology (Ramsden et al., 
2005, Murakami et al., 2006, Rosenmann et al., 2008, Flunkert et al., 2013). 
There has been a great deal of discussion about the pathological substrates of 
behavioural deficits seen in animal models of tauopathy. The rTg4510 mouse model 
over-expresses P301L mouse tau under the CaMK-II promoter and develops 
progressive tau pathology associated with forebrain atrophy, hippocampal neuronal 
loss, spatial working memory deficits in the Morris water maze, as well as the 
phenotypic weight loss and hind limb paralysis typical of mutant tau lines (Ramsden 
et al., 2005). Studies in these mice indicated that different lines expressed different 
dosage of mutant tau and the rate at which mice developed neurofibrillary pathology 
was directly related to the amount of tauP301L expression. Suppression of tau 
transgene rescued spatial memory and neuron numbers but NFTs continued to 
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accumulate indicating that NFTs are not sufficient to cause cognitive decline or 
neuronal death (SantaCruz et al., 2005). 
Yoshiyama et al. (2007 – Table 2) showed that the PS19 mouse line (over-expressing 
human P301S tau under the mouse prion promoter at 5-fold greater levels than 
endogenous mouse tau) had median survival of around 9 months. Tau was 
hyperphosphorylated and formed insoluble, randomly oriented tau filaments in the 
neocortex, amygdala, hippocampus, brain stem and spinal cord. There were early 
defects in axonal transport in PS19 mice which resulted in axonal degeneration. 
Microtubule destabilisation, impaired axonal trafficking, and axonal degeneration are 
associated with the decreased binding affinity of tau protein and are recurrent 
features of animal models (Table 2) (Ishihara et al., 1999, Spittaels et al., 1999, 
Tatebayashi et al., 2002, Zhang et al., 2004, de Calignon et al., 2012, Gilley et al., 2012). 
Tau mutations destabilise microtubules and affect axonal transport (Cuchillo-Ibanez 
et al., 2008, Dixit et al., 2008, Morfini et al., 2009) and it is thought that the disturbance 
in axonal transport impairs essential trafficking to the distal parts of the cell resulting 
in ‘dying back’ (whereby synaptic regions gradually degenerate toward the intact cell 
body). 
Yoshiyama et al. (2007) also demonstrated early synaptic loss and reduced synaptic 
function which preceded NFT formation, these are recurrent hallmarks of dementias 
(Table 2) (Terry et al., 1991, Selkoe, 2002, Ingelsson et al., 2004). The literature on the 
role of tau protein in synaptic deficits is contradictory (Kopeikina et al., 2013). The 
predominant view is that tau results in regional synaptic loss in vulnerable cells 
however overall synaptic density is preserved, which is likely due to compensatory 
increases in synaptic density in other neuronal populations (Kopeikina et al., 2013) 
and several of the models in Table 2 indicate this regional synaptic loss or dysfunction 
(David et al., 2005, Murakami et al., 2006, Schindowski et al., 2006, Rosenmann et al., 
2008, Hoover et al., 2010, Alldred et al., 2012, de Calignon et al., 2012, Koss et al., 2016). 
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Tau pathology in PS19 mice also correlates regionally and temporally with 
microgliosis and astrogliosis in PS19 mice (Yoshiyama et al., 2007). Astrogliosis and 
microgliosis are recurrent hallmarks of tauopathy dementias and are also associated 
with tau pathology in animal models expressing human mutant tau protein. These 
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1.1.6 Other models of tauopathies 
Other models of inherited human tauopathy include Caenorhabditis elegans and 
Drosophila melanogaster. In a C. elegans model expressing P301L and V337M tau there 
was hyperphosphorylation and accumulation of insoluble tau, a presynaptic defect 
in cholinergic neurotransmission and neurodegeneration (Kraemer et al., 2003).  
Overexpression of wild-type human tau (0N3R) in Drosophila led to impaired axonal 
transport but not cell death. Transport impairments were visualised by vesicle 
aggregation and loss of locomotor function. These impairments were rescued by co-
expression of constitutively active glycogen-synthase kinase-3β (GSK-3β) and the 
rescue reversed by GSK-3β inhibitors indicating a role of tau phosphorylation in 
impaired transport (Mudher et al., 2004). 
In vitro studies using cell lines expressing AD truncated tau (AT tau, 151-391 4R) or 
full length tau (Tau 40) showed that overexpression of either tau reduced metabolic 
activity of the cells indicative of slowing of cell proliferation. AT tau was more toxic, 
and cell death appeared to occur via apoptosis; there was cell shrinkage, nuclear, and 
DNA fragmentation. However, there was no activation of executive caspases 
involved in the initiation of apoptosis or the caspase cleavage products (PARP and 
fodrin) (Zilkova et al., 2011).  
Contrary to these findings, it has even been suggested by some that tau 
hyperphosphorylation might in fact be neuroprotective; the surprising lack of 
evidence tying tau hyperphosphorylation to apoptosis has led some to postulate that 
tau hyperphosphorylation causes abortion of apoptosis. Tau-expressing cell lines 
exposed to different types of pro-apoptotic factors, including staurosporine, 
camptothecin, hydrogen peroxide, ER stress, Aβ, death associated protein kinase-1, 
and GSK-3β, unexpectedly showed reduced apoptosis compared with controls (Li et 
al., 2007, Wang et al., 2010b, Liu et al., 2012a). Authors of an interesting review (Wang 
et al., 2014) postulate that tau hyperphosphorylation prevents apoptosis by substrate 
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competition, preventing Bcl-2 phosphorylation and thus preventing the release of 
cytochrome-c from mitochondria into the cytosolic fraction, while also inhibiting Bax 
expression and caspase-9/3 activity. Instead they postulate that the mechanism of cell-
death in neurodegeneration does not occur via apoptosis or any alternative 
previously described pathway but is in fact a distinct type of cell death which they 
call “neurodegenerasis”. 
1.1.7 The P301S Tau Family 
It was originally thought that CBD and FTD were two distinct entities based on the 
clinical presentation and gross pathology; FTD patients suffer emotional, behavioural 
and intellectual decline before developing motor symptoms, whereas CBD patients 
present with dystonic limb, progressing to rigidity but retain cognitive faculties until 
later in disease. 
However, the P301S mutation was encoded in 1999 in a father and son who suffered 
FTD and CBD respectively therefore demonstrating that this tau mutation is sufficient 
to trigger neurodegeneration and dementia (Bugiani et al., 1999), while also 
demonstrating that CBD and FTD are distinct clinical phenotypes of a single disease. 
The father and son were both in their late twenties when they began to experience 
symptoms which included depressive mood changes, memory loss, personality 
changes, and both experienced motor deficits and rigidity (Bugiani et al., 1999).  
The mutation was sufficient to induce hyperphosphorylation of tau; antibodies 
against AT8, AT100 and AT180 labelled most neurons in the cortex as well as axons 
and dispersed grains and threads. Cells contained abundant filamentous structures, 
which appeared to be straight filaments, width ~10 nm, sometimes forming filament 
bundles. Tau pathology was associated with gliosis often including tufted astrocytes. 
Tau pathology was sufficient to cause nerve cell loss, vacuolation and gliosis in the 
cortex, caudate nuclei, substantia-nigra and locus coerulus. 
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DNA sequence analysis identified a C-to-T transition in the first base of codon 301 of 
the tau gene resulting in a proline-to-serine mutation in tau. 
1.1.8 The history of the P301S Tau Mouse 
The P301S mouse over-expresses human mutant P301S tau under neuronal promoter 
Thy 1.2 on a C57BL/6J background. P301S homozygous mice were generated in the 
Goedert laboratory as previously described (Allen et al., 2002). Briefly, the P301S 
mutation was introduced by site directed mutagenesis to cDNA encoding the shortest 
of the 4R tau isoforms (4R0). The mutant tau cDNA was cloned into a genomic 
expression vector containing the thy1.2 promoter sequence prior to pronuclear 
injection. Founders were generated and cross breeding generated a line with 
expression of human mutant tau at twice the levels of endogenous tau.  
The original paper on the P301S mouse sought to demonstrate that this animal model 
recapitulates key hallmarks of disease; they showed by immunoblotting that there is 
indeed successful expression of the 4R0 isoform of human tau at approximately two-
fold endogenous mouse tau levels in both brain and spinal cord tissue of mice aged 
5-6 months, and that it is hyperphosphorylated. There is strong labelling of 
hyperphosphorylated tau in nerve cell bodies and processes, in layers 2, 4, and 5 of 
the frontal and temporal cortices, in the hippocampal formation, and predominantly 
in the brainstem and spinal cord. By electron microscopy it was shown that there were 
large numbers of abnormal ribbon-like tau filaments which positively labelled with 
hyperphosphorylated tau antibody, AT8. Sarkosyl-insoluble tau filaments were 
predominantly “half-twisted” ribbons as is commonly found in FTDP-17 and a 
minority of filaments were more like Alzheimer-paired helical filaments. 
The P301S mouse develops a neurological phenotype dominated by a severe 
paraparesis at 5 – 6 months of age hence they investigated the lumbar spinal cord; 
they found a 49% motor neuron loss in the ventral grey matter of the spinal cord at 6 
months of age compared with control mice, and the skeletal muscle fibres showed 
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signs of denervation atrophy. Thus, as in human tauopathies, the accumulation of 
hyperphosphorylated tau correlated with neuronal loss. This nerve cell loss is also 
associated with GFAP-positive astrogliosis and denervation of hind-limb skeletal 
muscle (Allen et al., 2002). The mechanism of neuronal loss was not determined; 
authors were unable to demonstrate apoptosis by in situ end labelling (ISEL) or 
staining for caspases.  
There is also microgliosis in the spinal cord of P301S mice at end stage as indicated 
by a bushy morphology and expression of CD11b – a receptor involved in migration 
and complement recognition – and MHCII proteins involved in antigen presentation 
and interaction with T-cells. There was also co-localisation of IL-1β and COX-2 with 
cells of neuronal morphology, although the cells producing the IL-1β were not 
formally identified (Bellucci et al., 2004). 
In 2010 Hampton et al. expanded on the original work, demonstrating significant 
cortical neuronal loss which was specific to the superficial layers of the cortex, as seen 
in FTD. By immunohistochemistry there was a significant loss of cresyl-violet positive 
cells, NeuN positive neurons and GABA-ergic neurons in the superficial cortex and 
not in the deeper layers of the cortex and qPCR showed a decrease in superficial 
marker reelin and not cux-1 a marker of deeper neurons. This neuronal loss was 
progressive; there was no significant difference between P301S mice and control mice 
at 8 weeks of age but there was significant neuronal loss at 12 weeks of age and more 
so at 20 weeks of age. There was also progressive astrogliosis in the same area of the 
cortex.  
P301S tau mice were crossed with YFP-H mice expressing yellow fluorescent protein 
in a subset of cortical neurons and long-term two-photon in vivo imaging was used to 
follow the fate of individual dendritic spines in 4-month-old P301S mice. Dendritic 
spines were lost and replaced in control mice at equal rates such that there was no 
overall change in synaptic density, however in P301S mice more dendritic spines 
were lost than gained resulting in an overall decrease in spine density (Hoffmann et 
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al., 2013). By immunohistochemistry there was little overlap between phospho-tau 
(AT8) and YFP expressing neurons or NFTs and YFP, and no AT8 staining was 
observed in the dendritic spines hence authors conclude it is unlikely that the cells 
imaged in vivo contained phospho-tau which otherwise might account for dendritic 
spine abnormalities.  
A behavioural study by Scattoni et al. (2010) investigated early phenotypic markers 
of disease in P301S mice and demonstrated enhanced motor and exploratory activity 
in P301S mice at 8 weeks of age in the Morris water-maze and in the openfield task 
without any deficit in cognitive performance. A later study demonstrated impaired 
learning in the Morris water maze at 10 weeks of age; control mice repeatedly exposed 
to the MWM showed decreased latency to find the platform whereas P301S mice 
showed a significant impairment in platform acquisition over 5 days (Xu et al., 2014) 
however this finding directly contradicts that of Scattoni et al. (2010). This apparent 
deficit occurred at a time when tau pathology was detected in the hippocampus by 
MC1 (conformational epitope) and CP13 (pSer202) as well as reduced average spine 
density, length, area and volume compared to wild type mice at 2.5 months of age 
(Xu et al., 2014). They also found lower spine density and larger spine size in P301S 
mice at 5 months which might be indicative of impaired synaptogenesis or synapse 
elimination (Xu et al., 2014). 
Scattoni et al. (2010) also showed that P301S mouse pups emitted more ultrasonic 
vocalisations (USVs) than controls at postnatal days 3, 5 and 7; a pup is taken away 
from its mother and placed in a sound-attenuating Styrofoam box to record emitted 
sounds. USVs are reportedly related to emotional development (Scattoni et al., 2009, 
Wöhr et al., 2015).  
P301S mice were also able to acquire the rotarod task aged 1 month, however there 




Unpublished data from our lab shows that at 10 weeks of age, in the elevated plus 
maze (EPM) P301S mice cover significantly less distance in total and in the open arms 
of the maze, compared with control mice. This is at an age where P301S mice show 
no signs of hind limb phenotype and are hyperactive in the openfield and MWM. 
Taken together with the increased activity in the openfield and MWM and increased 
USVs, this indicates that the mechanisms regulating how P301S mice respond to 
novelty are perturbed.  
1.1.9 Conclusion of Part 1 
Here I have introduced dementia and more specifically tauopathy dementias, I have 
provided background information on the role of tau protein in the healthy and 
diseased CNS and have introduced various tauopathy mouse models including the 
P301S tau mouse model of neurodegeneration that will be the subject of my 
experiments. 
On that background, the aim of this thesis is to determine the effect of acute illness on 
tauopathy disease and vice versa, hence, in the next section I will introduce the broad 
topic of inflammation: inflammation in the periphery and in the central nervous 




1.2 Introduction Part 2: Inflammation  
1.2.1 Inflammation 
Part 1 introduced the concept of dementia as a group of proteinopathies, with 
accumulation of different proteins and with a whole host of complex aetiologies and 
neurodegenerative processes, however one significant hallmark all dementias have 
in common is inflammation in the CNS.  
A major part of this thesis is to study how peripheral inflammation influences central 
inflammation in the context of neurodegenerative disease. In order to understand the 
relationship between dementia and systemic inflammation it is first necessary to 
discuss peripheral and central inflammation, their similarities, their differences and 
ultimately their interactions. 
1.2.2 Peripheral Immunity 
The ability to mount an immune response is essential for survival of any organism. 
The inflammatory immune response is the series of events whereby the body is able 
to: 
1. Detect tissue damage or the presence of foreign bodies (e.g. bacterial or viral) 
2. Recruit the appropriate cellular – and with them molecular – components to 
the site of damage or infection in order to... 
3. Isolate and destroy the foreign bodies 
4. Initiate repair and restore homeostasis 
The immune response occurs in two waves; first is the innate immune response which 
is immediate and short lived. This is followed by the adaptive response which is more 




Here I will focus primarily on the innate immune response because it is the innate 
tissue-resident immune cells that underpin the main differences between central and 
peripheral inflammation. It is likely that the adaptive immune system also plays an 
important role in neurodegenerative diseases too, especially given the breakdown of 
the blood brain barrier in disease context, however the field is not quite there yet, 
hence my decision to focus predominantly on innate immunity. 
1.2.3 Innate Immunity in the Periphery 
 Key Players in Innate Immunity 
The key players in innate immunity are: the endothelial and epithelial cells, which 
provide the first line of defence by forming a barrier to keep pathogens out, and the 
white blood cells or “leukocytes” some of which reside in tissue – macrophages and 
dendritic cells – and some of which circulate in the blood and lymph vessels – these 
include neutrophils, eosinophils, basophils, monocytes and natural killer cells (NK 
cells).   
 Initiating the innate immune response – DAMPs, PAMPs and PRRs 
The initiation of the innate immune response depends on the recognition of 
conserved molecular signatures called danger- or pathogen- associated molecular 
patterns (DAMPs or PAMPs, respectively) by pattern recognition receptors (PRRs).  
DAMPs and PAMPs are chemical moieties associated with tissue damage (DAMPs) 
or bacterial and viral infections (PAMPs). DAMPs are usually intracellular molecules 
which are externalised when a cell is ruptured e.g. adenosine triphosphate (ATP) and 
high-mobility group box-1 protein (HMGB1). PAMPs include chemical moieties such 
as mannose-rich oligosaccharides and peptidoglycans often found on the outer 
surfaces of bacteria, and double stranded RNA, which is released by viruses.  
PAMPs are evolutionarily conserved structures; this characteristic has allowed 
coevolution of appropriate receptors on host cells. PRRs are expressed by innate 
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immune cells such as epithelial and endothelial cells, macrophages, dendritic cells 
and NK cells. PRRs include toll-like receptors (TLRs), NOD-like receptors (NLRs) and 
scavenger receptors. PRRs can be membrane bound or cytosolic and intra- or extra-
cellular, as required; bacteria tend to exist in the extracellular milieu whereas viral 
PAMPs are often inserted into the cytoplasm of host cells – PRRs are positioned 
accordingly.  
PRR binding triggers a rapid intracellular signalling cascade, leading ultimately to 
the synthesis of diverse and pleiotropic inflammatory mediators; chemokines, 
cytokines (IL-1β, TNF-α, IL-6, IL-12) and acute phase proteins.  
 LPS and TLR4 
Lipopolysaccharide (LPS) –  often used to experimentally mimic a bacterial infection 
– is a PAMP found on the outer surface of many gram-negative bacteria such as 
Escherichia coli. LPS consists of three parts: lipid A (the main PAMP), a core 
oligosaccharide, and an O side chain (see Figure 2). It can cause systemic 
inflammation and at high doses can cause sepsis. LPS stimulates the PRR TLR4 
through interactions with LPS binding protein (LBP), CD14 and MD-2 (Lu et al., 
2008). LBP is a soluble protein which binds to LPS and facilitates binding of LPS to 
CD14 which then passes the LPS on to the TLR4:MD2 complex (Wright et al., 1989, 
Wright et al., 1990). Binding of LPS causes oligomerization of TLR-4 bringing the Toll-
interleukin-1 receptor (TIR) domains into proximity; the TIR domains recruit several 
signal transduction adaptor proteins including MyD88 (myeloid differentiation 
primary response gene 88), TIRAP (TIR domain-containing adaptor protein), TRIF 
(TIR domain-containing adaptor inducing IFN-β) and TRAM (TRIF-related adaptor 
molecule) (Lu et al., 2008). Signalling via MyD88 dependent or independent 
pathways results in NFκB and IRF-3 or -5 (interferon regulatory factor 3 or 5) 





Figure 2 – Lipopolysaccharide (LPS) schematic. LPS is a chemical moiety found on the outer surface of gram 
negative bacteria, consisting of three parts: lipid A (the main PAMP), a core oligosaccharide, and an O side chain. 
Borrowed from ©2016 Pearson Education, Inc. 
 Scavenger Receptors 
Another type of PRR - the scavenger receptor - found on the surface of macrophages 
and dendritic cells -  allows cells to bind, phagocytose and degrade pathogens. These 
cells may become antigen presenting cells (APCs); they degrade the pathogen and 
present “non-self” peptides bound to major histocompatibility complex (MHC) 
receptors, along with co-stimulatory molecules expressed on their cell surface, which, 
together, interact with T-cell receptors (TCRs) to activate T – cells of the adaptive 
immune response.  
 Chemokines and Cytokines 
Chemokines are chemotactic factors which recruit cells with the correct chemokine 
receptors to the site of damage or infection – cells of the innate and adaptive immune 
systems which may be pro- or anti-inflammatory.  
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Cytokines are secreted proteins which may have pro- or anti- inflammatory effects. 
Cytokines bind to their specific cytokine receptors and in doing so they stimulate 
further cytokine production, as well as proliferation, activation and differentiation of 
adaptive immune cells which themselves might be pro- or anti-inflammatory. For 
example, pro-inflammatory cytokine TNF-α binds TNF receptor 1 which initiates a 
signalling cascade whereby NFκB- and JNK-signalling regulate apoptosis and 
inflammation. TNF-α also signals through the fas-associated death domain triggering 
caspase-8 which is involved in IL-1β production. IL-1β activates mitogen-activated 
protein kinase (MAPK) and resulting in further proinflammatory cytokine 
production.  
IL-10 on the other hand used to be known as cytokine synthesis inhibitory factor 
(CSIF) and it also downregulates expression of MHCII costimulatory molecules 
CD80/CD86 (Moore et al., 2001). 
More than one type of cytokine is present at any one time, and each is present in 
different concentrations. These varying combinations, which show dynamic changes, 
are extremely important in orchestrating the amplitude, polarity and duration of 
immune responses.  
 Complement System 
Another important component of innate immunity is the complement system – a 
group of more than 30 complement proteins.  Through a tightly coordinated series of 
events complement proteins recognise and bind to the surface of bacteria and then 
two things can happen. Complement proteins completely coat the bacteria – a process 
called opsonisation - enabling recognition by immune cells with complement 
receptors. Those immune cells can then bind, engulf and destroy the pathogen. 
Alternatively, the complement proteins recruit more complement proteins which are 




1.2.4 Resolution and regulation 
The resolution and regulation of inflammation is essential to avoid tissue damage. 
Phagocytic cells involved in clearing up the aftermath of inflammation phagocytose 
pathogens and debris, which stimulates release of regulatory cytokines including IL-
10 and TGF-β which are involved in dampening the immune response and resolution 
of the inflammation including by inhibition of cytokine synthesis, downregulation of 
costimulatory receptors.  
The importance of a well-balanced immune response was underscored by an 
infamous phase 1 clinical study in 2006; six healthy volunteers were injected with a 
CD28 superagonist TGN1412 – the CD28 superagonist was supposed to activate T-
regulatory cells which are useful in the treatment of autoimmune diseases. Just a few 
minutes after injection all six volunteers suffered severe cytokine release syndrome 
which lead to multiple organ failure (Suntharalingam et al., 2006).  
Dysregulation of the immune response also causes autoimmune diseases such as 
rheumatoid arthritis and multiple sclerosis where the immune system is activated by 
self-antigens. On the other hand, failure to mount an immune response leaves hosts 
vulnerable to infection. 
The peripheral immune response must therefore be carefully regulated at many 
stages in order to minimise damage to bystander host cells.  To discuss all the 
regulatory mechanisms of the immune response is beyond the scope of this thesis but 
it is important to highlight that there are many mechanisms in place. Examples which 
are relevant for central immunity include: inhibitory molecules which prevent 
destruction of host cells; regulatory immune cells which release cytokines involved 




1.2.5 CNS Immunity 
Since most neurons of the central nervous system are post-mitotic and must last a 
lifetime, the immune response must be even more tightly regulated than in the 
periphery since any inappropriate immune reaction would be extremely costly. One 
key difference between the central and peripheral immune response is the cellular 
components.  
 Key Components in CNS Immunity 
The key players in immunity in the CNS are the astrocytes, paraventricular 
macrophages and microglia; the resident macrophage cells of the brain. Neurons and 
epithelial cells are also capable of expressing cytokines and receptors at low levels. 
 Endothelial Cells of Blood Brain Barrier 
The central nervous system was previously thought to be completely isolated from 
circulating peripheral inflammatory mediators by the blood brain barrier (BBB) – a 
specialised endothelial layer with tight junctions. It is now understood that 
circulating pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β – all of which 
are elevated in dementias – can influence BBB permeability (Wong et al., 2004). The 
BBB actively transports cytokines such as TNF-α and IL-1β (Gutierrez et al., 1993, 
Gutierrez et al., 1994) and can also be stimulated to release proinflammatory 
mediators and allow extravasation of leukocytes into the brain parenchyma 
(Laflamme et al., 1999, Terrando et al., 2011).  
 Brain lymphatic system 
Two groups independently discovered the existence of a brain lymphatic system in 
2015, which will have huge implications for the field (Aspelund et al., 2015, Louveau 
et al., 2015). The lymph vessels express markers of lymphatic endothelial cells 
including lymphatic vessel endothelial hyaluronan receptor 1 (Lyve-1) and vascular 
endothelial growth factor receptor 3 (VEGFR3). They run alongside blood vessels in 
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the meninges and drain into deep cervical lymph nodes (dcLN). Genetic ablation of 
the vessels or ligation of lymph vessels near the dcLN blocks drainage of dyes to the 
dcLN and led to an increase in T-cell density in the vessels. This discovery contradicts 
what was previously thought to be true about T-cell circulation in the brain. There is 
still, however, no evidence for a cell which exists in the normal brain parenchyma and 
is capable of antigen presentation and migration from the CNS to the lymph nodes for 
stimulation of T- and B- lymphocytes, as is seen in the periphery. This difference is 
likely to be key in the immune-privilege status of the CNS. 
 Astrocytes 
Astrocytes, so called because of their often star-like morphology, make up ~70% of 
cells in the cerebral cortex. Astrocytes play an important role in maintaining 
homeostasis in the CNS and are also involved in CNS immunity.  
1.2.5.1.3.1 Astrocytes - Role in the healthy brain  
Astrocytes found in grey matter are “protoplasmic” and have lots of shorter branches, 
whereas astrocytes of the white matter are “fibrous” and have longer unbranched 
processes. Astrocytes form syncytial networks around neurons to provide physical 
support and enable provision of energy and removal of toxic waste as required.  
Generation of an action potential by neurons is extremely metabolically demanding; 
astrocytes are the only cells in the brain capable of “energy storage” in the form of 
glycogen, which can be rapidly converted into glucose, astrocytes can convert glucose 
to lactic acid which is subsequently taken up by neurons and converted to pyruvate 
for energy metabolism (Danbolt, 2001). Astrocytes make contact via end-feet-
processes with capillaries and with the Node of Ranvier and the synapse of neurons 
and in this way they are able to provide neurons with energy and remove waste.  
Astrocytes contribute to a tripartite-synapse, where they maintain neurotransmitter 
concentrations; they take up glutamate, GABA and glycine thus avoiding over-
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stimulation and resulting neurotoxicity. Astrocytes contain glutamate transporters 
GLT-1 (glutamate transporter-1) and GLAST (glutamate-aspartate transporter) which 
allow glutamate uptake, thereby avoiding glutamate induced neurotoxicity, and 
glutamine synthetase which enables conversion of glutamate back into glutamine for 
uptake by presynaptic neurons which can then convert glutamine back into 
glutamate for reuse (Martinez-Hernandez et al., 1977). 
Astrocyte end feet make contact with synapses and also with brain vasculature thus 
modulating blood flow in an activity dependent manner; glutamate activates 
metabotropic glutamate receptors on astrocytes, and downstream signalling results 
in local release of calcium, prostaglandins, and nitric oxide which regulate capillary 
dilation (Hirase, 2005).  
Astrocytes also provide neurotrophic support for neurons (Zhou et al., 1994, 
Friedman et al., 1998), maintain pH, ion homeostasis, and help to maintain proper 
functioning of the BBB (Fuller et al., 2010). 
Emerging evidence suggests that astrocytes release signals which induce expression 
of complement C1q protein by synapses, thereby labelling them for synaptic pruning 
by microglia (Stevens et al., 2007). 
1.2.5.1.3.2 Astrocytes – Role in Immunity 
The phenomenon of immune activation of astrocytes is referred to as astrogliosis. 
Astrocytes detect change in their environment and switch to a “reactive” phenotype, 
i.e. they proliferate and undergo morphological changes. Reactive astrogliosis can be 
triggered by a whole host of molecules including cytokines (IL-6, LIF, CNTF, TNF-α, 
INF-γ, IL-1α/β, IL-10, TGF-β, FGF-2), TLR ligands (e.g. LPS), neurotransmitters, ATP, 
ROS, NOS, products of neurodegeneration (Aβ) (Sofroniew, 2009). 
Glial fibrilliary acidic protein (GFAP) is the key astrocyte-specific intermediate 
filament protein which mediates the cytoarchitectural changes during reactive 
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astrogliosis. During mild reactive astrogliosis there is little proliferation of astrocytes 
but there is upregulation of GFAP in cells which did not previously express GFAP 
giving the impression of increased numbers. There is very little overlap between 
astrocytes, and the lack of reorganization of tissue means that astrocytes may return 
to their previous appearance once the initial trigger of gliosis is resolved. In severe 
astrogliosis there is vast upregulation of GFAP and mature astrocytes re-enter the cell 
cycle, proliferate and invade the site of injury where they switch to a reactive 
morphology with lots of overlapping and interaction between densely packed 
astrocytes in a bid to isolate the damaged area; this is called a glial scar. This 
concentrates inflammatory cells where they are needed and prevents spread to 
surrounding healthy tissue. Glial scar formation also prevents the spread of 
demyelination. 
GFAP is such a consistent marker of reactive astrogliosis that it is often used alone to 
demonstrate astrogliosis in pathological context giving the false impression that 
astrogliosis is a homogenous event. In reality increased GFAP expression, is a 
universal response of astrocytes to environmental changes such as injury and disease, 
but astrogliosis is a spectrum of molecular, cellular and functional changes of 
astrocytes in response to injury or disease; different stimuli initiate different astrocyte 
expression profile and thus the role of reactive astrocytes varies and can be damaging 
or beneficial (Zamanian et al., 2012). These differences are not discriminated by 
GFAP.  
Cluster analysis of GeneChip expression profiling data from astrocytes isolated from 
mice following either middle cerebral artery occlusion (MCAO) to induce ischemia 
or LPS-injection showed an increase in several genes common to both insults but also 
indicated that the different injuries produced different patterns of reactive astrocyte 
gene expression (Zamanian et al., 2012). LPS mostly fails to cross the BBB (Banks et 
al., 2010) and thus exerts its effects by proinflammatory cytokine signalling 
downstream of TLR4 activation whereas in MCAO all cell types are exposed to 
ischemia, and astrogliosis is triggered by dying cells, hypoxia, acidosis, direct trauma, 
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and pro-inflammatory cytokines. LPS-induced reactive astrocytes upregulated genes 
involved in the antigen presentation and complement pathway activation and are 
therefore considered detrimental, whereas MCAO reactive astrocytes expressed 
genes involved in increased metabolic activity, cell-cycle genes, transcription factors 
and neurotrophic factors and appear to be neuroprotective (Zamanian et al., 2012). 
These deleterious and neuroprotective astrocyte profiles have since been referred to 
as A1 and A2 astrocytes respectively (Liddelow et al., 2017), in line with (now out-
dated) terminology used to refer to polarised microglial subtypes (discussed in 
section 1.2.5.1.4.2 Microglia – Role in immunity) . 
Astrogliosis can have dual role in CNS inflammation, the switch towards reactive 
astrocytes with a proinflammatory profile can result in loss of previously described 
essential functions of astrocytes leading to loss of homeostasis in the brain. Astrocytes 
can inhibit axonal regeneration following spinal cord injury (McKeon et al., 1991, 
Fitch et al., 2008) and are also capable of producing molecules which can exacerbate 
CNS inflammation including proinflammatory cytokines and chemokines (Brambilla 
et al., 2005). 
However astrocytes have several beneficial roles in pathological conditions 
including: protection from cytotoxic effects of glutamate by glutamate uptake; 
protection from oxidative stress; facilitation of BBB repair; restoration of homeostatic 
water levels and ion concentrations and more (Faulkner et al., 2004, Sofroniew et al., 
2010). 
Activated astrocytes upregulate a whole host of molecules involved in cell adhesion, 
antigen presentation, growth factors and their receptors, cytoskeletal proteins 
(vimentin, GFAP), molecules involved in calcium signalling (Eddleston et al., 1993). 
Astrocytes are capable of producing pro- and anti-inflammatory cytokines depending 
on their context; astrocytes close to lesion sites are more likely to acutely produce 
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proinflammatory cytokines however astrocytes distal to lesion site, or after some time 
produce anti-inflammatory cytokines.  
 Microglia 
Microglia are ubiquitous tissue resident innate immune cells. They enter the CNS 
very early in embryonic development before formation of the BBB where they make 
up ~10% of the adult brain cell population (Lawson et al., 1990). They play a role in 
development and homeostasis but they are also the macrophages of the brain and 
therefore have an important role in neuroinflammation. 
1.2.5.1.4.1 Microglia – Role in the healthy brain 
Microglia exist relatively evenly spaced throughout the brain parenchyma and with 
very little overlap between cells. There is evidence to suggest different populations of 
microglia exist within different regions of the CNS (Elkabes et al., 1996, Ren et al., 
1999, Sriram et al., 2006, Grabert et al., 2016). 
Microglia are important during development for synaptic pruning. In normal 
conditions microglia exist in a ramified morphology; they have a relatively small 
soma and they extend long, motile processes which are constantly palpating and 
detecting changes in their microenvironment, as was seen using two-photon 
microscopy (Nimmerjahn et al., 2005). These processes make contact with dendrites 
and synapses of neighbouring neurons where they are able to detect synaptic 
dysfunction and remove dysfunctional synapses by phagocytosis.  
Microglia also release growth factors; for example, insulin-like growth factor 1 which 
is involved in layer V cortical development (Ueno et al., 2013) and BDNF which is 
involved in learning-dependent synapse formation. Resting microglia are also 
involved in the removal of debris and apoptotic cells during development. 
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1.2.5.1.4.2 Microglia – Role in immunity 
However, microglia are also the tissue-resident innate immune cells – the 
macrophages of the brain. Many useful parallels can be drawn between macrophage 
and microglial biology. 
There is a great deal of discussion around microglial and macrophage phenotypes. 
Historically peripheral macrophages were understood to be either pro- or anti-
inflammatory. Macrophages were thought to be “classically activated” by pro-
inflammatory cytokines such as IFN-γ or TNF-α, resulting in a pro-inflammatory, M1 
cytokine profile including interlukin-1β (IL-1β), IL-6, IL-12 and tumour necrosis 
factor a (TNF-α); or “alternatively activated” by IL-4, inducing an anti-inflammatory 
M2 profile including IL-10, and TGF-β expression. However, in recent years it has 
become apparent that there is in fact a subtler spectrum of activation states rather 
than two polarised states. Macrophages respond to extracellular factors and can 
simultaneously express pro- and anti-inflammatory mediators.  
Since microglia are the macrophages of the brain this begs the question, does this 
spectrum of activation also apply to microglia? The quick answer is “Yes”. Microglia 
are extremely dynamic and their morphology and expression profile is dependent on 
their microenvironment. When microglia detect a change in their environment they 
too are capable of phenotypic switching. 
Experiments where microglia are artificially exposed to LPS or IL-1β show that they 
are indeed capable of an M1-like proinflammatory state (Herrera et al., 2000, Hauss-
Wegrzyniak et al., 2002). However, since neurons are mostly post-mitotic and an 
over-zealous immune response in the central nervous system would be extremely 
costly, microglial activation is in actual fact repressed.  
While the CNS is not completely isolated by the BBB, microglial cells are, for the most 
part, sheltered from circulating serum proteins and the extracellular milieu in the 
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healthy brain is generally anti-inflammatory with relatively high levels of TGF-β and 
anti-inflammatory prostaglandin E2 (PGE2).  
The activation (or not) of microglia depends on their relative expression of activating 
and inhibiting receptors, which have either immunoreceptor tyrosine-based 
activation motifs (ITAMs) or immunoreceptor tyrosine-based inhibition motifs 
(ITIMs) on their intracellular domain. 
Microglia express CD200R a receptor with an inhibitory motif. CD200R binds CD200, 
a neuronal membrane bound protein which inhibits microglial activation (Barclay et 
al., 2002, Koning et al., 2009). Microglia from CD200 deficient mice have an 
exaggerated response to TLR2 and TLR4 stimulation (Costello et al., 2011) and real-
time PCR indicated increased CD11b, MHCII and CD40 expression in hippocampus 
of CD200 deficient mice (Denieffe et al., 2013). Fractalkine (CX3CL1) is a neuronal 
secreted protein which binds to microglial fractalkine receptor (CX3CR1) (Harrison 
et al., 1998) to elicit a “quiescent” phenotype (IL-10, TGF-β). TREM2 (Triggering 
receptor expressed on myeloid cells 2) is another microglial protein which belongs to 
the immunoglobulin (Ig) superfamily of receptors is involved in phagocytosis and 
downregulation of pro-inflammatory cytokines. There is also evidence that microglial 
cells express neurotransmitter receptors and are repressed by neurotransmitters e.g. 
acetylcholine and gamma-aminobutyric acid (GABA) and hence neuronal activity is 
important in microglial activation (Pocock et al., 2007). In this way neuronal loss in 
neurodegenerative diseases might lead to progressive microglial activation. 
Microglia are therefore not only sensitive to DAMPs, PAMPS and cytokines as seen 
in peripheral macrophages but are also responsive to small changes in their micro-
environment; the absence of neuronally-expressed inhibitors (CD200 and CX3CL1, 
neurotransmitters) due to neuronal dysfunction, or presence of serum proteins 
(fibrinogen binds CD11b) due BBB breakdown can activate microglial cells.  
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Microglial activation occurs within hours of injury or proinflammatory stimulus. 
Activated microglia upregulate surface receptors including chemokine receptors 
(enables chemotaxis), complement receptors and Fc receptors (enables phagocytosis 
of opsonised antigen), MHC proteins and accessory proteins (enables antigen 
presentation and interaction with infiltrating T-cells). They produce ROS, NO, along 
with release of proinflammatory cytokines which influence BBB permeability and 
allow recruitment of adaptive immune cells to the site of infection.  
When microglia are activated they withdraw their long processes and adopt a bushy 
morphology with thickening of proximal processes, there is visible membrane 
ruffling as they become migratory in response to chemokine expression at the site of 
infection (Lively et al., 2013). Microglia are capable of phagocytosis of pathogens and 
cellular debris. This phagocytosis results in expression of anti-inflammatory 
cytokines (Fadok et al., 1998, Huynh et al., 2002) which together with regulatory T-
cells help to dampen the local inflammatory response and in this way the acute 
immune response is self-limiting and ultimately leads to repair and restoration of 
homeostasis. 
1.2.6 CNS Inflammation associated with Dementias 
Neuroinflammation is often described as a double-edged sword; in section 1.2 I 
described the inflammatory response as an adaptive sequence of events which aims 
to remove pathogens, repair damage and restore homeostasis, however I have also 
highlighted the importance of regulation of the immune response.  
Chronic inflammation in the central nervous system (CNS) is a consistent hallmark 
of all dementias. CNS inflammation can be beneficial when it is acute and transient 
as discussed above, however chronic inflammation associated with CNS disease can 
become deleterious. 
Astrogliosis and microgliosis were both described in post-mortem AD by Alois 
Alzheimer over a century ago. These and other hallmarks of inflammation have been 
60 
 
described in most neurodegenerative conditions since then; including AD, PD, 
amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Wallerian 
degeneration.  
The vast literature on the role of neuroinflammation in neurodegeneration 
predominantly focuses on AD where studies suggest that Aβ-plaques provide a 
proinflammatory stimulus for astrocytes and microglia (Giulian et al., 1996, 
McDonald et al., 1998, Liu et al., 2012c). For extensive reviews on the role of 
neuroinflammation in neurodegeneration, in particular AD, see (Akiyama et al., 2000, 
Schwab et al., 2010, Cunningham, 2013).  
However little attention is focused on the role of neuroinflammation in the context of 
pure tauopathies in the absence of Aβ. Here I will introduce what is currently 
understood on the subject. 
There are notable differences between microglia in AD and in pure tauopathies; in 
AD brain there are greatly elevated numbers of microglial cells even in areas lacking 
Aβ-deposition, whereas in a pure tauopathy such as Pick’s Disease there were 
relatively fewer microglial cells, and microglial activation was seen only in areas of 
extreme tau pathology (Paulus et al., 1993). This is in line with several other studies 
showing regional association of microglial activation with tau pathology in post-
mortem tissue from pure tauopathies including PSP and CBD (Kida et al., 1992, Sheng 
et al., 1997, Ishizawa et al., 2001, Sasaki et al., 2008). This regional association has also 
been observed in patients diagnosed with FTLD, CBD and PSP visualised by positron 
emission tomography using [11C](R)-PK11195, a marker of peripheral 
benzodiazepine binding sites (PBBS) expressed by activated microglia (Cagnin et al., 
2004, Henkel et al., 2004, Gerhard et al., 2006). 
The regional association of microglia with tau pathology has been recapitulated in 
many transgenic models of tauopathies. A study in a P301L tau transgenic mouse 
showed that microglial activation correlated with the degree of tau pathology and 
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that where there was only mild tau pathology there was no microglial activation. 
Interestingly where there was tau pathology and associated increase in IBA1-positive 
microglia they did not cluster around cells containing  AT8-positive structures such 
as NFTs, pretangles and neuropil threads as is often the case with Aβ-laden cells and 
immune-electron microscopy using IBA1 showed lysosomal dense bodies but no 
filamentous structures corresponding with NFTs (Sasaki et al., 2008).  
The role of microglial cells in CNS disease is not clear cut. As mentioned before, 
experiments which attempt to model microglial activation by artificially exposing 
microglia to IL-1β and LPS do not realistically model microglia found in CNS disease 
where they often adopt an activated morphology but do not express the full 
complement of typically proinflammatory cytokines. 
A study of transgenic rats expressing pathological truncated tau indicated that NFTs 
were associated with upregulation of complement receptor 3, CD4 and CD45. 
Furthermore, double immunofluorescence staining showed co-localisation of 
phospho-tau (AT8) with microglial marker of lysosomal degradation - glycoprotein 
CD68 indicative of phagocytosis of tau protein (Zilka et al.). 
In CNS disease, neuronal damage and the accumulation of mis-folded proteins 
provide a persistent trigger for inflammation and since the immune response cannot 
successfully remove the threat as it could if it were an invading pathogen, there is no 
resolution of the inflammatory response. It is likely that the chronic nature of CNS 
diseases combined with the immune-suppressive environment of the brain might 
provide persistent and conflicting signals.  
There are examples indicating that microglia have both beneficial and detrimental 
effects in CNS disease (Hanisch et al., 2007), for example, microglia are capable of 
phagocytosis with concomitant expression of anti-inflammatory cytokines (Magnus 
et al., 2001). Loss of TREM2 leads to impaired phagocytosis and increased production 
of proinflammatory cytokines and rare polymorphisms in TREM2 are a risk factor for 
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AD and FTD (Guerreiro et al., 2012, Jonsson et al., 2013, Singaraja, 2013). CCL2, also 
known as monocyte chemoattractant protein 1 (MCP1), is a chemokine for microglial 
activation and monocyte attraction and is upregulated in AD (Sly et al., 2001). 
Depletion of Ccr2, the chemokine receptor on microglial cells, in Tg2576 AD mice 
impaired microglial accumulation, accelerated Aβ accumulation and increased 
mortality (El Khoury et al., 2007). Microglia transplantation led to improved Aβ-
clearance (Takata et al., 2007). However, it seems that microglia are surprisingly poor 
at phagocytosis in the context of CNS disease (Wisniewski et al., 1991).  
Yoshiyama et al (2007) demonstrated early microgliosis which preceded tangle 
formation in the PS19 mouse. Microgliosis was visualised by staining for MHCs and 
CD11b and also by radiograms using radiotracer [3H]-DAA1106. Microglial 
activation corresponded with regions of tau pathology and was characterized by 
bushy, thickened and branched processes. Astrogliosis visualised by GFAP staining, 
was demonstrated in the same areas.  
Interestingly, immunosuppression with FK506 increased the life span of PS19 mice, 
dramatically rescued neuronal counts, attenuated markers of inflammation (CD11b, 
and neuronally expressed Cox-2 and IL-1β) and reduced hyperphosphorylated and 
insoluble tau burden (Yoshiyama et al., 2007). Authors attribute these beneficial 
effects to repressed microglial activation, although FK506 functions through binding 
calcineurin which is also expressed in T-cells, astrocytes and neurons (Ho et al., 1996, 
Solà et al., 1999, Furman et al., 2014). The effect of FK506 on T-cells might be 
significant since in a similar model and in a P301L tau FTD patients there was 
infiltration of CD8+ T-cells into the brain parenchyma (Laurent et al., 2016). However, 
the point stands that immunosuppression was beneficial in this instance. 
As previously described, there is age related phosphorylation and accumulation of 
tau protein in the hTau mouse model (section 1.1.5 and (Andorfer et al., 2003)) the 
accumulation of tau in this model is associated with neuronal loss and progressive 
microgliosis (IBA1) (Bhaskar et al., 2010). Microglia from hTau mice showed elevated 
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levels of cleaved fractalkine (CX3CL1), inducible nitric oxide synthase (NOS2) and 
MCP1, however TNF-α, INF-γ, IL-1β and IL-6 levels remained unchanged.  
Since fractalkine is essential in modulating microglial activation, hTau mice were 
crossed with fractalkine knock out mice to determine the effect of dysregulation of 
microglia on disease pathology. hTau-CX3CR1−/− mice displayed increased 
microgliosis compared with age matched hTau-CX3CR1+/+ mice, determined by 
increased IBA1 staining with thickened, bushy microglial morphology as well as 
increased CD68, CD11b and iNOS staining. This increased microgliosis was 
associated with elevated levels of pathological hyperphosphorylated and insoluble 
tau compared with hTau-CX3CR1+/+ mice. Further mechanistic studies identified p38-
MAPK as the responsible kinase involved in the increased microglial mediated tau 
phosphorylation.  
Astrogliosis is another recurrent hallmark of tauopathy dementia and has been 
repeatedly demonstrated in transgenic mutant tau animal models of tauopathies 
(discussed in section 1.2.5.1.3.2 and summarised in Table 2).  
Astrogliosis in CNS disease is typically characterised by hypertrophy, proliferation 
and GFAP expression (Sajja et al., 2016) and, as with microgliosis, the degree of 
astrogliosis correlates with the degree of tau pathology (Sheng et al., 1997). 
Astrocytes in tauopathies often have tau positive inclusions and the profile of those 
glial inclusions correlates with the type of tauopathy; astrocytic tufts of abnormal 
fibres are found in PSP, astrocytic plaques in the distal dips of glial cells and dense 
glial threads are seen in CBD and ramified astrocytes and small Pick body-like 
inclusions in PiD (Feany et al., 1995, Komori, 1999, Broe et al., 2004). It is likely that 
the intracellular tau deposits result from glial expression of aberrant tau protein since 
there is no evidence of tau uptake by glia. This is supported by the lack of astrocytic 
tau in animal models expressing tau under neuronal promoters. 
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Astrocytic tau deposits result in loss of neuroprotective astrocyte function in disease. 
Animal models expressing tau under the GFAP promoter develop astrocytic tau 
inclusions typical of tauopathies and have reduced glutamate transporter (GLT-1 and 
GLAST l) expression as was also reported in CBD post-mortem tissue (Dabir et al., 
2006).  
Some loss of neuroprotective function will come from phenotype switching to 
reactive astrocytes. Indeed in our own model of P301S tau there is progressive 
reactive astrogliosis detected by GFAP and transplantation of astrocytes and 
progenitor cells which differentiated into astrocytes led to astrocyte-mediated 
neuroprotection perhaps, but not exclusively, by increased secretion of neurotrophic 
factors (Hampton et al., 2010). 
In addition to microgliosis and astrogliosis, there is evidence of T-cell infiltration in 
AD tissue (Itagaki et al., 1988, Rogers et al., 1988, Togo et al., 2002). However there 
has been limited research into the role of infiltrating adaptive immune cells in 
tauopathy dementia.  
THY-Tau22 mice express full length mutant tau (G272V and P301S) under the thy 1.2 
promoter; tau is hyperphosphorylated and develops into NFT like inclusions, rare 
ghost tangles and PHF-like filaments. Tau pathology is spatiotemporally associated 
with astrogliosis (GFAP) and microgliosis (lectin, CD11b, CD68, IBA1) and recent 
studies indicate CD8+ T-cell infiltration. T-cell depletion improved performance on 
the Y-maze but did not alter tau expression, truncation or phosphorylation. T-cells 
were also present in the brain parenchyma of P301L tau FTD patients (Laurent et al., 
2016). 
1.2.7 Dementia and systemic inflammation 
There is a body of evidence which suggests that systemic illnesses with an 
inflammatory component such as diabetes, increase the risk of dementia (Engelhart 
et al., 2004, Yaffe et al., 2004, Perry et al., 2007, Tobinick, 2008).  
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Numerous inflammatory medical conditions are associated with increased risk of 
dementia, including stroke, diabetes, midlife hypertension, midlife obesity and 
midlife hypercholesterolaemia. A case-control study of patient records from the 
General Practice Research Database, with 9954 valid cases, and 9374 valid controls, 
showed an increased risk of dementia diagnosis following infection (Dunn et al., 
2005). A population-based prospective cohort study, demonstrated an association 
between plasma levels of inflammatory proteins (α-antichymotrypsin, IL-6, and C-
reactive protein (CRP)) and increased risk of dementia (Engelhart et al., 2004). 
In a prospective study of 300 subjects with mild to severe AD, patients were 
cognitively assessed using the Alzheimer’s Disease Assessment Scale (ADAS-COG), 
carers provided details of incident systemic inflammatory events and a blood sample 
was collected. Patients were followed up at 2, 4, and 6 months. Increased circulating 
TNF-α at baseline was associated with a 4-fold increase in the rate of cognitive decline 
over the 6-month follow-up period. Acute systemic inflammatory events were 
associated with increased circulating TNF-α and a 2-fold increase in the rate of 
cognitive decline over a 6-month period. Subjects with elevated TNF-α at baseline 
and subsequent acute systemic inflammatory events had a 10-fold increased rate of 
cognitive decline during the 6-month period compared with subjects with low TNF-
α and no acute inflammatory events (Holmes et al., 2009). Infection and raised serum 
IL-1β levels are also associated with increased rate of cognitive decline in patients 
with AD (Holmes et al., 2003). 
There is evidence that long term exposure to non-steroidal anti-inflammatory drugs 
(NSAIDs) is protective against AD and Parkinson’s disease (PD) (Rogers et al., 1993, 
Breitner, 1996, Weggen et al., 2001, Sastre et al., 2003, Szekely et al., 2004, Chen H et 
al., 2005) which is regularly quoted as evidence that neuroinflammation has a 
causative role in progression of disease with no mind to the fact that the NSAIDS 
were prescribed to treat systemic illness.  
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 Systemic inflammation and the CNS: Sickness Behaviour 
There was a long-held misconception that the CNS is an immune-privileged region, 
isolated from circulating inflammatory mediators of the peripheral immune system 
by the BBB. We now know however that isolation of the brain is not absolute; there 
are a number of pathways which allow deliberate communication of the systemic 
inflammatory state with the CNS.  
While circulating pro-inflammatory cytokines are too large to cross the BBB 
themselves, they are able to communicate across the BBB via a number of means; they 
are able to initiate expression of cytokines and cyclooxygenase (COX) enzymes by 
endothelial cells (Matsumura et al., 2004); enter the brain via the circumventricular 
organs (CMVOs) where there are no tight junctions between endothelial cells (Blatteis 
et al., 1983); and they stimulate afferents of the vagus nerve (Blatteis et al., 1998, 
Konsman et al., 2002, Romanovsky, 2004, Szekely et al.), subdiaphragmatic vagotomy 
attenuates the fever response to systemic LPS (Roth et al., 2001).  
The pathways of communication between peripheral immunity and the CNS  enable 
systemic inflammation to initiate fever and sickness behaviours including anorexia, 
decreased locomotor activity and decreased social interaction, all of which are 
coordinated by the CNS (Dantzer, 2001).  
These sickness behaviours are adaptive and serve to reduce the risk of further spread 
of the pathogen however it is thought that an aberrant sickness response to systemic 
inflammation arises when systemic inflammatory signals are superimposed onto 
CNS disease and this aberrant response might be the biological substrate of delirium 
caused by systemic inflammation with dementia (Cunningham et al., 2013). 
1.2.8 Delirium 
Delirium is a common and profound neuropsychiatric condition, characterized by 
altered levels of arousal, inattention, cognitive deficits and psychoses with a 
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fluctuating pattern as described by the Delirium Rating Scale - Revised - 98 (DRS-R98) 
or the Confusion Assessment Method (CAM). It is a short-term, reversible condition, 
with acute onset. 
Delirium is an extremely complex condition with a vast range of predisposing and 
precipitating factors; it is usually caused by a combination of factors and hence 
teasing apart mechanisms is complicated. However, elderly people and those with 
pre-existing dementia are particularly susceptible to delirium compared with non-
demented counterparts (Fick et al., 2002).  
 Dementia as a risk factor for Delirium 
In 1986 a study of two-thousand medical inpatients found that 41.4% of demented 
patients experienced delirium compared to only 12.4% of non-demented patients 
(Erkinjuntti et al., 1986). 
In a population-based longitudinal study Davis et al. (2015) showed that increased 
dementia severity, determined by Mini-Mental State Exam (MMSE) correlated with 
increased risk of delirium; for every MMSE point lost the risk of delirium increased 
5% (Davis et al., 2015).  
Still relatively little is known about how different types of dementia impact on the 
likelihood of delirium. After an extensive search of the literature for examples of 
“delirium” or “confusion” in the context of different types of dementia I found only 
one  relatively small study from 1997 of 175 patients with AD, vascular AD and FTD 
which indicated a higher rate of delirium in patients with late onset AD (LAD – 57%) 
than early onset AD (EAD – 14%) or FTD (19%) and higher rates in VAD (40%) than 
EAD (Robertsson et al., 1998). The differences could not be explained by age. There 
was a relationship between disease severity (mild, moderate or severe) and 
occurrence of delirium but authors suggested the different rates of delirium between 
different types of dementia might relate to the areas of the brain affected, since EAD 
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and FTD are predominantly cortical whereas pathology is more widespread in LAD 
and VAD. 
 Delirium has long-term cognitive impacts 
Delirium is not just a benign and transient state of confusion as was previously 
thought. A population-based cohort study showed that delirium increases the risk of 
incident dementia and it exacerbates the severity and trajectory of pre-existing 
neurodegenerative conditions (Davis et al., 2012).  
A large prospective cohort study of the Massachusetts Alzheimer's Disease Research 
Centre's patient registry showed that delirium accelerates the rate of cognitive decline 
measured by the Information-Memory-Concentration (IMC) subtest of the Blessed 
Dementia Rating Scale. Prior to delirium dementia patients showed a decline in IMC 
performance of 2.5 points per year, following delirium the average decline was 
accelerated to 4.9 points per year. There was no change in the rate of decline seen in 
patients who did not experience delirium (Fong et al., 2009).  
The duration of follow up in this study was unclear, however, another study of 
hospitalised patients with AD showed that the rate of decline in patients prior to 
hospitalisation did not differ, whereas, in the 5-year period following hospitalisation 
the rate of decline in patients who developed delirium during their stay was double 
that of those who did not experience delirium during their stay (Gross et al., 2012). 
Not only does delirium increase the risk and trajectory of long term cognitive 
impairment but there is also evidence that longer duration of delirium is associated 
with worse long term cognitive impairment (Pandharipande et al., 2013). 
A meta-analysis of studies published between January 1981 and April 2010 with 
minimum follow-up of 3 months found that delirium is also associated with increased 
risk of permanent institutionalisation, dementia and death (Witlox et al., 2010). 
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Importantly it is estimated that delirium could be prevented in up to a third of 
hospital inpatients (Inouye et al., 1999).  
It is thought that delirium is the result of an aberrant psychoneuroimmunological 
response to systemic inflammatory signals caused by the already inflammatory 
environment within the CNS during neurodegeneration (Cunningham et al., 2013); 
more specifically it is thought to be underpinned by microglial priming. 
1.2.9 Microglial priming  
The microglial priming hypothesis describes the phenomenon whereby microglia in 
the diseased brain exist in an altered state of activation such that a subsequent 
inflammatory insult – central or systemic – induces an exaggerated inflammatory 
response. 
Pioneering work in the ME7 prion disease mouse model of chronic 
neurodegeneration showed that during CNS neurodegeneration microglia exist in an 
atypical state of activation (Cunningham et al., 2003).  
Prion diseases, otherwise known as transmissible spongiform encephalopathies 
(TSEs), are a group of infectious progressive neurodegenerative diseases where the 
infectious agent is mis-folded prion protein which cannot be broken down. 
Pathological mis-folded prion protein seeds self-propagating mis-folding and 
recruitment of prion protein (Prusiner, 1982) leading ultimately to the demise of 
neurons with associated neuronal dysfunction, neuroinflammation, and clinical 
phenotype. The transmissible nature of prion disease makes it a useful tool for 
creation of animal models of neurodegeneration, including the ME7 prion disease 
mouse model which is created by injection of ME7-infected C57BL/6 brain 
homogenate into the brain.  
This model recapitulates key hallmarks of prion disease including extracellular 
amyloidosis, synaptic loss, microglial activation, neuronal death and mice show 
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progressive cognitive decline. Microglia were initially thought to be in pro-
inflammatory M1 state in prion disease, based on their morphology and the 
expression of inflammatory markers such as MHCI and CR3. There is a 10-fold 
increase in the number of microglia in the hippocampus of ME7 mice 23-weeks post-
inoculation compared with control animals. There were also CD8+ve T-lymphocytes 
and associated astrogliosis (Betmouni et al., 1996). However, elevated levels of anti-
inflammatory cytokine TGF-β were found along with very limited expression of 
archetypal pro-inflammatory cytokines IL-1β, IL-6, TNF-α (Cunningham et al., 2003, 
Cunningham et al., 2005). 
Cunningham et al. (2009) showed that subsequent peripheral injection with 
lipopolysaccharide, which mimics bacterial infection, resulted in exaggerated 
sickness behaviour in prion diseased mice compared with injected controls. This 
sickness behaviour was associated with dramatically exaggerated LPS-induced 
production of pro-inflammatory mediators by microglia, including IL-1β, IL-6 and 
TNF-α; there was also increased iNOS expression, increased neutrophil infiltration 
and increased apoptosis. However, the peripheral cytokine response was the same in 
prion diseased mice and control mice hence the exaggerated central pro-
inflammatory response to LPS and resulting sickness behaviours must be determined 
within the CNS. The increased proinflammatory capacity of microglia due to 
neurodegeneration is termed “microglial priming”  (Perry et al., 2007, Cunningham 
et al., 2009). 
The group also found that the degree of underlying disease pathology at the time of 
systemic inflammation influences the severity of the deficits induced by the same 
inflammatory insult; mice challenged with LPS 16-weeks post-ME7-inoculation had 
a significantly worse transient cognitive deficit than mice exposed to LPS just 12-
weeks post-ME7-inoculation (Davis et al., 2015). 
More recently research from the same group indicated astrocyte priming in ME7 
mice. There was astrogliosis visualised by increased GFAP expression in ME7 mice 
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and astrocytes in ME7 mice given intra-hippocampal IL-1β or TNF-α showed 
increased nuclear localization of p65 indicative of NFκB activation. This was 
associated with vast increase in astrocytic production of CCL2 and neutrophil 
chemoattractant CXCL1. TNF-α also induced T-cell chemoattractant chemokine 
RANTES (Hennessy et al., 2015). This indicates a “primed” neuroinflammatory state 
of the brain in general, not just in microglia, during neurodegeneration. 
The priming hypothesis is not just a peculiarity of systemic LPS insult, since 
peripheral viral infections also trigger exaggerated sickness in ME7 mice and in this 
case primed microglia produce an elevated type 1 interferon response (Field et al., 
2010). Nor is it a peculiarity of ME7 prion disease since microglial priming has now 
been demonstrated in alternative models of ageing (Chen et al., 2008) and CNS 
disease including models of AD, PD, tauopathies, and Wallerian degeneration (Sly et 
al., 2001, Lee et al., 2002, Kitazawa et al., 2005, Palin et al., 2008, Lee et al., 2010, Sy et 
al., 2011) (summarised in Table 3 and discussed below).  
Microglial priming is a functional definition, hence in 2015 Weighted Gene Co-
expression Network Analysis (WGCNA) was used to investigate microglial gene 
expression in mouse models of aging, Alzheimer’s disease (AD), and amyotrophic 
lateral sclerosis (ALS) and compared with microglia isolated from mice 4-hours post-
intraperitoneal LPS-injection in order to investigate whether or not microglial 
priming might be a homogeneous phenotype with a specific transcriptional signature 
(Holtman et al., 2015). The study demonstrated a transcriptional signature of 
microglial priming which was distinct from that of acutely LPS-induced microglia. 
Both LPS-induced and primed microglia showed increases in genes associated with 
immune and stress responses (innate immune receptor Tlr2, proinflammatory 
cytokine Il-1β, and chemokine Cxcl10). LPS-induced microglia were enriched with 
NFκB factor p65 (RelA) and genes associated with TLR and NLR signalling whereas 
primed microglia had a signature associated with Alzheimer’s disease signalling 
(Apoe), antigen presentation (MHC proteins), lysosomes and phagosomes suggesting 
that neurodegenerative conditions initiate a phagocytic microglial phenotype 
72 
 
(Holtman et al., 2015). Specifically, genes enriched in primed microglia included: Axl, 
a tyrosine kinase receptor involved in dampening the immune response, regulating 
cytokine secretion, clearing apoptotic cells and debris, and maintaining cell survival 
(Weinger et al., 2011, Chiu et al., 2013); Clec7a gene, encoding pattern recognition 
receptor dectin-1, a transmembrane receptor with intracellular immunoreceptor 
tyrosine-based activation (ITAM)-like motif – this receptor is associated with 
phagocytosis and increased cytokine and chemokine production (Tsoni et al., 2008); 
itgax, encoding CD11c, a subunit of complement component 3 receptor (Chiu et al., 
2013); Lgals3 (also known as Galectin-3 and Mac2) which is involved in phagocytosis 
(Rotshenker, 2009); Cybb, encoding pro-inflammatory oxidase Nox2 (Chiu et al., 
2013); and finally Csf1 encoding macrophage colony-stimulating factor (M-CSF) – a 
cytokine involved in microglial proliferation in chronic neurodegenerative conditions 
(Smith et al., 2013, Holtman et al., 2015). Microglial CD14 expression has also been 
associated with microglial priming in AD; it is capable of binding amyloid protein 
and LPS and is upregulated in AD (Fassbender et al., 2004, Liu et al., 2005).  
Mouse brain tissue from rTg4510 mice over expressing human P301L mutant tau 
transgene downstream of the tetracycline inducible CaMKIIα promoter indicated 
significant overlap with genes identified as markers of primed microglia (Holtman et 
al., 2015)  although not described in detail.  
Studies in old mice indicate age-related neuroinflammation. Microgliosis was 
characterised by altered morphology stained with tomato lectin, increased MHCII 
expression, and elevated IL-1β and TNF-α expression. LPS-injection impaired T-maze 
performance in mice at all ages but had a greater impact on older mice. Working 
memory deficits were associated with LPS-induced IL-1β, IL-6, IL-10, TNF-α and 
TLR2 expression which were all elevated in older LPS-injected mice compared with 
younger LPS-injected mice. It was later shown that CX3CL1 protein was reduced in 
older mice and that LPS insult enhanced CX3CR1 expression in young mice but 
caused a marked decrease in CX3CR1 in aged mice. Impaired CX3CL1–CX3CR1 
signalling corresponded with delayed recovery from sickness behaviour, prolonged 
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IL-1β induction and decreased TGF-β expression.  Impaired CX3CL1–CX3CR1 
mediated regulation, resulting in microglial activation, thus contributed to the 
exaggerated sickness response in aged mice compared with younger mice following 
peripheral LPS challenge (Henry et al., 2009, Wynne et al., 2010). 
Studies in Tg2576 mice which express mutant amyloid precursor protein (APP - 
K670N/M671L) showed mild microglial activation and pro-inflammatory cytokine 
expression in 6-month-old transgenic mice and more severe microglial activation in 
16-month-old transgenic mice compared with controls – the degree of microglial 
activation correlated with Aβ-plaque load. Intravenous LPS induced over-production 
of IL-1β in the brains of 16-month transgenic animals but not 6-month-old animals 
suggesting that the degree of microglial priming depends on the degree of underlying 
disease pathology. LPS-induced inflammation lead to an increase in Aβ burden (Sly 
et al., 2001), a result which has since been replicated in alternative models of AD 
(Sheng et al., 2003, Lee et al., 2008).  
An APP/PS1 model was crossed with a Col1-IL-1βXAT Cre-inducible model of 
osteoarthritis, a common medical condition with known inflammatory component 
which is associated with increased risk of dementia (Huang et al., 2015). The systemic 
inflammation associated with the model of osteoarthritis was sufficient to increase 
microglial activation and amyloid deposition, and the APP/PS1 x Col1-IL-1βXAT Cre 
inducible model had no detectable circulating IL-1β which might explain this result 
(Kyrkanides et al., 2011).  
Mice with presenilin 1 M146V knock-in mutation have increased soluble Aβ, though 
there are no deposits of aggregated Aβ, no differences in cytokine profile and no 
differences in the number of microglia in the hippocampus compared with wild-types 
at baseline. Peripheral LPS injection induced an exaggerated cytokine response; IL-
1β, TNF-α, IL-6 levels and iNOS expression were all elevated in PSmutK1 mice 
following LPS injection compared with LPS injected wild-types. Authors attribute the 
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exaggerated cytokine response to the expression of mutant PS1 in microglia rather 
than amyloid pathology (Lee et al., 2002).  
Intracerebral injection of LPS was seen to induce reduction of amyloid burden in 
mouse models of amyloidopathy. Reduced amyloid burden correlated with the dose 
of LPS (DiCarlo et al., 2001, Herber et al., 2004). This was likely due to increased 
phagocytic properties of LPS-induced microglia, these findings highlight the poor 
phagocytic capacity of microglia in the context of AD and highlight the important 
differences between central and peripheral LPS-injection. 
Taken together studies from amyloid models of AD indicate that amyloid pathology 
is sufficient to prime microglia; primed microglia are not fully activated and are 
inefficient at phagocytosis but subsequent inflammatory insult causes a dramatic over 
production of proinflammatory cytokines, especially IL-1β and is generally 
associated with increased disease amyloid pathology – but what about tau 
pathology? 
Kitazawa et al. characterised the temporal profile of the triple transgenic (3xTgAD) 
mouse model of AD (with APP K670N, M671L, PS1 M146V, Tau P301L mutations). The 3xTgAD 
mouse develops age-related Aβ plaques and NFTs composed of 
hyperphosphorylated tau and shows progressive microglial activation which 
correlated with extracellular Aβ deposition. LPS was administered at 4 months of age 
by intraperitoneal injection twice per week for 6 weeks (500 μg/kg) and tissue 
analysed 24 hours after the final injection. This chronic LPS regime dramatically 
increased microglial burden and induced 5-fold IL-1β expression in 3xTgAD mice 
compared with PBS treated counterparts. Levels of amyloid precursor protein (APP) 
and Aβ deposition were unaffected, however, LPS-treatment significantly impacted 
tau hyperphosphorylation – total tau levels were unchanged but staining with 
phosphorylation specific antibodies AT8 and AT180 was increased two-fold 
(Kitazawa et al., 2005). Further probing of the mechanism indicated that LPS-induced 
tau phosphorylation might be mediated by cdk5 through increased expression of co-
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activator protein p25. p25 is a cleaved fragment of p35, the constitutively expressed 
co-activator of CDK5 which exists near the plasma membrane and has a very short 
half-life whereas p25 is cytosolic and has a longer half-life. Elevated p25 levels and 
resulting cdk5 deregulation have been reported in post-mortem AD brain tissues 
(Patrick et al., 1999). The chronic LPS-induced phosphorylation of tau was reversed 
with cdk5-specific inhibitor Roscovitine. 
The same lab went on to investigate the effects of the same LPS protocol later in 
disease, when mice were 12 months old rather than 4 months. LPS-injection similarly 
did not alter Aβ-deposition but was associated with increased neuroinflammatory 
markers, increased phosphorylated and insoluble tau burden and working memory 
impairments measured by MWM. Increased tau phosphorylation at this late stage in 
disease was attributed to GSK-3β activation. Inhibition of GSK-3β rescued tau 
pathological markers without impacting neuroinflammatory markers (Sy et al., 2011).  
Hence studies in the 3xTgAD mouse model have demonstrated that systemic-LPS-
induced microglial activation increases tau pathology, however the acute 
neuroinflammatory response of 3xTgAD mice was not compared with that of LPS-
injected non-transgenic mice. Authors did comment that this chronic LPS regime was 
sufficient to induce tau pathology in control mice however data is not shown and 
therefore cannot be compared with 3xTgAD mice – hence this LPS-induced increase 
in tau pathology might be a response to neuroinflammation and not dependent on 
microglial priming.  
Furthermore, viral infection of the same 3xTgAD mice and wild type mice by injection 
of neuroadapted JHM strain of mouse hepatitis virus (MHV) into the hippocampus 
caused microglial activation and infiltration of macrophages and T-cells. There was 
no difference in acute immune response between transgenic and control mice 
however there were long term impacts: 4-weeks post-infection there was an increase 
in tau pathology in MHV-infected compared to sham-injected 3xTgAD mice 
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however, again, results were not compared with infected non-transgenic mice (Sy et 
al., 2011).   
Another study in the rTg4510 mouse, carrying the P301L mutation in tau, 
demonstrated age-related microgliosis (CD45-positive) in the cortex and 
hippocampus compared with control mice. Intracerebral LPS induced equivalent 
CD45-positive and Arginase-1-positive microgliosis in rTg4510 mice compared with 
control mice, however there was increased expression of microglial marker YM1. 
YM1 historically was associated with “M2 -alternatively activated” macrophages but 
it has also been known to display chemotactic activity for T lymphocytes, bone 
marrow cells, and eosinophils the precise function of this lectin is still unclear (Zhao 
et al., 2013, Rőszer, 2015). LPS also exacerbated tau pathology, further supporting the 
claim that a proinflammatory environment drives tau pathology in rTg4510 mice and 
not control mice. It remains to be seen whether this increased tau pathology reflects a 
difference in the neuroinflammatory response in rTg4510 mice compared with 
controls, as indicated by increased YM-1 expression or whether it is a result of 
increased vulnerability of mutant-tau-positive neurons to inflammation-induced tau 
phosphorylation. This study also used intracerebral injection of LPS rather than 
peripheral injection and hence does not tell us about the effects of systemic 
inflammation on tau pathology (Lee et al., 2010).  
As previously described (section 1.1.5 and 1.2.6) hTau mice show progressive 
accumulation of insoluble phospho-tau and associated microgliosis with increased 
levels of fractalkine, iNOS and CCL2. CD45-positive microgliosis was later shown to 
correlate spatially and temporally with the spread of tau pathology in the 
hippocampus and with memory deficit (Maphis et al., 2015b). hTau mice were 
crossed with fractalkine knock out mice to generate hTau-CX3CR1−/− mice which 
displayed exacerbated microgliosis and tau pathology. Intraperitoneal LPS injection 
(1 mg/kg or 10 mg/kg) resulted in a dose dependent increased tau phosphorylation at 
the phospho-thr231 (TG3) and AT8 epitopes in hTau mice compared with non-
transgenic control mice and a further increase in tau phosphorylation in hTau-
77 
 
Cx3cr1−/− mice. (Bhaskar et al., 2010). In a further study the group went on to show 
that adoptive transfer of purified microglia derived from hTau-Cx3cr1−/− mice was 
able to induce tau hyperphosphorylation in recipient non-transgenic mice, which 
could be blocked by an IL-1R agonist.  
Hence these data indicate that microglia are activated in tauopathy dementia but that 
they are still subject to immune-modulation by CX3CL1–CX3CR1 signalling. LPS 
induced increased tau phosphorylation in transgenic mice but not non-transgenic 
mice which was mediated via microglia and exacerbated by further microglial 
activation by ablation of CX3CL1–CX3CR1 signalling however the magnitude of the 
LPS-induced inflammatory response in hTau mice was not compared to that of non-
transgenic mice and hence, again, it remains unclear whether the increased tau 
hyperphosphorylation in mutant tau mice is the result of a differential inflammatory 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In conclusion, dementia is a major public health problem. The estimated global cost 
of dementia in 2015 was 818 billion US dollars and set to reach 1 trillion USDs by 2018 
(Wimo et al., 2017). In the absence of disease modifying treatments and with the 
rapidly ageing population this burden will only intensify. 
Tau protein is a microtubule associated protein which is implicated in many 
dementias where it becomes hyperphosphorylated and forms insoluble aggregates 
referred to as neurofibrillary tangles. The precise role of tau protein in 
neurodegeneration is unclear. However, the discovery of causative inherited 
mutations in the gene encoding tau protein indicate that tau dysfunction alone is 
sufficient to cause dementia. Identification of inherited mutations has also enabled 
the development of animal models of tauopathy dementia including the P301S mouse 
used here. 
Neuroinflammation is a robust hallmark of all dementias including tauopathy 
dementias. There is evidence that systemic inflammation is associated with increased 
risk of dementia. Those with dementia are prone to an exaggerated sickness response. 
Systemic inflammation, for example caused by infection, can cause delirium in 
patients with pre-existing dementia which might be underpinned by microglial 
priming in the brain. Evidence suggests that systemic inflammation and/or delirium 
exacerbate the rate of decline of dementia. Infection and systemic inflammation are 
potentially modifiable. Even just delaying the onset of dementia will have a huge 
positive impact in terms of reducing the socioeconomic burden and improving 




1.3.1 Project Aims & Objectives 
This project aims to use a known model of neurodegeneration which recapitulates 
key hallmarks of tauopathies including accumulation of hyperphosphorylated tau, 
neuronal loss and gliosis, to explore the effect of systemic inflammation on disease 
progression in a mutant tau mouse model of neurodegeneration with both 
pathological and behavioural outcomes.  
The hypothesis I will be testing is that over-expression of mutant tau protein is 
sufficient to influence the inflammatory status of the CNS and that this will in turn 
affect the response to systemic inflammatory insult.  
In order to address this hypothesis in the P301S mice, I will first characterise the 
temporal pathological profile as well as identify a behavioural measure of disease 
progression before examining the pathological and behavioural impact of 
intraperitoneal LPS-injection at two timepoints.   
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2 Chapter 2 – General Methods 
All analyses were blinded to genotype and intervention unless otherwise specified.  
2.1 Animals 
All procedures were performed in compliance with the UK Animals (Scientific 
Procedures) Act 1986 and University of Edinburgh regulations. Mice were bred, 
maintained and terminated in compliance with project license 60/4240. Animals were 
group-housed in environmentally-enriched cages within humidity and temperature 
controlled rooms, with a 12-hour light dark cycle, and access to food and water ad 
libitum.  
The P301S mouse line was originally generated in Cambridge as previously described 
(Allen et al., 2002). P301S mice over-expresses human mutant P301S tau under 
neuronal promoter Thy 1.2 on a C57BL/6J background. Mice were maintained as a 
homozygous colony. The same C57BL/6J strain were used as control mice throughout 
this thesis and will be referred to as ‘C57BL/6’ or ‘control’ mice. This is important 
since genomic and phenotypic analysis of different C57BL/6 strains have identified a 
number of genetic and phenotypic differences among strains, including SNPs in 
genes involved in CNS degeneration (Mekada et al., 2009, Simon et al., 2013). For 
behavioural tasks, age-matched control C57BL/6J mice were transferred to the home 
room at least two weeks prior to experiments in order to allow acclimatisation. All 
mice were earmarked prior to behavioural testing. 
Only female mice were used for all experiments to avoid fighting and injury since this 
is likely to influence performance on behavioural tasks and might also have an impact 
on pathology. Unpublished data from the lab has also demonstrated significant sex 
differences in the behaviour and pathology of P301S mice. 
The main phenotype of P301S mice is a progressive hind limb paralysis that is driven 
by loss of ventral spinal cord motor neurons. Animals were terminated when 20% 
body weight loss persisted for 48 hours and/or a phenotypic score of 4 was attained, 
as shown in Table 4.  
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Table 4 - P301S hind limb paralysis phenotype scoring system 
2.2 Behaviour 
Assessment of burrowing was performed in the home room. For all other behavioural 
tasks, mice were taken to an ‘experimental room’ 15 minutes prior to the task so that 
they could acclimatise to the new environment. 
2.2.1 Spontaneous Alternation T-maze 
The spontaneous alternation task has previously been used to detect working 
memory and spatial memory deficits. Measurement of spontaneous alternation in the 
T-maze relies on an innate reproducible behaviour of mice; when mice are placed at 
the start arm of a T-shaped maze (Figure 6A), mice will explore the maze, they will 
Score Description 
0 Normal 
1 Beginning of phenotype (typically observed from 4 months onwards). 
Animals develop a wobble in their movement and/or may show hind 
limb clasping reflex when hind end lifted, but no problems with feeding 
or drinking and still active. Begin weighing every 2-3 days. 
2 Movement is slower but still able to reach food and water. Start feeding 
mash and or gel. Continue weighing every 2-3 days 
3 Wobbling is pronounced, walking speed is slow. Weakness/poor motor 
control in one or both hind limbs. Tremor may be present and weight loss 
may now be evident. Still has righting reflex and still reach food. Begin 
daily weighing.  
4 Hind limb paralysis 
5 Mouse not walking at all, lost control/movement of both hind limbs and 
trembling. Marked loss of weight and possible eye inflammation. No 
righting reflex and the mouse cannot stand upright therefore unable to 
reach food and/or water 
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travel towards the two goal arms and either turn left or right. When replaced in the 
maze, seconds to minutes later, their natural tendency is to explore the previously un-
explored arm of the maze, assuming successful recollection of their previous visit and 
this is recorded as a correct alternation (Dember, 1989, Deacon et al., 2006). 
Spontaneous alternation relies on working memory and spatial memory, and the 
alternation task has been used previously to detect lesions of the hippocampus 
(Roberts et al., 1962), septum (Douglas et al., 1966), and prefrontal cortex (Divac et al., 
1975).  
 Apparatus 
The apparatus is a plastic T-shaped maze with black walls 20 cm high and a white 
base. The arms are 30 cm length by 7 cm width (see Figure 6A). There is a removable 
central partition and two guillotine doors. Bedding taken from a cage of mice of the 
opposite sex was spread in the goal arms to increase motivation to explore.  
 Acclimatisation 
During the acclimatisation period, mice were first taken to the experimental room and 
handled for five minutes each. The next day mice were introduced to the apparatus 
for the first time with cage mates to encourage exploration. The following day mice 
underwent a single trial run prior to testing.  
 Protocol 
Mice were tested weekly between 8 and 22 weeks of age through application of the 
following protocol.  
“Decision trial”: With the central partition in place, the mouse was placed at the base 
of the start arm always facing away from the goal arms. The mouse travelled down 
the start arm and either turned left or right; the guillotine door was closed and the 
mouse was allowed to explore the first goal arm for 30s. Then the mouse was removed 
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and placed in a holding cage for a 20 second interval. The central partition and the 
guillotine doors were removed. The first goal arm was recorded, that is, left or right.  
“Alternation trial”: The mouse was returned to the starting position for a second trial, 
travelled up the starting arm and the decision to turn left or right was recorded before 
returning the mouse to the home cage. If on the alternation trial the mouse chose the 
arm not visited before this was recorded as a correct alternation. The decision to turn 
was only counted once all four paws cross the line of the goal arm. This whole 
protocol was repeated 5 times per animal per session.  
 Statistics 
The number of correct alternations made by each mouse were converted into 
percentage correct alternations and a mean determined for each group using this 
formula: 
= (∑ (
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑎𝑙𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛𝑠 
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑙𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛 𝑡𝑟𝑖𝑎𝑙𝑠 
)  𝑥 100) /𝑛 
The percentage of correct alternations made by individuals was used for T-test 
comparison of the C57BL/6 within-time-point mean performance to the overall mean 
of the performance at all other time points. 
2.2.2 Burrowing  
Burrowing is another innate behaviour in mice and one that is often impaired during 
CNS disease. In the wild, mice create burrows by displacing soil; the burrowing task 
quantifies this behaviour by measuring displacement of food from a tube. Burrowing 
is reduced by acute illness (LPS) and the burrowing task has previously been used to 
detect hippocampal and medial prefrontal cortex lesions (Deacon et al., 2002, Deacon 




A tube measuring 6.8 cm diameter and 20 cm length, with one closed end, was filled 
with 425g of dried food pellets. The open end of the tube was elevated 3 cm. The tube 
was placed in the back, right corner of a cage along the longest edge with wood 
chippings on the cage floor and bedding in the back-left corner (see Figure 6C for 
experimental set up). Mice were provided with water ad libitum. 
 Acclimatisation 
For the first two nights of the acclimatisation phase mice were allowed to explore the 
apparatus along with their cage mates. This was followed by several nights of 
individual burrowing acclimatisation.  
 Protocol 
Each mouse had its own experimental cage and was returned to the same cage for 
each trial; the chippings on the cage floor were not changed so that the mouse would 
recognise its own scent. Burrowing cages were kept on a cage rack in the same room 
as home cages to minimise disturbance. Mice were transferred to their experimental 
cage with burrowing apparatus at 5pm. The dark cycle begins at 7pm and ends at 
7am. At 9am mice were returned to their home cage. The cage lid was used to filter 
the food pellets from the chippings of the cage floor and chippings were returned to 
the cage floor. The food pellets remaining in the tube and food pellets displaced from 
the tube after the over-night burrowing session were weighed, recorded and returned 
to the tube. Both measurements were recorded as a mistake-proofing precaution. Any 
food that had been eaten overnight was replaced, then the tube was topped up to 




The total weight of food burrowed from the tube measured in grams was converted 




)  𝑥 100) /𝑛 
“Percentage burrowed” data was used for statistical analysis. Initial inspection of the 
longitudinal change in burrowing behaviour identified three distinct phases (see 
Figure 6D): an initial phase of improving performance (phase 1), a second phase of 
stable performance (phase 2), and a final phase of declining performance (phase 3). 
Piecewise mixed effects linear regression was therefore used to evaluate genotype 
and age (weeks) with random effects for individual animals. Cut points were as 
follows: phase 1, 8-12 weeks of age; phase 2, between 12-17 weeks of age; phase 3, 
between 17-22 weeks of age. 
2.2.3 Horizontal Bar Task 
The horizontal bar task is a physical task which gives a measure of muscle strength 
and coordination (Cunningham et al., 2005). 
 Apparatus 
The apparatus consists of a metal bar 0.2 cm in diameter, 26 cm long, which is elevated 
19.5 cm between two plastic pillars. There is a metal mesh on the platforms to enable 
grip. See photograph Figure 6E. The horizontal bar task was carried out in a large 
chamber with 25cm high walls. 
 Acclimatisation 
During the acclimatisation period, mice were taken to the experimental room and 
were handled for 5 minutes each. The next day mice were introduced to the 
apparatus. Pilot data from the first cohort demonstrated an initial difference in 
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performance between P301S mice and controls. Mice in every experiment thereafter 
were subjected to ‘training exposures’ as required to minimise this initial difference. 
During these training sessions, mice were first placed with all four paws on the bar 
facing a platform and were encouraged to crawl along the bar whilst supported by 
the tail. Later, mice were placed with only fore-paws on the bar and were encouraged 
to raise their hind limbs.  
 Protocol 
Mice were suspended by the tail above the metal bar and allowed to grip the bar with 
their forelimbs and the tail was gently released leaving them suspended in the centre 
of the bar, hanging by their forelimbs. Mice then had to crawl along the bar to reach 
one of the platforms at either end. A maximum of 60 seconds was allowed to complete 
the task. A healthy mouse will complete this task in approximately 3 seconds (once it 
has learned the optimal way to cross the beam) however as the P301S mice develop 
hind limb paralysis the task becomes more difficult, they take longer to complete it 
and eventually they are unable to complete the task and fall off the bar. The time 
taken for the mouse to either reach the platform or fall from the bar was recorded 
using a stop clock and converted to a score between 1-10 according to the criteria 
described in Table 5. 
A previously published horizontal bar scoring method recorded only the time spent 
on the bar prior to falling up to a maximum of 60 seconds. If the mouse did not fall 
because it reached a supporting column, it attained the maximum score of 60 
(Cunningham et al., 2005). Here the scoring method was modified to increase 
sensitivity. Whereas all mice that reached the platform in the published method 
attained the same score, here the time taken for mice to reach the platform was also 
recorded and used as part of the score such that the quicker mice reached the 
platform, the higher their score. The horizontal bar task was repeated three times per 
mouse per session. Horizontal bar performance of P301S mice was assessed weekly 
from 9 weeks of age until they were sacrificed at 20-22 weeks of age.  
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Score Time to Fall (s)  Score Time to Platform (s) 
0 0-5  10 0-5 
1 6-10  9 6-10 
2 11-20  8 11-20 
3 21-40  7 21-30 
4 41-59  6 31-59 
5 60  5 60 
Table 5 - Horizontal bar task scoring system 
 Statistics 
For each trial the time taken to reach the platform or time taken to fall from the bar 
were converted to a score as described above (Table 5) and the mean score for that 
session was calculated for each mouse (three trials per session). This “within animal” 
mean was used as the primary data in statistical analysis. Piecewise linear regression 
was used with random intercept for ID to compare the trajectory of the longitudinal 
performance of the two or four groups. 
2.3 Histochemistry 
2.3.1 Tissue Collection for Histochemistry 
Mice were sacrificed by a lethal intraperitoneal injection of 0.3 ml/100 g body weight 
of sodium pentobarbital (euthetal). They were transcardially perfused with 30-50 ml 
of 1% phosphate buffered saline (PBS) using a peristaltic infusion pump. Animals 
were then perfused with 50-100 ml 4% paraformaldehyde (PFA) in 1% PBS. Brains 
and cervical spinal cords (c5-c7) were removed and post fixed in 4% PFA over night 
before cryoprotection in 25% sucrose in PBS solution. Brains and spinal cords were 
frozen and cut on a cryostat at 25µm and 16 µm respectively (Leica CM1950). Sections 
were mounted onto superfrost slides (VWR, UK) and stored at -20 °C whilst being 
collected and then transferred to -80 °C for long term storage. 
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2.3.2 Cresyl stain 
Slides were defrosted and air dried for 1 hour. Serial dehydration in 70%, 95% and 
then 100% ethanol (5 minutes each), was followed by 20 minutes in 50/50 
chloroform/ethanol to de-fat sections. Slides were then rehydrated in 95%, then 70% 
ethanol, and then distilled water (5 minutes each). Sections were stained in cresyl 
violet (Fisher Scientific) for 2 hours. Before the stain was differentially removed to 
achieve optimal staining and dehydrated in 70% then 95% ethanol (2.5 minutes each), 
then 100% ethanol (3 minutes) and finally xylene (5 minutes) before mounting with 
DPX (Fisher Scientific). 
2.3.3 Fluorescent Staining 
Slides were allowed to defrost and air dry, then a hydrophobic barrier was drawn 
around the section (PAP pen, molecular probes, UK) before two ten minute washes in 
1% PBS, on a shaker. Sections were blocked and permeabilised with 3% normal serum 
(goat or horse depending on secondary antibody, S-1000 or S-2000, Vector 
Laboratories) and 0.2% Triton-X (X-100, Sigma) as required, in PBS (~300µl per slide) 
for 1 hour. They were incubated with primary antibodies (see relevant chapters for 
details) with 1% blocking serum in 1% PBS or 0.2% Tx-PBS, as required over-night. 
Three ten minute washes in 1% PBS on a shaker were followed by a 1.5-hour 
incubation with secondary antibodies (see relevant chapters for details), with 1% 
blocking serum and Bis-benzamide (1:4000, B1155, Sigma Aldrich) in 1% PBS. If a 
biotinylated secondary was used, bis-benzamide was omitted from the secondary 
antibody step and included instead with the tertiary antibodies (see relevant chapters 
for details). Slides were washed in PBS, as before, to remove secondary antibodies 
and then incubated with a tertiary antibody and bis-benzamide in 1% PBS for 1.5 
hours. Slides were washed twice in 1% PBS (10 minutes) and then twice in TNS (Tris 
non-saline solution) for 10 minutes, and then stayed in TNS until mounting in 
fluorosave reagent (345789, Millipore). Slides were stored in the dark at 4 °C.  
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2.3.4 DAB Staining 
Slides were defrosted and air dried before quenching of endogenous peroxidase in 
1% H2O2 in methanol followed by two five minute washes in 1% PBS. For antigen 
retrieval slides were incubated in citric acid solution (2.1g in 1L ddH2O, pH 6) for 10 
minutes. Following two five minute washes in 1% PBS, sections were blocked with 
10% normal goat or horse serum in 1% PBS (~300µl per slide) for 1 hour. They were 
incubated with primary antibody as required (see relevant chapters for details), with 
10% NHS in 1% PBS over-night. Three ten minute washes in 1% PBS on a shaker were 
followed by incubation with biotinylated secondary antibody for 1.5 hours (see 
relevant chapters for details). Three ten minute washes in PBS were followed by 
incubation in ABC-peroxidase solutions containing Reagent A (1: 200, Avidin DH 
solution) and Reagent B (1: 200, biotinylated enzyme), both also from the 
VECTASTAIN UNIVERSAL Elite ABC Kit (Vector Laboratories, PK-6200) in 1% PBS 
for 45mins.  
After thorough washing the reaction product was visualized using avidin-biotin and 
3′,3′-diaminobenzidine (DAB) as the chromagen (DAB kit, Vector Laboratories). 
Slides were serially dehydrated in 70%, 80%, 95% and then 100% alcohol (5 secs, 5 
secs, 5 secs and 30 secs respectively) followed by two 2 minute washes in xylene. 
Slides were mounted with DPX mounting media. Slides were stored at room 
temperature.   
2.4 Imaging of Brain and Spinal Cord 
A Zeiss upright A1 microscope was used in conjunction with Axiovision 4.8 software 
and a digital camera unless otherwise stated.  
When imaging the brain, the camera was rotated such that the surface of the brain 
was aligned with the edge of the image (see Figure 3).  Images of the superficial layers 
of the motor cortex were taken 0.75-1.25 mm from the midline of sections identified 
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as 0.5-2.3 mm rostral of bregma. Multiple hemispheres were imaged per animal; 
specific details are given below or within each relevant section.  
Lamina 9 of the spinal cord was identified using anatomical features and reference to 
the online Allen Brain Atlas, which includes a mouse spinal cord reference atlas (see 
Figure 3). The camera was aligned with the white- / grey-matter boundary. 
 





2.5 Automated Image Processing and Data Acquisition using 
ImageJ/Fiji software – Percentage area containing positive 
signal 
ImageJ/Fiji software (Schindelin et al., 2012, Schneider, 2012)  was used for automated 
image analysis. ImageJ is commonly used image analysis software and Fiji is a version 
of ImageJ with additional plugins, which is freely available to download. 
A template macro (a kind gift from Dr Mélissa Cizeron) was used to batch process 
images. The template macro included steps for recognising and opening all “.tif” files 
within a specified input folder, duplicating them and saving the duplications with a 
new name in a chosen output folder such that any modifications to the images during 
the processing did not overwrite the original images.  
The macro was edited to include the following additional steps: 1) Subtract the 
background from the duplicated images; 2) Impose an intensity threshold; 3) Create 
a binary mask; 4) Select an area of interest; 5) Determine the percentage of the selected 
area containing positive signal. 
The “Subtract backround” tool removes smooth continuous background based on a 
“rolling ball” algorithm. If one were to plot the coordinates of a cross section of the 
image (x axis) against the grayscale intensity (y axis) as illustrated in Figure 4 (Image 
J/FIJI documentation - https://imagej.nih.gov/ij/docs/guide/user-guide.pdf) and if one 
were able to roll a ball of a given radius along the profile of the plot, then the troughs 
reachable by the ball are the background to be subtracted. Subtraction of the 
background minimises the false positives detected when using of the threshold tool.  
The threshold tool sets upper and lower grey-scale threshold values (between 0-255) 
and allows creation of a binary image or “mask”.  
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An area of interest was selected and the percentage area positive signal was 
determined (defined in Analyze > Set measurements > Area Fraction). 
Parameters were determined by iterative optimisation on a sample of randomly 
selected images prior to batch processing. 
Figure 4 - “Subtract Background: This command uses a ‘sliding paraboloid’ or a legacy ‘rolling ball’ algorithm that 
can be used to correct uneven illuminated background as shown in the profiles (Analyze. Plot Profile [k]) below 
each image. Rolling ball radius should be set to at least the size of the largest object that is not part of the 
background.”  Image and caption accredited to Image J/FIJI documentation  
(https://imagej.nih.gov/ij/docs/guide/user-guide.pdf 
2.6 qPCR 
2.6.1 Tissue collection for qPCR 
C57BL/6 and P301S mice were sacrificed at 16 weeks of age 4-hours post 
intraperitoneal injection with LPS or saline solution. Mice were euthanized by a lethal 
intraperitoneal injection of 0.3 ml/100 g body weight of sodium pentobarbital 
(euthetal). Blood samples were immediately collected by cardiac puncture whilst the 
heart was still pumping – a 23-gauge needle attached to a 2-ml syringe was inserted 
into the right atrium with the bevelled edge down and the atrium gently lifted to 
encourage blood flow. Blood samples were spun at 6,000 rpm to remove cells. Pellet 
and supernatant were separated and instantly frozen on dry ice. Meanwhile, brain 
and spinal cord (c5-c7) were rapidly removed. Brains were cut along the midline and 
then the cortex carefully dissected out, using a scalpel. Approximately 30 µg of 
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cortical and spinal tissue was collected. Samples were placed in Eppendorf tubes and 
frozen on dry ice and were stored in the -80°C freezer. Brain and spinal cord samples 
were used for gene expression assays. 
2.6.2 RNA Isolation 
The frozen samples and labelled Precellys lysing tubes were placed on dry ice. 
Samples were weighed to ensure each lay in the range of 20–40 mg and transferred 
immediately to lysis tubes.  Samples were lysed and homogenised in 1ml of QIAzol 
Lysis Reagent (Cat No./ID: 79306, Qiagen, Crawley, UK) using the Precellys ®-24 
high-throughput tissue homogenizer – brain samples were spun at 5000 rpm for 15 
second twice, and spinal cords were spun four times because of the high fat content. 
Samples were left at room temperature for 5 minutes and then transferred to new 
labelled tubes.  
Total RNA was extracted from brain and spinal cord samples using Qiagen RNeasy 
Mini Kit (Cat No./ID: 74104 Qiagen, Crawley, UK) in accordance with manufacturer’s 
instructions. 200µl chloroform was added and samples shaken for 15 seconds before 
resting at room temperature for 2-3 minutes. Samples were centrifuged at 12000 x g 
for 15 minutes at 4°C and then the clear aqueous phase was transferred to a new tube. 
600µl of 70% ethanol was added to the sample and vortexed. 700µl of the sample was 
transferred to a labelled RNeasy mini spin column with a 2-ml collection tube. 
Columns were centrifuged for 15 s at 8000 x g and flow-through discarded. This was 
repeated with the remaining sample and flow-through discarded again. 700µl of 
Qiagen Buffer RW1 was added to the column, centrifuged for 15 s at 8000 x g and 
flow through discarded as before. 500µl Qiagen Buffer RPE was added, centrifuged 
for 15 s at 8000 x g and flow through discarded. This step was repeated and the 
second-time columns were spun for 2 mins to dry. Columns were placed into a new 
collection tube, 30µl of RNase-free water was added and columns were centrifuged 
at 8000g for 2 minute to elute RNA. The eluate was then added onto the column again 
and centrifuged again to increase the yield.  
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2.6.3 DNase Digestion 
TURBO DNA-free™ Kit, (Ambion Life Technologies), was used to remove DNA 
contamination. 3µl DNase buffer and 1µl DNase 1 (TURBO DNA-free™ Kit, AM1907) 
was added to each 30µl sample for DNase digestion at 37 °C for 30 minutes on the 
heat-block. 6µl of DNase inactivation reagent was added and samples left at room 
temperature for 5 minutes. Samples were centrifuged at 10,000 rpm for 5 minutes and 
supernatant was transferred to a fresh tube. RNA yields were determined by 
spectrophotometry using the NanoDrop® ND-1000 (Thermo Scientific). Quantified 
RNA was stored at −80°C until cDNA synthesis and PCR assay. 
2.6.4 Reverse Transcription – RNA to cDNA 
Thermo Scientific DyNAmo cDNA Synthesis Kit was used for reverse transcription 
as per kit instructions. 500ng of RNA is required for the reaction (for IL-1β 750ng RNA 
was converted); the volume of sample required was calculated from the concentration 
and made up to a final volume of 6µl with nuclease free water. 2µl of 80 µg/µl 
Random Hexamers was added. Samples were incubated in a BioRad PCR machine 
for 5 minutes at 65°C and then placed on ice for 2 minutes. 
12µl master mix (containing 10µl of 2 x RT Buffer and 2µl M-MuLV RNase H+ reverse 
transcriptase) was added to samples. PCR tubes were placed in a C1000™ Thermal 
Cycler PCR machine (Bio-Rad Laboratories, Inc). Dynamo cycling conditions as 
follows: Hot lid 105°C 30s, 25°C for 10 minutes, 37°C for 40 minutes, 85°C for 300 
seconds. Samples were held at 4°C until collection and then stored at −20°C until 
assay.  
2.6.5 Gene Expression Assay by Taqman 
96-well plates were used for quantitative (q)-PCR of brain and spinal cord tissue from 
C57BL/6 and P301S mice treated with either saline or LPS by real-time PCR with 
TaqMan gene expression assay. There were 4 groups (C57BL/6 + Saline, C57BL/6 + 
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LPS, P301S + Saline and P301S + LPS) and 6 animals per group. Brain and spinal cord 
tissue was analysed from each animal and triplicates of each sample were required 
hence samples were split across two plates. Plate design is illustrated in Figure 5. 
 
The following gene expression assays were used (Thermo Fisher Scientific): GFAP, 
(Mm01253033_m1), CD11b (Mm00434455_m1) and IL-1β (Mm00434228_m1). The 
levels of GFAP and CD11b mRNA were determined relative to the endogenous 
control gene HPRT (Mm01545399_m1) in duplex reactions. However, due to the 
relatively low abundance of IL-1β mRNA levels were compared to HPRT in 
singleplex gene expression assays. 
For duplex reactions, each well had 20µl total volume which included: 10µl Taqman 
iQ Supermix (Cat. no:1708862, BioRad; iQ Supermix contains dNTPs, 6 mM MgCl2, 
50 U/ml hot-start iTaq™ DNA polymerase); 1μl of target gene expression assay; 1µl 
 
Figure 5 - Gene expression assays - plate design. Brain and spinal cord tissue from C57BL/6 and P301S mice 




of HPRT gene expression assay; 7µl of PCR water; and 1µl cDNA. For singleplex IL-
1β gene expression assay 1µl of HPRT assay was replaced with an additional 1µl of 
PCR water, and for singleplex HPRT assay 1µl of target gene expression assay was 
replaced with an additional 1µl of PCR water. 
A master-mix was made including all components apart from the cDNA. The master-
mix was then pipetted into labelled tubes; 57µl per tube – enough for triplicates. 3µl 
cDNA was added to each tube. The cDNA sub-master-mix was pipetted up and down 
to mix and was then pipetted into triplicate wells.  
An adhesive film was used to seal the plate before qPCR was performed using Bio 
Rad CFX96 Real‐Time PCR Machine. Forty cycles were run with the following 
conditions: 3 minutes at 95°C and for each cycle 15 seconds at 95°C to denature and 
50 seconds at 60°C for transcription.   
2.6.6 Quantification of gene expression 
The relative abundance of mRNA in the four groups was calculated by the 
comparative CT method as follows: 
𝑅𝑄 =  2(−∆∆𝐶𝑇) 
𝑅𝑄 =  2−(∆𝐶𝑇(𝐺𝑂𝐼)−∆𝐶𝑇(𝐻𝑃𝑅𝑇)) 
RQ =  2−((𝐶𝑇(𝐺𝑂𝐼)𝑆𝑎𝑚𝑝𝑙𝑒 𝐴−𝐶𝑇(𝐺𝑂𝐼) 𝑅𝑒𝑓−(𝐶𝑇(𝐻𝑃𝑅𝑇)𝑆𝑎𝑚𝑝𝑙𝑒 𝐴− 𝐶𝑇(𝐻𝑃𝑅𝑇)𝑅𝑒𝑓) 
Where RQ is the relative quantity or fold change, CT(GOI) is the CT value of the gene 
of interest, CT(HK) is the CT value of the house keeper or internal control, CT( )Sample A 
refers to the CT value of an individual and CT( )Ref refers to the average CT value of the 




Data clean-up: rodents were excluded where the CT(HK) was more than 3 SD from 
the mean of the group but the CT(GOI) was not as this implies a technical error. Mixed 
effects linear regression with random intercept for ID was used for primary analysis 
of RQ values. To investigate the potential influence of outliers a sensitivity analysis 
was run. Individuals with RQ more than 3 SDs from the mean were excluded, new 
CT(GOI)Ref and CT(HK)Ref were determined and the RQ recalculated. 
2.7 Solutions 
PBS: 137mM NaCl; 2.7mM KCl;10mM Na2HPO4; 1.8mM KH2PO4; pH=7.4 adjusted 
with HCL 
PFA: 4% Paraformaldehyde in 1% PBS 




3 Chapter 3 – Characterising the P301S mouse 
3.1 Introduction 
Dementia and Alzheimer disease (AD) were the leading cause of death in England 
and Wales in 2015 (ONS, 2016). Tau protein is implicated in AD. In tauopathy 
dementias such as frontotemporal dementia (FTD), corticobasal degeneration (CBD), 
progressive supranuclear palsy (PSP) and Pick’s disease (PiD) tau becomes 
hyperphosphorylated, forms insoluble intracellular aggregates and ultimately leads 
to the demise of neurons. The realisation that mutations in tau protein are sufficient 
to cause dementia (Clark et al., 1998, Hutton et al., 1998, Poorkaj et al., 1998, Spillantini 
et al., 1998) led to the development of animal models of tauopathy (discussed in 
section 1.1.5), including the P301S mouse model used in this thesis, which expresses 
human mutant tau under neuronal Thy 1.2 promoter.  
Previous work using this model demonstrated that the P301S mouse accurately 
recapitulates many of the pathological features of tauopathy, including 
hyperphosphorylation and aggregation of pathological tau throughout the CNS and 
neuronal loss, astrogliosis and microgliosis in the spinal cord (Allen et al., 2002, 
Bellucci et al., 2004) along with age-related, region specific cortical neuronal loss 
(Hampton et al., 2010). Abnormal ultrasonic vocalisations (USVs) have also been 
identified in P301S mice as early as postnatal day 3 and enhanced motor and 
exploratory activity in the openfield at 8 weeks of age (Scattoni et al., 2010). P301S 
mice develop a gradual hind-limb paralysis as a result of neuronal loss in the spinal 
cord. 
Here I aimed to determine a detailed temporal profile of disease-associated 
behavioural and pathological changes: firstly to identify an appropriate behavioural 
task which would accurately and non-invasively reveal the progressive trajectory of 
the disease in P301S mice; secondly to use this task to determine the longitudinal 
behavioural profile of the P301S mouse compared with control mice; thirdly to 
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investigate key pathological hallmarks – neuronal loss, astrogliosis and microgliosis 
at multiple time points throughout the trajectory of the disease.  
These experiments will provide key details that will inform the timing of 
interventions in future experiments. 
3.2 Methods 
3.2.1 Behaviour  
This chapter aimed to identify a behavioural task that would provide a non-invasive 
tool to monitor the trajectory of the disease in P301S mice. To detect a disease-related 
decline in performance of P301S mice it is necessary to identify an appropriate 
behavioural task which meets the following criteria: control mice must be able to 
maintain a steady baseline performance so that any difference in performance 
between controls and P301S mice is necessarily the result of the disease; P301S mice 
must be able to achieve a steady initial baseline performance; the task must reliably 
and reproducibly expose a disease-related decline in performance in P301S mice 
compared with control mice.  
In order to identify an appropriate behavioural task to capture the longitudinal 
profile of the P301S mice, three behavioural cohorts were tested on two of three 










Genotype C57BL/6 P301S C57BL/6 P301S C57BL/6 P301S 
<20 14 16 15 17 15 15 
21 14 16 12 14 12 12 
22 14 16 7 9 7 7 
Table 6- Animals used in chapter 3 - characterising the longitudinal behavioural profile of P301S mice. 
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3.2.2 Histochemistry  
Cresyl violet neuronal staining was performed on brain sections as described in 
section 2.3.2.  Immunohistochemistry was performed for GFAP-positive astrocytes 
and IBA1-positive microglia in brain and spinal cord tissue as described in sections 
2.3.3 and 2.3.4 and either visualised by fluorescent antibodies or by DAB staining. 
Details of antibodies used are given in Table 7. 
3.2.3 Imaging, Quantification and Statistics 
 NeuN in the Brain 
 Imaging  
Fluorescent images were taken of two NeuN-stained cortical hemispheres per animal 
as described in section 2.4, at 20x objective.  
 Quantification  
Cell counts were conducted in each hemisphere using Zen 2011 software; two digital 
areas 150 μm x 150 μm were carefully aligned with the pial membrane such that 
counts were conducted in the first 150 μm of the superficial motor cortex. The 
“Events” tool was used to keep track of counted cells. Where the border of the 
counting area bisected a cell only cells with more than half of the soma inside the area 
were counted.  
 Statistical Analysis 
Cell counts were converted to cells per mm2 in Excel and this “Cells per mm2” data 
was used for statistical analysis. Mixed effects linear regression with random 
intercept for animal ID was used for within time-point comparison of P301S mice 























































































































































































































































































































































































































































































































































































 Cresyl Stain in the Brain:  
 Imaging 
Brightfield images of cresyl violet-stained sections were taken as described in section 
2.4 at 20x objective, with an exposure 12 ms.  
 Quantification 
Counts were conducted in the first 150 μm using Zen 2011 software as described for 
NeuN-positive cell counts. Both hemispheres from a minimum of 2 sections were 
counted per animal (total of 4 hemispheres were imaged per animal).  
 Statistical Analysis 
Raw cell counts were converted to cells per mm2 in Excel. The summary data 
indicated three possible options for the trajectory of decline in cell density in P301S 
mice:  
1) a linear decline in cell numbers between 8 and 20 weeks;  
2) a bi-phasic decline, whereby there is a steady phase up until 10 weeks of age 
followed by a progressive decline until 20 weeks;  
3) a tri-phasic decline whereby there is a steady stage from 8 to 10 weeks followed by 
a progressive neuronal loss from 10 to 12 weeks and this is followed by a plateau 
between 12-16 weeks. Three linear mixed effects models with random effects for 
individual animals were fitted in order to test these three models and the Bayesian 
Information Criteria (BIC) was used to indicate the appropriateness of the model. 
Comparison of the three models using the BIC was done by Dr Pete Connick using 
STATA software. C57BL/6: n=4, P301S: 8wk n=5, 9wk n=7, 10wk n=7, 11wk n=4, 12wk 
n=5, 16wk n=5 20wk n=5. 
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 Astrogliosis in the Brain: GFAP Stain 
 Imaging 
Fluorescent images of the motor cortex from brain sections stained for glial fibrillary 
acidic protein (GFAP) – a marker of reactive astrocytes – were taken with 20x 
objective and 810 ms exposure.  
 Quantification 
Manual cell counts were conducted, using Axiovision 4.8 software. A digital area 150 
μm x 300 μm was carefully aligned with the pial membrane such that counts were 
conducted in the first 150 μm of the superficial motor cortex. Both hemispheres from 
a minimum of 2 sections were counted per animal. Counts were converted to cells per 
mm2 and these data used for statistical analysis (See section 3.2.3.7). C57BL/ 6; pooled 
n=8 (8 weeks n=2, 12 weeks n=1, 20 weeks n=5), P301S; 8 weeks n=5, 9 weeks n=5, 10 
weeks n=5, 11 weeks n=5, 12 weeks n=5, 16 weeks n=5, 20 weeks n=4. 
 Astrogliosis in the Spinal Cord: GFAP Stain 
 Imaging 
Bright field images were taken of lamina 9 of GFAP stained spinal cord sections, 
visualised by DAB. Sections were imaged at 20x objective. An average of 4 images 
were taken per animal (min = 3, max = 5).  
 Quantification 
GFAP-positive cell counts were conducted using Zen 2011 software. A digital area 
400 μm x 200 μm was positioned in the centre of the image and counts conducted 
therein using the “Events” tool used to keep track of counted cells. Cell counts were 
converted to cells per mm2 in Excel and this data used for statistical analysis (See 
section 3.2.3.7). C57BL/6 n=8, 8 weeks n=4, 9 weeks n=4, 10 weeks n=3, 11 weeks n=4, 
12 weeks n=5, 16 weeks n=5, 20 weeks n=4. 
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 Microgliosis in the Brain: IBA1 Stain 
 Imaging 
Brightfield images were taken of IBA1-DAB stained motor cortex. Both hemispheres from a 
minimum of 2 sections (total 4 hemispheres) were imaged per animal. 
 Quantification 
Cell counts were conducted using Zen 2011 software, within two digital areas each 200 x 200 
µm. Cells were only counted if there was a clear cell body. Cell counts were converted to cells 
per mm2 and these data used for statistical analysis (See section 3.2.3.7). C57BL/6 n=13, 8 
weeks n=6, 9 weeks n=4, 10 weeks n=6, 11 weeks n=5, 12 weeks n=5, 16 weeks n=6, 20 weeks 
n=6. 
 Microgliosis in the Spinal Cord: IBA1 Stain 
 Imaging 
Images of the whole IBA1 DAB-stained spinal cord were generated by taking multiple 
brightfield images at objective 20x and exposure 1 ms using the Panavision tool in 
Axiovision 4.8 software and manually stitching them together.  
 Quantification 
IBA1-positive cell counts were conducted using Zen 2011 software in three digital areas 200 
µm x 200 µm positioned over lamina 9 of the ventral horn. Microglial cells were counted if 
there was a clear cell body. Cell counts were converted to cells per mm2 and these data used 
for statistical analysis (See section 3.2.3.7). (C57BL/6 n=15, 8 weeks n=4, 9 weeks n=3, 10 weeks 
n=7, 11 weeks n=4, 12 weeks n=3, 16 weeks n=5, 20 weeks n=4). 
 Statistical Analyses 
Mixed effects linear regression with random intercept for animal ID was used for 
within time-point comparison of P301S mice with pooled C57BL/6 mice.  
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To investigate the trajectory of astrogliosis and microgliosis in P301S mice mixed 
effects linear regression with random intercept for animal ID was used and a dummy 
variable was created for age in weeks to re-centre data. 
3.3 Results 
This project aims to use the P301S mouse as a model of neurodegeneration, to 
determine whether systemic inflammation can influence the trajectory of disease 
progression. In order to answer this question, a robust understanding of the usual 
trajectory of disease progression in this mouse model is required, hence, an 
appropriate behavioural task must be identified, and appropriate pathological 
readouts defined. 
3.3.1 Behaviour 
 Spontaneous alternation 
Spontaneous alternation of P301S and C57BL/6 mice in the T-maze was tested weekly. 
Most animals alternated in the T-maze at above chance levels, although visual 
inspection of weekly performance among C57BL/6 mice showed marked apparent 
variability (Figure 6B). Comparing the C57BL/6 within-time-point mean performance 
to the overall mean of the performance at all other time points, statistically significant 
differences were seen at weeks 9, 12, 13, 14 and 16 (Figure 6B) The lack of any 
temporal patterning suggests low test-retest reliability. In order to test this formally 
a repeated-measures one-way ANOVA was performed, confirming differences in 
percentage alternation in the control group over the 15 weeks of the experiment, F(14, 
182) = 3.51, p < 0.00005.   
Alternation in this apparatus is typically a spontaneous behaviour in mice and the 
reason for this failure to establish stable alternation in normal animals is not clear but 
lack of stability of performance among control mice makes conclusions about 
working memory in these animals unreliable and suggests that spontaneous 
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alternation in the T-maze was not a suitable model to determine whether there is any 
significant disease-related difference between P301S mice and controls or in which to 
test interventions. 
In any case, P301S mice also showed no decline over time; indeed, at 22 weeks of age 
P301S mice were still able to attain 80.0 ± 5.6% successful alternation compared with 
59.3 ± 8.0% for the control mice.  
 Burrowing 
Overnight burrowing performance of P301S and C57BL/6 mice was tested weekly. 
Comparison of the grand means shows that across the whole longitudinal period, 
P301S mice burrowed significantly less than control mice (48.0 ± 1.9% and 54.2 ± 2.0% 
respectively Holm-Sidak ANOVA, p=0.022) (Figure 6D). However, analysing the data 
as one epoch may be misleading because there appear to be three distinct phases to 
the burrowing behaviour of P301S mice; phase 1, 8-12 weeks of age; phase 2, between 
12-17 weeks of age; and phase 3, between 17-22 weeks of age (see Figure 6D). 
At the outset of phase 1 there was an apparent reduction in performance of P031S 
mice compared with controls although this did not reach statistical significance at α= 
0.05 (difference in initial performance -17.1%; p = 0.067; 95% CI -35.5 to 1.29). 
C57BL/6 mice showed no evidence of change in their burrowing performance during 
phase one of the experiment (weekly change in percent burrowing -0.5%; p = 0.540; 
95% CI -2.3 to 1.2). In contrast P301S mice, who initially burrowed less, showed an 
improvement in their performance during phase 1 (weekly change 4.5%; p < 0.001; 
95% CI 2.1 to 6.9). During Phase 2 neither control mice nor P301S showed any change 
in burrowing performance (C57BL/6 weekly change in percentage burrowed 1.1%; p 
= 0.117; 95% CI -0.3 to 2.5; P301S weekly change in percentage burrowed 0.0%; p = 
0.968; 95% CI -2.0 to 1.9). During the phase 3 control mice appeared to show a slight 
downward trend, but this did not reach significance at α=0.05 (weekly change -0.8%; 
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p = 0.397; 95% CI -2.8 to 1.1), whereas P301S mice showed a significant, progressive 
decline (weekly change -4.1%; p = 0.003; 95% CI -6.7 to -1.4). 
 Horizontal bar task 
While horizontal bar task performance of control mice remained constant throughout 
the experiment, visual inspection of horizontal bar performance of P301S mice over 
time showed two obvious distinct phases (Figure 6F): the stable phase (phase 1; 9-15 
weeks) and the declining phase (phase 2; 15-22 weeks). At the outset of phase 1 there 
was a very slight reduction in performance of P301S mice compared with controls 
(difference in initial performance -0.7; p = 0.001; 95% CI -1.1 to -0.3). During phase 1 
control mice and P301S mice showed a subtle improvement (C57BL/6 weekly change 
in horizontal bar score 0.1; p = 0.007; 95% CI 0.0 to 0.1; P301S additional weekly change 
in horizontal bar score 0.0; p = 0.760; 95% CI -0.1 to 0.1).  
During phase 2 control mice maintained a steady baseline performance (C57BL/6 
weekly change in horizontal bar score 0.0; p = 0.694; 95% CI -0.1 to 0.1) whereas P301S 
mice showed an age-related decline in horizontal bar score (P301S weekly change   
-0.8; p < 0.001; 95% CI -0.9 to -0.6). The apparent improvement in performance at 22 
weeks compared with 21 weeks is artefactual, arising because several mice with the 
most severe hind limb phenotype had to be sacrificed after 20 and 21 weeks of age in 
line with Home Office regulations. 
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Figure 6 – Behavioural tasks: Longitudinal burrowing and horizontal bar behavioural tasks detect 
progressive decline in performance of the P301S mouse. Three behavioural tasks are shown, spontaneous 
alternation in the T-maze, burrowing and horizontal bar task. Tasks were first evaluated for stable performance of 
controls, where this was met the temporal chance in P301S mice was explored. A) Diagram of spontaneous 
alternation apparatus – the T-shaped maze has arms 30 cm x 7 cm with walls 20 cm high, removable guillotine 
doors and a central partition. B) Spontaneous-alternation T-maze results - Percentage of 
correct alternations made by C57BL/6 mice (blue, n=14) and P301S mice (red, n=16), tested weekly from 8-22 
weeks of age. Highly variable performance was seen for the control group (significant differences on t-test 
comparing within-time-point means vs. grand mean (blue line), indicated by *p<0.05). This task was therefore 
rejected for comparison of P301S vs controls. C) Photograph of filled burrowing tube in-situ prior to burrowing 
session.(Photograph by Kerry Lavin Thomson). D) Burrowing results - Percentage of total weight burrowed over-
night (12h) by C57BL/6 and P301S mice, tested weekly from 8-22 weeks of age. Stable performance of control mice 
was seen throughout. P301S mice displayed three distinct temporal phases: learning phase (8-12 weeks); stable 
phase (12-17 weeks); and declining phase (17-22 weeks) (see results for further details). E) Photograph of horizontal 
bar apparatus: a 26 cm bar is suspended between two pillars at height 19.5 cm. Scores were assigned 0-10 (see 
methods). F) Horizontal bar results - C57BL/6 performance stable throughout 9-22 weeks. P301S mice displayed 




Tissue from control mice sacrificed at 8, 12, and 20 weeks of age was stained, imaged 
and quantified alongside P301S tissue. There was no age-related change in any of the 
markers quantified in control mice, hence in every experiment data from control mice 
of all ages were pooled and P301S mice sacrificed at 8, 9, 10, 11, 12, 16 and 20 weeks 
of age were compared to this pooled group. 
 Progressive Neuronal loss in the Motor Cortex of P301S Mice 
Previous work demonstrated significant superficial, frontal, cortical neuronal loss in 
M2 of the motor cortex of P301S mice at 12 weeks of age and end stage (20-24 weeks) 
compared with controls (Hampton et al., 2010). Previous findings were first verified 
and then a more detailed temporal profile of this neuronal loss was determined.  
Fixed brain sections collected from C57BL/6 and P301S mice at 8, 12 and 20 weeks of 
age were stained with an antibody against neuronal nuclei (NeuN) (Figure 7A-D), a 
neuronal specific nuclear protein in vertebrates (Mullen et al., 1992). 
At 8 weeks of age, NeuN positive cell counts conducted in the superficial layers of 
the motor cortex indicated that there was no difference between control mice (818.8 
cells per mm2; p < 0.001; 95% CI 688.7 to 948.9) and 8-week-old P301S mice (-68.8 cells 
per mm2; p = 0.53; 95% CI -302.5 to 164.8). There was a decline in cell density, which 
was significant at 12 (-361.8 cells per mm2; p = 0.001; 95% CI -538.1 to -185.5) and 20 
weeks of age (-390.5 cells per mm2; p = 0.036; 95% CI -750.4 to -30.7) (Figure 7I).  
In order to determine when the decline in cell density in the P301S mouse began and 
investigate the functional form of the decline, coronal sections from mice aged 8, 9, 
10, 11, 12, 16, and 20 weeks were stained with cresyl violet and cells were counted in 




Previously published work by Hampton et al. (2010) demonstrating that neuronal 
density of control mice did not vary between 8 and 20 weeks was verified, and hence 
cell density of P301S mice at each time point was compared to cell density of C57BL/6 
mice age 20 weeks. 
Cresyl-positive cell density in P301S mice was different from control mice at 11 weeks 
of age (see Table 8 for details of estimated difference in mean cell counts compared 
with controls).  
P301S Age 
in Weeks  
Cells per 
mm2  






C57BL/6 1437.8 - < 0.001 1077.4 1798.2 
8 1202.1 -235.7 0.289 -719.9 248.5 
9 1091.2 -346.6 0.160 -858.6 165.4 
10 1342.6 -95.2 0.559 -451.4 261.1 
11 923.6 -514.2 0.036 -982.0 -46.3 
12 468.0 -969.8 0.000 -1328.1 -611.5 
16 469.0 -968.8 0.001 -1369.3 -568.3 
20 405.7 -1032.1 0.000 -1425.0 -639.1 
Table 8 -  Change in cresyl-positive cell density in P301S mice compared with C57BL/6. The first term 
represents Cresyl-positive cells per mm2 for the reference group: C57BL/6 mice. The following terms test for an 
independent effect of genotype by within time-point comparison of P301S mice with C57BL/6 mice. 
Visual inspection of the summary data in Figure 7 J suggests three possible models of 
the decline in cresyl-positive cell density: the first - linear decline throughout the 
experiment; second - a bi-phasic course, initially stable up to week ten followed by a 
period of linear progressive neurodegeneration and finally a tri-phasic course, stable 
up to week 10 followed by a period of rapid neurodegeneration up to week 12 and 
then a period of relative stability until week 20. 
In order to test these three competing models, linear mixed effects models with 
random effects for individual animals were fitted to raw data cell counts per mm2 and 
we evaluated "goodness-of-fit" using the Bayesian Information Criteria (BIC). For the 
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bi- and tri-phasic models these were piece-wise with cut points at 10 and 12 weeks of 
age. For the single linear model, BIC was 4347.9, for the biphasic model BIC was 
4347.9, for the tri-phasic model BIC was 4333.0, the difference in BIC of 14.9 
comparing linear to tri-phasic model provides very strong support that the tri-phasic 
model is a better fit to the observed data (Raftery, 1995 - Table 6). 
Thus cresyl-positive superficial neuronal cell counts in P301S mice indicate a stable 
phase, from 8 until 10 weeks of age, followed by a decline phase from 10 to 12 weeks 





Figure 7 - NeuN-positive and cresyl-positive cell counts show progressive reduction in cell density within the 
superficial layers of the cortex. A-D) Representative examples of NeuN stained 20 week old C57BL/6 mouse (A) 
and P301S mice at 8 (B), 12 (C) and 20 weeks of age (D). E-H) Representative examples of cresyl-stained 20 week 
old C57BL/6 mouse (E) and P301S mice at 8 (F), 12 (G) and 20 weeks of age (H). Scale bars 100 μm (A-D, E-H).  
I) NeuN positive cell counts in the motor cortex (to sub-pial depth of 150 μm) from control (blue) and P301S (red) 
mice showed neuronal loss in P301S mice from 12 weeks onwards (mixed effects linear regression, indicated by 
*p<0.05) (C57BL/6 n=9, P301S 8wk n=4, 12wk n=6, 20wk n=3). J) Cresyl positive cell counts indicate neuronal 
loss from 11 weeks onwards (mixed effects linear regression, indicated by *p<0.05, **p≤0.001). The temporal course 
of neuronal loss was evaluated by piecewise mixed effects linear regression. Optimum fit to the observed data was 
achieved with a tri-phasic model (see results for further details); stable phase (phase 1; 8-10 weeks), declining cell 
density phase (phase 2; 10-12 weeks) and stable phase (phase 3; 12-20) (see results section 3.3.2.1 for details). 




 Progressive Astrogliosis in the Motor Cortex of P301S Mice 
Hampton et al. (2010) showed that astrogliosis was absent in the cortex of P301S mice 
at 8 weeks of age compared with controls but there was astrogliosis in the P301S mice 
at 12 weeks which progressed further at 20 weeks of age. Astrogliosis was visualised 
with an antibody against glial fibrillary acidic protein (GFAP) - an intermediate 
filament protein which is upregulated in reactive astrocytes (Figure 8 A-D).  
Here a more detailed temporal profile of astrogliosis in the cortex has been 
determined. There was no change in astrogliosis in control mice at 8, 12 or 20 weeks 
of age, hence C57BL/6 mice were grouped.  
GFAP-positive cell counts indicated that there was already astrogliosis in P301S mice 
at 8 weeks of age, the youngest age examined, compared with controls (see Figure 8 
I and see Table 9). 
P301S Age 









C57BL/6 9.7 - 0.326 -10.4 29.8 
8 70.0 +60.3 0.001 31.3 89.3 
9 36.6 +26.9 0.033 2.6 51.3 
10 65.5 +55.8 0.000 31.9 79.8 
11 95.5 +85.8 0.003 34.1 137.6 
12 140.0 +130.3 0.000 78.1 182.4 
16 132.3 +122.5 0.000 74.2 170.8 
20 175.0 +165.3 0.000 129.7 200.9 
Table 9 - Progressive increase in GFAP-positive cell density in the cortex of P301S mice. The first term 
represents GFAP-positive cells per mm2 for the reference group: C57BL/6 mice. The following terms test for an 
independent effect of genotype by within time-point comparison of P301S mice with C57BL/6 mice. 
Astrogliosis was progressive, as indicated by the increasing estimated means and the 
increasingly significant p-values across time. This was confirmed by mixed effects 
linear regression, which indicated that there was a weekly increase in GFAP-positive 




Figure 8 - GFAP positive reactive astrocytes in the brain and spinal cord indicate regional and progressive 
astrogliosis. A-D) Representative examples of GFAP stained cortical tissue from C57BL/6 at 20 weeks, and P301S 
at 8, 12 and 20 weeks. E-H) Representative examples of GFAP stained spinal cord (lamina 9 of c5-c7) from C57BL/6 
at 20 weeks, and P301S at 8, 12 and 20 weeks. Scale bar 100 μm (A-H). I) GFAP-positive cell counts conducted 
in the motor cortex (to sub-pial depth of 150 μm) of C57BL/6 (blue) and P301S mice (red) showed astrogliosis in 
P301S mice from 8 weeks onwards (mixed effects linear regression, indicated by; *p<0.05, **p≤0.005, ***p<0.0001). 
The temporal course of astrogliosis was evaluated by mixed effects linear regression; astrogliosis is progressive (see 
results for further details). (C57BL/6 n=8, P301S 8wk n=5, 9wk n=5, 10wk n=5, 11wk n=5, 12wk n=5, 16wk n=5 
20wk n=4). J) GFAP positive cell counts in lamina 9 of the spinal cord also showed astrogliosis already significant 
at 8 weeks (mixed effects linear regression indicated by; *p<0.05, **p<0.005, ***p<0.0001). Again, evaluation of the 
temporal course by mixed effects linear regression showed that astrogliosis in the spinal cord was progressive (see 





 Progressive Astrogliosis in the Spinal Cord of P301S Mice 
Allen et al. (2002) focussed primarily on the spinal cord because spinal cord pathology 
dominates the phenotype of P301S mice ultimately leading to hind limb paralysis. 
They showed astrogliosis in the spinal cord of 20 week P301S mice compared with 
controls. However, previous observations of astrogliosis in the spinal cord have been 
at end stage only. It is important to have an understanding of the nature of the 
progression of pathology in the spinal cord since understanding the chronology of 
pathology might both improve our understanding of disease pathology per se and 
inform any future interventions, hence I determined a longitudinal profile of 
astrogliosis in the ventral horn of the spinal cord; specifically, in lamina 9 of the spinal 
cord where there is severe motor neuron loss in P301S mice (Figure 8 E-H). 
GFAP-positive cell density in the ventral horn of the spinal cord was elevated in 
P301S mice compared with controls as early as 8 weeks of age and continued to 
increase with age (Figure 8 J and Table 10). Mixed effects linear regression of GFAP 
cell counts confirms progressive astrogliosis in the P301S spinal cord (weekly increase 
in cell counts 19.9 cells per mm2; p<0.001; 95% CI 14.2 to 25.6).  










C57BL/6 204.0 - < 0.001 174.1 233.9 
8 255.4 +51.4 0.048 0.7 102.2 
9 269.8 +65.8 0.001 30.2 101.5 
10 345.8 +141.7 0.002 68.2 215.2 
11 346.2 +142.2 0.000 84.7 199.8 
12 380.5 +176.5 0.000 128.7 224.3 
16 369.7 +165.7 0.000 132.7 198.8 
20 537.8 +333.8 0.000 278.1 389.5 
Table 10 - Progressive astrogliosis in the spinal cord of P301S mice compared with controls. The first 
term represents GFAP-positive cells per mm2 for the reference group: C57BL/6 mice. The following terms test for 
an independent effect of genotype by within time-point comparison of P301S mice with C57BL/6 mice. 
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 No Apparent Disease- Associated Microgliosis in the Motor Cortex 
of P301S Mice 
Ionized calcium binding adaptor molecule (IBA1) is a cytoplasmic protein 
constitutively expressed by microglia, which is upregulated in inflammation. IBA1 is 
involved in cytoskeletal reorganization and actin cross-linking needed for cell 
migration and palpitation of processes (Ohsawa et al., 2004). It is widely used as a 
pan-microglial marker. IBA1 positive cell counts in the superficial layers of the cortex 
showed no difference between controls and P301S mice at any time point (Figure 9 
A-D and I and Table 11) and there was no change in the number of IBA1 positive 
microglial cells across the lifespan of P301S mice (weekly change in IBA1-positive cell 
counts 1.3; p = 0.424; 95% CI -2.0 to 4.7). 
P301S Age 
in Weeks  
Cells 
per mm2  






C57BL/6  260.4 - < 0.001 236.1 284.8 
8 272.9 +12.5 0.716 -87.0 111.9 
9 254.9 -5.5 0.808 -54.7 43.7 
10 265.8 +5.4 0.758 -32.3 43.2 
11 280.5 +19.6 0.352 -25.3 64.5 
12 267.3 +6.9 0.742 -38.2 52.0 
16 270.1 +9.7 0.545 -24.4 43.8 
20 284.8 +24.4 0.320 -27.3 76.2 
Table 11 - IBA1-positive cell counts in the motor cortex indicate no microgliosis. The first term represents 
IBA1-positive cells per mm2 for the reference group: C57BL/6 mice. The following terms test for an independent 






Figure 9 -IBA1-positive microglial cell counts indicate progressive microgliosis in the P301S spinal cord but not 
in the brain. A-D) Representative examples of IBA1-stained cortical tissue from C57BL/6 at 20 weeks (A), and 
P301S at 8 (B), 12 (C) and 20 weeks (D). E-H) Representative examples of IBA1 stained spinal cord (lamina 9 of 
c5-c7) from C57BL/6 at 20 weeks (E), and P301S at 8 (F), 12 (G) and 20 weeks (H). Scale bar 100 μm (A-D). 
I) IBA1-positive cell counts conducted in in the motor cortex (to sub-pial depth of 150 μm) of C57BL/6 (blue) and 
P301S mice (red) showed no difference between C57BL/6 and P301S mice at any age and mixed effects linear 
regression showed no change over time. (C57BL/6 n=14, P301S 8wk n=4, 9wk n=3, 10wk n=5, 11wk n=5, 12wk 
n=5, 16wk n=6 20wk n=5). J) IBA1-positive cell counts in lamina 9 of the spinal cord indicated regional microgliosis 
in P301S mice from 10 weeks onwards (mixed effects linear regression indicated by; *p<0.05, **p<0.0001). The 
temporal course of microgliosis was evaluated by mixed effects linear regression; microgliosis in the spinal cord 
was progressive (see results section 3.3.2.5 for further details). (C57BL/6 n=15, P301S 8wk n=6, 9wk n=3, 10wk 




 Progressive Microgliosis in the Spinal cord of P301S Mice 
Contrary to findings in the motor cortex, however, IBA1-positive cell counts in lamina 
9 of the spinal cord indicated microgliosis in P301S mice compared with controls, 
apparent at 10 weeks of age (Figure 9 E-H and J and Table 12). 
P301S Age 
in Weeks  
Cells per 
mm2  






C57BL/6  270.3 - < 0.001 224.9 315.7 
8 257.7 -12.6 0.702 -82.6 57.4 
9 306.5 +36.2 0.334 -40.7 113.1 
10 325.2 +54.9 0.037 3.7 106.0 
11 342.7 +72.4 0.038 4.5 140.3 
12 407.0 +136.7 0.002 59.4 214.1 
16 439.1 +168.8 0.000 102.7 235.0 
20 450.2 +179.9 0.000 112.5 247.2 
Table 12 - Progressive microgliosis in the spinal cord indicated by IBA1 positive cell counts. The first 
term represents IBA1-positive cells per mm2 for the reference group: C57BL/6 mice. The following terms test for 
an independent effect of genotype by within time-point comparison of P301S mice with C57BL/6 mice 
IBA1 positive cell counts indicated progressive microgliosis in the spinal cord 
(weekly increase in IBA1 positive cell counts 15.5; 95% CI 11.1 to 19.8; p < 0.001). The 
increase in cell numbers was associated with a change in morphology from a 
senescent phenotype with a small cell body with long fine projections towards a 







To capture the progressive decline of the disease it was important to identify a task 
that a young, pre-symptomatic P301S mouse could master and achieve a steady 
baseline performance, which would be progressively impacted as the disease 
progressed. Since the mice would be retested weekly throughout their lifespan, it was 
also important to identify a task which would not be complicated by test-retest 
variation; mice in a novel environment are usually very active and keen to explore, 
however activity generally decreases with repeated reintroduction into the same 
environment; hence a behavioural task such as openfield or novel object recognition 
might have been inappropriate. Another important consideration in choosing a 
behavioural task is that P301S mice develop a hind limb paralysis as they age, as a 
result of neuronal loss in the spinal cord, hence if a cognitive test is chosen which 
involves movement then this motor dysfunction might either contribute to, or mask 
any subtle changes in performance. This hind limb paralysis has been viewed by 
many as one of the major draw backs of the P301S mouse model, however the onset 
of paralysis in the P301S mouse is a robust and extremely consistent feature of the 
disease hence a task which measures the degree of motor dysfunction is ideal for 
tracking the progression of the disease.  
 Spontaneous alternation in the T-maze 
Often the alternation in the T-maze is used as a learning and memory test; rodents 
are trained to alternate, by blocking off the alternative goal arm and by motivating 
correct alternation with a food treat in the goal arm or the temptation of escape from 
the T-maze into the safety of a home cage  (Deacon et al., 2006). In that context, the 
task is used to test the ability to learn to alternate and to test working memory and if 
mice successfully acquire alternation it can be used to detect a decline or deficit in 
spatial and working memory. In this instance, however, the T-maze was used to test 
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spontaneous alternation, that is to say there is no motivation for mice to alternate, 
beyond their own innate curiosity of the previously unexplored arm.  
The drive to explore a novel environment is strong and this test is able to detect 
hippocampal lesions in mice and rats however in this instance there was a huge 
degree of variability in performance of P301S mice and controls, potential 
explanations are discussed below. 
This test depends on the desire of mice to explore a recently unexplored environment 
(Deacon et al., 2006) and it might be argued that the task therefore does not optimally 
lend itself to repeated retesting; mice are tested 5 times each week, from 8 until 22 
weeks of age so very quickly the curiosity of the so called “previously unexplored 
arm” may decline.  
This protocol requires handling of mice into and out of the maze. This can cause 
anxiety which might manifest as passivity or hyperactivity thus impacting the 
“decision making” capacity of mice. Handling of mice may also serve as negative 
reinforcement and therefore influence behaviour as observed by Gerlai (1998) who 
suggests an alternative continuous alternation protocol where mice are not removed 
from the maze between alternations but are allowed to return to the start arm after 
the decision trial where they are held until they are released for the next trial. 
Thus, there are potential sources of variability across longitudinal testing but the most 
important factor in the rejection of this task is that it was unable to detect a progressive 
disease-associated decline in behaviour in the P301S mice. Exploration of novel 
environments, spatial learning and memory are all dependent on hippocampal 
function and this task is able to detect hippocampal lesions (Roberts et al., 1962). 
Hence this is suggests that hippocampal function is not significantly impacted by 
disease.  
Pennanen et al. (2006) showed increased alternation in the Y-maze in mice expressing 
P301L human mutant tau under the Thy1.2 and authors put this increase down to 
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increased exploratory behaviour (Pennanen et al., 2006). P301S mice display increased 
exploratory behaviour in the openfield and increased interaction with novel objects; 
together these tasks indicate an impact on the pathways involved in reaction to 
novelty (Scattoni et al., 2010, Torvell et al., 2013). The fact that P301S mice are capable 
of 80% successful alternation at 22 weeks of age suggests there is no progressive 
decline in hippocampal function. 
 Burrowing data  
Burrowing is another innate behaviour; the task was originally developed in an 
attempt to investigate hoarding tendencies of mice – a tube filled with food pellets 
was left in the cage and the next morning all of the food pellets had been displaced 
from the jar but they were haphazardly strewn across the cage floor not hoarded in 
any deliberate location. This behaviour also occurs with different substrates hence it 
is unlikely to be exclusively related to hoarding of food (Deacon, 2006). The reasons 
for burrowing activity remain unclear, in the wild animals create burrows to live in 
and escape predation and mice are often found with nesting materials in the tube the 
next day, however mice will still burrow in a full tube placed next to an empty tube 
(Deacon, 2006). 
Here burrowing data showed three distinct phases. During phase 1 control mice 
showed no change in their performance, whereas P301S mice, who were initially 
lagging behind control mice, improved week on week. There are several possible 
explanations to explain why P301S mice were lagging behind; firstly, social 
facilitation is an important element of the acclimatisation phase – mice are introduced 
to the burrowing apparatus overnight alongside their littermates to encourage 
exploration of the apparatus – C57BL/6 mice were housed in cages of 7, 3 and 5 
whereas P301S mice were housed in cages of 6, 3, 3 and 5. The group sizes may have 
affected the degree of social facilitation. Indeed, further analysis of the data shows 
that mice from smaller groups burrowed less during phase 1, and hence the smaller 
group sizes of P301S mice might therefore have introduced social facilitation bias. 
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P301S mice appear to be anxious compared with control mice; this might manifest as 
increased time taken to acclimatise to the burrowing apparatus. While P301S mice 
show increased exploration of novelty on some tasks (openfield and novel object) 
unpublished data from the lab indicates decreased exploration of open arms in the 
elevated plus maze (EPM) which is indicative of increased anxiety. 
It is possible that phase 1 reflects a genuine developmental or learning delay in P301S 
mice; P301S mice are smaller than control mice; the initial difference in performance 
in phase 1 might reflect a physical developmental difference, which P301S mice must 
compensate for.  Alternatively, since the tau transgene is expressed from as early as 
post-natal day 1 and this task has previously been able to detect lesions of the 
hippocampus and prefrontal cortex (Deacon et al., 2002, Deacon et al., 2003) it is 
plausible that this initial phase reflects a genuine developmental learning difference 
in P301S mice.   
Irrespective of their slow start, P301S animals eventually burrow at similar rates to 
normal animals and continue to do so, throughout ‘phase 2’, until disease-related 
decline begins. Then during phase three P301S mice showed a gradual decline in 
burrowing performance whereas control mice do not. This decline in burrowing 
correlates with, and is likely to be the result of the progressive hind limb deficits. It is 
possible that there is an element of decline in performance that can be attributed to 
motivational or affective decline, however the neurological impacts cannot be teased 
apart from the muscle wastage that occurs as a direct result of neuronal loss and 
denervation.  
 Horizontal Bar 
The horizontal bar task is a measure of motor strength and coordination; mice are 
suspended by their forelimbs from a bar; their innate response is to reach the platform 
at the end of the bar rather than fall – In similar studies, mice placed on a bar which 
is suspended from one end, facing the “open” end will spontaneously turn and travel 
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towards the supported end (Deacon, 2013). Hence this is a very simple “forced task” 
which measures physical ability and unlike many behavioural tasks horizontal bar 
task is not influenced by uncontrolled variables such as anxiety or test-retest 
variation.  
The horizontal bar task has previously been published with a slightly different 
scoring method with “time spent on the bar” up to a maximum of 60 seconds as the 
variable and mice who reach the platform are given the maximum score of 60 seconds 
(Cunningham et al., 2005). Alternatively, the “time spent on the bar” was converted 
to an arbitrary score between 1 and 5 (Falling between 1-5 sec = 1; Falling between 6-10 
sec = 2; Falling between 11-20 sec = 3; Falling between 21-30 sec = 4; Falling after 30 sec = 5; 
Placing one forepaw on a bar support without falling = 5).  Here however the scoring 
method was modified slightly - a healthy mouse can reach the platform in under 3 
seconds whereas P301S mice took much longer to reach the platform as disease 
pathology progressed. This difference in the time taken to reach the platform was not 
captured using the previous scoring methods and hence a new scoring method was 
designed around that fact, thereby improving the sensitivity of the task. Using this 
scoring method, the data demonstrated a progressive decline in horizontal bar 
performance of P301S mice. 
Muscle weakness and muscle wasting associated with normal ageing is referred to as 
sarcopenia (Degens, 2007) and may be caused by 1) changes within the muscle (i.e. 
oxidation or glycation of the myosin filament), 2) changes in the environment which 
influence the regenerative capacity of skeletal muscles (i.e. elevated TNF-α which 
impairs myoblast differentiation), or 3) by denervation due to loss of alpha motor 
units from the spinal cord (Roubenoff, 2000, Degens, 2007). Muscle size and strength 
are proportional to usage hence denervation results in muscle wastage – denervation 
is also associated with loss of trophic signals from neurons (Roubenoff, 2000). 
Importantly, there is a 49% motor neuron loss in the lumbar spinal cord (L2-L3) of 
P301S mice at 6 months of age which is associated with muscle denervation and 
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ultimately leads to hind limb wastage and paralysis (Allen et al., 2002). This is the 
most likely cause of decline in horizontal bar performance in P301S mice. 
The time course of the motor neuronal loss in the spinal cord, however, remains to be 
determined. It is plausible that horizontal bar decline may precede α-motor neuronal 
loss. Firstly, because functional decline might result from neuronal dysfunction rather 
than death (e.g. synaptic dysfunction resulting from tau pathology). Secondly α-
motor neurons receive inputs from upper motor neurons via corticonuclear, 
corticospinal and rubrospinal tracts, as well as sensory neurons and interneurons 
(Halliday et al., 2013), hence horizontal bar decline might be attributed to loss or 
dysfunction of any of these inputs. These inputs converge on the α-motor neurons 
which innervate muscles, hence death of motor neurons ought to cause immediate 
horizontal bar decline. However, there is plasticity in the system; neighbouring motor 
neurons are able to compensate for neuronal loss by “adoption” of muscle fibres 
(Roubenoff, 2000) hence motor neuron loss in the spinal cord might in fact precede 
horizontal bar impairment. Indeed very early evidence from rats indicated that 
weakness and atrophy were only detectable when 30% of motor neurons innervating 
a group of muscles was lost (Wohlfart, 1958).  
The area assessed will be important in determining a relationship between motor 
neuronal loss and horizontal bar decline because the cord is organised in the 
rostral/caudal dimension such that cervical motor neurons innervate upper 
extremities and lumbar motor neurons innervate the lower extremities (Halliday et 
al., 2013). 
This progressive hind limb phenotype is seen by many as a limitation of this and other 
rodent models of tauopathy dementia and has led to the development of transgenic 
models expressing tau under the control of inducible and cell- or region-specific 
promoters in order to generate mice with cognitive deficits, which mimic those seen 
in AD (As discussed in section 1.1.5)(Tatebayashi et al., 2002, Ramsden et al., 2005, 
Murakami et al., 2006, Rosenmann et al., 2008, Flunkert et al., 2013). 
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However here this disease-associated decline in motor function is exploited as a 
surrogate measure for disease severity. This task provides us with an excellent tool 
for following the trajectory of the disease; control mice and P301S mice are both 
capable of reaching and maintaining a consistent baseline score and the task 
sensitively and reproducibly picks up the gradual decline in performance and this 
decline in performance is a direct consequence of neuronal dysfunction in P301S mice.  
3.4.2 Pathology  
The P301S mouse expresses human mutant tau under the thy 1.2 promoter. This 
neuron-specific expression of mutant tau has previously been demonstrated 
sufficient to cause neuronal loss in the spinal cord and regional and progressive 
cortical neuronal loss with associated with astrogliosis. 
 Neuronal loss 
Allen et al. (2002) focused on end point pathology in the spinal cord since there is 
hind limb paralysis and obvious spinal cord pathology; this paper demonstrated a 
49% reduction in the number of motor neurons but was unable to demonstrate 
apoptosis by in situ end labelling (ISEL), caspase-3 or α-fodrin staining.  
Hampton et al. (2010) later showed significant, progressive cortical neuronal loss in 
the superficial layers of the cortex at 12 weeks of age and at end stage by cresyl 
staining, immunohistochemistry for neuronal markers NeuN, GABA, and qPCR 
using neuronal marker Reelin.  
A previous finding of progressive neuronal loss by NeuN staining at 8, 12 and 20 
weeks of age was first replicated here and a more detailed temporal profile for the 
progressive cortical neuronal loss by cresyl staining was then conducted. The analysis 
indicated that neuronal loss followed a tri-phasic course; initially there was no 
significant difference between P301S mice and controls, between 10-12 weeks there 
was a rapid reduction in cell numbers followed by a period of relative stability at 
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which point there was roughly a 70% reduction in cresyl-positive cells in the area 
compared with control mice. 
Hampton et al. (2010) indicated progressive neuronal loss such that there were fewer 
cells at end stage than at 12 weeks of age, whereas I have shown neuronal loss at 12 
weeks of age which plateaus thereafter. It is likely that this disparity is due to the 
tissue used as well as the methods of analysis. Hampton et al. conducted cell counts 
in mice that were sacrificed at “end stage”, which was determined by phenotype 
severity and ranged from 20 to 24 weeks whereas mice used here were sacrificed at 
exactly 20 weeks of age regardless of variation in the severity of phenotype. Hampton 
et al. conducted cell counts in the first 200 μm of the superficial layers of the cortex 
whereas I conducted cell counts in the first 150 μm – both factors which might 
contribute to loss of information between 12 and 20 weeks of age; cell counts in a 
larger area might detect ongoing neuronal loss. 
Hampton et al. previously demonstrated, with immunohistochemistry and qPCR for 
superficial vs. deeper cortical neuronal markers, that neuronal loss in the P301S mice 
is restricted to the superficial cortex and not the deeper layers, hence in this instance 
only the first 150 μm were sampled. This approach is not ideal because it is plausible 
that an increase in the apparent size of layer one of the cortex, for instance due to 
superficial astrogliosis or due to the angle at which sections were cut, might cause an 
deceptive reduction in the cell numbers in the first 150 μm from the pial membrane, 
without genuine cell loss. This analysis might be improved by un-biased, random 
stereological sampling throughout the layers of the cortex in order to avoid 
introducing bias and demonstrate superficial neuronal loss which is absent in the 
deeper layers (West, 2012).  
The cortical neuronal loss seen here precedes the decline in performance on the 
horizontal bar. Neurons in the motor cortex are arranged in layers (1-6) with a 
predominantly top—down excitatory organization (Weiler et al., 2008) such that 
axons of cells in the superficial layers arborise locally in layers 2/3 or synapse onto 
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layer 5 pyramidal and corticospinal neurons (Kaneko et al., 2000, Weiler et al., 2008, 
Anderson et al., 2010). Superficial pyramidal neurons receive inputs from the 
somatosensory cortex (Kaneko et al., 2000). Lesions in the somatosensory cortex 
impair acquisition of new motor skills without detectable changes in previously 
acquired skills (Sakamoto et al., 1989, Pavlides et al., 1993). The superficial motor 
cortical pyramidal cells thus integrate somatosensory and motor information and are 
involved in learning new motor skills (Kaneko et al., 2000) but are not directly 
involved in movement. This might explain the lack of correlation between superficial 
cortical neuronal loss and decline in horizontal bar performance.  
Previously published work indicates faint staining of ring-like AT8-positive phospho-
tau accumulations in the cortex at 8 weeks of age and an obvious increase in somato-
dendritic accumulations by 12 weeks, there was a vast increase in AT8-positive cells 
at 20 weeks of age (Hampton et al., 2010). Unfortunately, there has been no temporal 
characterisation of the accumulation of NFTs in the P301S mouse so it is not possible 
to determine the relationship between different pathological tau species and neuronal 
loss, however the data do show progressive neuronal loss at a time when phospho-
tau is accumulating in the somatodendritic compartment of neurons in the same 
region.  
Although neuronal counts have showed progressive neuronal loss, the mechanism of 
cell death per se has not been identified. The original Allen et al., 2002 report suggested 
non-apoptotic neuronal loss in the spinal cord at 5-6 months of age on the basis of 
absence of in situ end labelling (ISEL) or caspase-3 staining. However, apoptosis at 
an individual cell level is a rapid event and ISEL only detects cell death which is on-
going at the time of fixation. In certain models of severe, rapid and synchronous cell 
death this might be appropriate, however in a chronic slow-burning 
neurodegenerative condition there are likely to be very few cells dying at any given 
time. Indeed, if there is a tri-phasic course of neurodegeneration, as suggested here, 
it is possible that the time window to detect cell death was missed. 
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The exact mechanism of cell death in tauopathy dementia is unclear and widely 
debated. The most common form of cell death is apoptosis, otherwise known as 
programmed cell death. Apoptosis can be initiated by a cell-intrinsic or -extrinsic 
pathway and follows a well characterised sequence of events including activation of 
caspase proteins, chromatin condensation, DNA fragmentation, nuclear 
fragmentation, cell shrinkage and membrane blebbing. This controlled mechanism 
ensures that the contents of the cell are not exposed to the extracellular milieu, which 
would trigger an immune response. These well-characterised steps allow 
identification of apoptotic cells based on morphology, staining for activated caspases 
and labelling of 3’-OH ends of broken DNA. However, studies of human post mortem 
tissue fail to show any association between tau pathology and neuronal apoptosis 
(Gleckman et al., 1999, Atzori et al., 2001, Broe et al., 2004). 
There is a large body of work focussing on cell-cycle re-entry as a mechanism of cell 
death in tauopathy dementias and indeed the inappropriate expression of many cell-
cycle markers has been demonstrated in human dementias (Smith et al., 1995, McShea 
et al., 1997, Nagy et al., 1997a, Nagy et al., 1997b, Vincent et al., 1997, Arendt et al., 
1998, Raina et al., 1999, Raina et al., 2000, Raina et al., 2001, Vincent et al., 2002, McShea 
et al., 2007, Previll et al., 2007, Lee et al., 2009).  For review see Vincent et al 2003.  
Cell cycle re-entry in the context of tauopathy is particularly interesting because of 
the role of tau and microtubules in spindle formation during cell division and the 
similarities between hyperphosphorylated tau during development and pathological 
tau found in dementias (Kanemaru et al., 1992, Brion et al., 1993, Brion et al., 1994, 
Pope et al., 1994, Illenberger et al., 1998). It has been postulated that mutant tau 
protein inhibits cell division by disrupting spindle formation. Pausing or disrupting 
mitosis results in cell death (Sorger et al., 1997) so not only are cells not being replaced 
but they also die – the mechanism of cell death is unclear but it is thought to resemble 
apoptosis.    
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Andorfer et al. (2005) investigated mechanisms of cell death in the hTau mouse model 
of tauopathy (described in section 1.1.5). Electron microscopy revealed neurons with 
morphological hallmarks of apoptosis including nuclear breakdown, chromatin 
condensation, membrane blebbing, however those cells with nuclear abnormalities 
did not contain tau aggregates, and cells which showed signs of DNA fragmentation 
(TUNEL staining) did not contain activated caspases. However, hTau brains showed 
a vast upregulation of cell-cycle regulating proteins including cyclin D1, ki67 and 
PCNA – all of which are tightly regulated in the healthy brain but have been 
identified in AD brains. These proteins are associated with the early G1/S-phase of the 
cell cycle and the absence of markers of the G2/M transition (cyclin B an cdc2) indicate 
failure to complete mitosis and cell division (Andorfer et al., 2005). 
Schindowski et al. (2008) investigated mechanisms of neuronal death in a mouse 
model of tauopathy, the THY-Tau22 mouse (described in section 1.1.5) which over 
expresses human tau mutated at G272V and P301S under the Thy1.2 promoter. 
Authors showed upregulation of cell cycle markers cyclin D1 (G1/S-phase), Cyclin B1 
(G2/M-phase) and in young mice markers of neurogenesis and maturation (DCX, 
TUC-4 and NeuroD) and a BrdU-pulse indicated that the increase in cell cycle 
markers lead to the production of viable cells. Interestingly levels of cyclin D1 
increased with age, along with cyclin-D-CDK4 complex inhibitors p21Cip1 and 
p27Kip1, however there was a progressive decrease in markers of neurogenesis and 
maturation, suggesting dysregulation of the cell cycle with age (Schindowski et al., 
2008). 
This is particularly relevant since an attempt to determine the mechanism of neuronal 
loss in our P301S mice focussed on cell-cycle re-entry as a potential pathway to the 
demise of neurons (Delobel et al., 2006). Authors found that none of the activators or 
co-activators of the cell cycle assessed were over expressed or upregulated in 20-week 
old P301S mice, however cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1 
levels were elevated in brain and spinal cord tissue at end stage and were found in 
cells containing hyperphosphorylated tau inclusions. The presence of p21Cip1 and 
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p27Kip1 in P301S mice at 20 weeks of age might therefore be indicative of prior 
activation of markers of cell cycle re-entry.  
It has also been suggested that neurodegeneration may occur by a distinct mechanism 
involving Wallerian degeneration-like dying-back of projections (Wang et al., 2014), 
the exact mechanism has not been provided but is tempting given the role of tau 
protein in axonal projections and the surprising lack of evidence for apoptosis in 
neurodegeneration.  
The alternative to apoptosis is necrosis or necroptosis which involves rupturing of the 
cell membrane, releasing intracellular contents into the extracellular milieu and thus 
initiation of inflammatory events; this seems an unlikely cause of neuronal loss in this 
instance given the absence of microgliosis, which will be discussed further below.  
In conclusion, here I provide evidence of progressive neuronal loss in the superficial 
layers of the motor cortex, but the mechanisms of cell loss remain unknown. The 
results I present here indicate that the most significant neuronal loss occurs between 
10 and 12 weeks of age, although it is likely that neuronal loss continues after 12 
weeks outside of the analysed field of view hence based on the literature and previous 
work in this mouse model it would be interesting to look for markers of apoptosis 
and cell-cycle re-entry in the cortex between 10 and 16 weeks of age. 
 Astrogliosis 
Astrogliosis is a recurrent hallmark of tauopathy dementias (Bugiani et al., 1999, Broe 
et al., 2004). Astrogliosis in pure tauopathies is often associated with intracellular 
astrocytic tau deposits which vary in their appearance depending on the type of 
tauopathy (Komori, 1999). Thy 1.2-driven neuron-specific expression of tau in this 
P301S mouse model of tauopathy denies the opportunity to model astrocytic 
expression of mutant tau however it allows investigation of the impact of neuronal 
tau pathology on phenotypic switch to reactive astrocytes. 
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The data presented here demonstrated disease-associated reactive astrogliosis in the 
superficial cortex and in the spinal cord of P301S mice compared to controls, as 
determined by glial fibrillary acidic protein (GFAP)-positive cell counts, which were 
elevated in P301S mice compared with controls at every time point investigated. 
Furthermore, there was a progressive increase in the number of GFAP positive cells 
with age.  
Progressive astrogliosis was present in other areas of the P301S brain and spinal cord. 
In line with similar P301S tau expressing mouse models astrogliosis was most 
apparent in the white matter (Yoshiyama et al., 2007) which is likely due to 
degeneration of white matter axons projecting from tangle-bearing neurons, 
however, here I aimed to identify pathological correlates of the neuronal loss seen in 
the superficial layers of the cortex and the previously published loss of motor neurons 
in the spinal cord (Allen et al., 2002). 
GFAP is a marker of reactive astrocytes. In the pathological context it is up-regulated 
in cells where it was not previously expressed during health, hence, it remains to be 
seen whether this age-related increase in GFAP is the result of astrocyte proliferation 
or increased GFAP expression associated with phenotype switching. Recent findings 
from our group demonstrated that pan-astrocyte marker aldehyde dehydrogenase 1 
family, member L1 (Aldh1l1) expression in the P301S spinal cord at 20 weeks was not 
altered at the mRNA or protein level compared with age-matched controls thus 
indicating that the increased GFAP signal in P301S mice is due to a switch in 
phenotype rather than proliferation of astrocytes (Hasel et al., 2017).  
The increasing presence of GFAP-positive astrocytes indicates that they are indeed 
reacting to some pathological stimulus, however further characterisation is required 
to determine the nature of that reaction and therefore the role of astrocytes in the 
progression of the disease. There is evidence to suggest that reactive astrocytes may 
adopt different profiles similar to the observed spectrum of activated microglia and 
thus may be neuroprotective or deleterious (Zamanian et al., 2012). 
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Proteomic analyses of the spinal cord of the PS19 mouse model expressing P301S tau 
identified upregulation of astrocyte proteins believed to have neuroprotective effects 
in tauopathies, including heat shock protein Hsp27 (Yata et al., 2011). However, 
recently published work identified a host of astrocyte genes which are affected by the 
P301S mutation and indicate loss of normal function of astrocytes (Hasel et al., 2017). 
First, several astrocyte genes were identified as neuronally-regulated; they were 
upregulated when astrocytes were co-cultured with healthy neurons and in vivo. The 
expression of these astrocytic genes was then investigated in the spinal cord of P301S 
mice at 20 weeks of age and there was a significant decrease in expression of genes 
involved in glutamate and GABA transport and metabolism compared with age 
matched control mice. Hence these data indicate impaired neurotransmitter uptake 
and metabolism in astrocytes of the P301S mice at 20 weeks of age. 
Previously published work from our lab indicated a neuroprotective effect of 
astrocyte transplant into P301S mice; although the mechanism of this neuroprotection 
was not determined there was a notable increase in neurotrophic factors following 
transplantation (Hampton et al., 2010).  
In depth characterisation of the expression profile of astrocytes at different stages in 
disease progression might reflect a neuroprotective role or a proinflammatory pro-
neurodegenerative role of astrocytes. There is important evidence that the expression 
profile and therefore function of reactive astrocytes is subject to changes in the 
environment. Reactive astrocytes may be either proinflammatory “A1” astrocytes, 
with increased expression of proteins involved in the antigen presentation pathway, 
complement pathway initiation, and cytokine and chemokine production, or they 
may be neuroprotective A2 astrocytes, a phenotype associate with increased 
production of neurotrophic factors (Zamanian et al., 2012). Importantly there is 
evidence that A1 astrocytes may be induced by microglia (Liddelow et al., 2017). Since 
the disease pathology in P301S mice is progressive and there are regional differences 
in microglial activation, there are likely to be important regional and temporal 
differences in astrocyte profile in P301S mice. 
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In conclusion, here I provided novel evidence for a progressive increase in GFAP-
positive reactive astrocytes as a result of neuron-specific mutant tau transgene 
expression.  
 Microgliosis 
Ionized calcium binding adaptor molecule 1 (IBA1) is a microglia/macrophage-
specific calcium-binding protein whose expression increases with activation (Ito et 
al., 1998). Using this marker, I found evidence of progressive disease-associated 
microgliosis in the spinal cord of P301S mice. However, despite the progressive 
accumulation of phosphorylated tau protein, neuronal loss and astrogliosis observed 
in the superficial layers of the cortex, the data presented here demonstrated an absence 
of detectable microgliosis in the cortex of P301S mice. There was no change in the 
number of IBA1 positive microglia in the cortex at any time point analysed and 
cortical microglia maintained a ramified morphology throughout, contrary to the 
morphological changes seen in the spinal cord.  
This is in line with work from human post mortem studies and animal models of 
tauopathy where the spatiotemporal correlation between microglial burden and 
pathological tau burden has been repeatedly observed and so too has the apparent 
lack of microglial activation in areas with only mild tau pathology (Kida et al., 1992, 
Paulus et al., 1993, Sheng et al., 1997, Ishizawa et al., 2001, Ikeda et al., 2005, Sasaki et 
al., 2008). A study of transgenic rats expressing pathological truncated tau 
commented “Here we showed that activated microglia occurred in the same regions as AT8 
immunoreactive tangles… but were conspicuously absent in areas with limited neurofibrillary 
degeneration such as thalamus, hypothalamus, striatum or cortex” (Zilka et al., 2009). 
The directionality of the association between tau pathology and microglial activation 
is unclear; the regional differences in microglial activation might be caused by the 
relatively mild pathological tau burden in cortex compared with the more severe tau 
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pathology in the spinal cord of P301S mice or conversely the tau pathology might 
depend on microglial activation.  
In AD, following the death of tangle bearing neurons, NFTs remain in the 
extracellular space as “ghost tangles” (Spillantini et al., 2013) – which are capable of 
activating microglia (Morales et al., 2013), whereas in CBD, Pick’s disease, PSP and 
other mutant tauopathies filamentous tau does not accumulate in the extracellular 
space (Spillantini et al., 2013). The intracellular deposition of tau is likely to curb the 
levels of microgliosis compared with neurodegenerative diseases associated with 
extracellular protein deposition. It is unclear at this stage what aspect of tau pathology 
triggers microglial activation, however, tau pathology as determined by tau 
phosphorylation and conformation-dependent staining is more extreme in the spinal 
cord of P301S mice compared with controls. There is AT8-positive tau pathology in 
the cortex of P301S mice but there is only very weak staining for NFTs in the cortex; 
AT8 binds tau protein phosphorylated at Ser 202 and Thr 205 which is a relatively 
early event, whereas NFT formation occurs later in pathology hence the cortical 
pathology is relatively mild (Allen et al., 2002, Hoffmann et al., 2013). 
Interestingly, while there are regional differences in pathological tau between brain 
and spinal cord, at end stage total human mutant tau expression is 2-fold that of 
endogenous wild-type tau in the brain and the spinal cord of P301S mice (Allen et al., 
2002). This indicates that differences in tau pathology between brain and spinal cord 
might result from different regional responses to tau expression rather than 
promoter-driven regional differences in mutant tau expression. 
One explanation for the absence of microgliosis in the brain might be the regional 
heterogeneity in the immune-vigilance status of different microglial populations 
(Lawson et al., 1990, de Haas et al., 2008, Grabert et al., 2016). Genome-wide analysis 
of microglia from discrete mouse brain regions shows that microglia have distinct 
region-dependent transcriptional identities (Grabert et al., 2016). Microglia in the 
cortex are more stringently regulated than those in the cerebellum, which are, by 
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comparison, immune-vigilant. Genes involved in energy production (mitochondrial 
biogenesis, glycolysis, TCA cycle, electron transport chain and ATP synthesis) and 
genes encoding the cell surface sensing receptors with immunoreceptor tyrosine-
based activation motifs (ITAMs) were more highly expressed in cerebellar microglia, 
whereas ITIM-containing inhibitory members were enriched in microglia of the 
cortex and striatum (Grabert et al., 2016). Fractalkine receptor (CX3CR1) was enriched 
in the cortex (Grabert et al., 2016). Fractalkine signalling reduces microglia reactivity 
to toxic stimuli, maintaining microglia in a modulated state; signalling reduces IL-1β 
levels and therefore minimises downstream damaging effects; modulates neuronal 
survival by increasing neurotrophic output; and influences phagocytic capacity 
(Limatola et al., 2014).  
Studies in hTau mice indicated only very mild microgliosis in the dentate gyrus 
despite the accumulation of tau pathology (Bhaskar et al., 2010). hTau-
Cx3cr1−/− mice were generated and immunohistochemistry for microglial markers 
IBA1, CD68, CD11b, CD45 and iNOS demonstrated increased microgliosis in hTau-
Cx3cr1−/− mice compared with hTau mice or Cx3cr1−/− mice (Bhaskar et al., 2010).  
Triggering receptor expressed on myeloid cells 2 (TREM2) was also enriched in the 
cortex (Grabert et al., 2016); which is a cell surface receptor of the immunoglobulin 
superfamily, involved in phagocytosis and downregulation of pro-inflammatory 
cytokines. Hence it is plausible that the pathological differences between brain and 
spinal tissue result from differences in regional immune regulation. 
Here I demonstrated age-related increase in abundance of IBA1 positive cells in the 
spinal cord. The progressive increase in IBA1-positive cells seemed to begin at the 
earliest time points measured, but within time-point comparisons indicated that cell 
counts became significantly different compared with controls at 10 weeks of age.  
IBA1 is a generic microglial marker and stains resting and activated microglia 
regardless of phenotype, giving no indication of their activation status other than by 
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morphological changes. The progressive increase in microglial counts was also 
associated with altered microglial morphology; shortening and thickening of 
microglial processes and enlarged soma typical of microglial activation. Un-
published work from our lab also indicated a progressive increase in CD68-positive 
microglia in the brainstem, and absence of CD68 staining in the cortex – CD68 is a 
marker of phagocytic microglia. Microglia have previously been shown to 
phagocytose pathological tau aggregates in vitro and in vivo in the PS19 mouse which 
also expresses P301S tau and by phagocytosis and exocytosis microglia are thought 
to be involved in the propagation of tau pathology (Asai et al., 2015). 
Microglial transcriptome profiling of animal models of aging and APP/PS1 and SOD1 
models of neurodegeneration identified several genes which are thought to be part of 
a consistent transcriptional profile of primed microglia, including Axl, Clec7a, CD11b, 
CD11c, Cybb and Cfs1 (Chiu et al., 2013, Holtman et al., 2015) – discussed in 
Introduction section 1.2.9. The same microglial priming associated genes were also 
shown to be elevated in rTg4510 mice overexpressing human mutant P301L tau under 
an inducible regional promoter although there was no detailed summary of 
expression levels in the rTg4510 mice.  
It will be interesting to investigate further the microglial expression profile in P301S 
mice in order to determine whether they demonstrate this signature primed microglia 
transcriptional profile. It would also be interesting to compare and contrast between 
brain and spinal cord tissue since there is an apparent difference in microglial 
activation.  
It seems unlikely that phospho-tau, insoluble tau or even NFTs would be able to 
directly activate microglia since they are intracellular however microglia are known 
to interact with synapses; synaptic loss and axonal degeneration caused by loss of tau 
function might impact microglial-synaptic connections and thus might provide a 
stimulus for microglial activation. Indeed, synaptic loss and microglial activation 
were both early events in the pathology of PS19 mice (Yoshiyama et al., 2007).  
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Alternatively, Bellucci et al. (2004) showed that at end stage the microglia in the brain 
stem and spinal cord of P301S mice are clustered around IL-1β and COX-2 positive 
neurons containing pathological tau. There might be other tau pathology-induced 
neuronally-expressed microglial activating signals. Interestingly there were COX-2, 
but not IL-1β, positive neurons in the cortex of P301S mice, which might also 
contribute to differences in microglial activation. The presence of IL-1β and COX-2 
stained neurons has however only been demonstrated at end stage and might be the 
result of neuroinflammatory changes rather than an early trigger of microgliosis. 
In a later study the same author examined human post-mortem tissue from a patient 
with P301S tau mutation and found CD68 and MHCII positive cells of amoeboid 
morphology and also bushy morphology. As seen in P301S mice there was co-
localisation of IL-1β and COX-2 with AT8-positive hyperphosphorylated tau. There 
were also COX-2 positive microglia (Bellucci et al., 2011). Together these results 
indicate a proinflammatory microgliosis in the brainstem and spinal cord of P301S 
mice with a phagocytic profile, certainly at end stage.  
It is apparent that some aspect of tau pathology, directly or indirectly, causes 
microglial activation, and it has also been demonstrated that microglial activation 
drives tau pathology via proinflammatory cytokine signalling which activates 
intracellular kinases such as CDK5, GSK-3β and p38-MAPK (Li et al., 2003, Kitazawa 
et al., 2005, Bhaskar et al., 2010, Sy et al., 2011, Maphis et al., 2015b) hence tau 
pathology and microglial activation could be in a self-exacerbating loop. 
Yoshiyama et al. (2007) demonstrated early microgliosis in PS19 mice, which 
preceded tangle formation and neuronal loss (details of PS19 mice discussed in 
Section 1.1.5 and summarised in Table 2). Unfortunately, the temporal profile of the 
aggregation of different types of tau pathology (oligomers, NFTs) and neuronal loss 
in the spinal cord of P301S mice remains to be determined. 
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The fact that tau pathology appears to start in the spinal cord and work its way up 
towards the brain and that the spinal cord phenotype limits the lifespan of mice has 
often been considered a limitation of this and other models of tau pathology when 
attempting to model cortical and hippocampal degeneration and associated cognitive 
changes. This spinal degenerative phenotype has previously been attributed to the 
Thy 1.2 driven expression of tau protein leading to the development of new inducible 
models. This has resulted in mouse models with controlled expression of tau under 
cell- and region-specific inducible promoters (See Table 2 and Section 1.1.5 for 
details).  
However, the regional differences in the severity of pathology in these mouse models 
ought not to be set aside as artefacts of promoter driven expression; firstly, there is an 
equivalent 2-fold human mutant tau expression compared with endogenous mouse 
tau in the brain and spinal cord; secondly, there are regional differences in the 
immune-regulation of microglia such that microglia in the cortex tend to exist in a 
more stringently regulated state and it is known that microglia are capable of driving 
tau pathology; third, there are differences in the vulnerability of neuronal 
subpopulations to tau pathology. 
In future, as well as investigating how microglia in the brain and spinal cord might 
be contributing to disease pathology in the brain compared with the spinal cord, it 
will be informative to investigate regulators of microglial activation such as 
microglial CX3CR1 and CD200R and corresponding ligands CX3CL1 and CD200, in 
order to ascertain how the micro-environment is influencing microglial activation.  
3.5 Conclusions 
Data presented here show that over-expression of human mutant P301S tau is 
sufficient to cause age-related neuronal loss, astrogliosis and microgliosis. 
Importantly there are regional differences in these pathologies which might reflect 
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variations in regional immune-vigilance, cell specific vulnerabilities, or might be 
attributable to thy 1.2 driven P301S tau expression. 
The data presented here indicate that microgliosis is not necessary to drive 
neurodegeneration, at least in the cortex, and that tau pathology associated cortical 
neuronal loss occurs via a mechanism which does not robustly stimulate microglia. 
A reliable behavioural task has been identified, which can be used to reproducibly 
and non-invasively monitor disease progression. This is a valid model for studies 
relevant to understanding how systemic inflammation influences key markers 




4 Chapter 4 – The Phenotypic Effects of Systemic 
Inflammation in the P301S Tau Model of Tauopathy 
4.1 Introduction 
Systemic inflammation is a common comorbidity with age-related 
neurodegeneration and it is proposed to be a driver of chronic neurodegeneration 
(Perry et al., 2007). During infection, the systemic inflammatory status is 
communicated to the brain via neural routes and via inflammatory mediators, such 
as cytokines, in the circulation (Dantzer, 2009). When these signals reach the brain, 
they coordinate the conserved “sickness behaviours”, characterised by fever, malaise, 
fatigue, depressed locomotor activity, decreased exploration and social activity, 
anorexia, increased threshold to thirst, and cessation of grooming (Hart, 1988, 
Dantzer, 2001).  
It has been proposed that in the context of dementia the same systemic inflammation 
might interact with the ongoing neuroinflammation resulting in both acute and long 
term detrimental consequences (Cunningham et al., 2009). A systemic infection in a 
person with dementia can be sufficient to induce delirium, an acute neuropsychiatric 
condition which in some cases is thought to be the clinical manifestation of an 
exaggerated, aberrant sickness response (Cunningham et al., 2013). Delirium and 
systemic inflammatory illness are associated with increased risk of dementia, and can 
exacerbate or accelerate pre-existing dementia (Rockwood et al., 1999, Engelhart et 
al., 2004, Yaffe et al., 2004, Perry et al., 2007, Tobinick, 2008, Fong et al., 2009). 
Several in vivo studies have used lipopolysaccharide (LPS), a chemical moiety found 
on the surface of gram-negative bacteria, to mimic a systemic infection. Studies 
modelling systemic inflammation superimposed onto rodent models of aging or 
neurodegeneration have successfully demonstrated exaggerated sickness behaviours 
and have been able to replicate advanced neurodegenerative decline (Chen et al., 
2008, Cunningham et al., 2009). Recent experiments in rodent models of 
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neurodegeneration indicate that the degree of underlying disease pathology at the 
time of systemic inflammation influences the severity of the acute deficits induced by 
the same inflammatory insult (Davis et al., 2015).  
Until now, studies of systemic inflammation and neurodegeneration have 
predominantly focussed on animal models with extracellular protein deposits and 
prominent microglial activation. There have been relatively few studies investigating 
the impact of systemic inflammation on animal models of pure tauopathy dementia 
(discussed in introduction section 1.2.11 (Kitazawa et al., 2005, Bhaskar et al., 2010, Sy 
et al., 2011)) and none investigating acute sickness behaviour in a pure tau model. It 
remains unclear whether tau pathology in the absence of amyloid-β is sufficient to 
induce microglial priming with subsequent increase in cytokine production following 
inflammatory insult and associated exaggerated sickness response.  
Thus, this study aimed to use non-invasive phenotypic and behavioural measures to 
investigate the interaction between systemic inflammation and disease in a pure tau 
mouse model of neurodegeneration. 
To test the prediction that P301S mice will show an exaggerated sickness response 
P301S mice and C57BL/6 control mice were injected intraperitoneally with 500 µg/kg 
of LPS or saline and the acute response was monitored. Mice were injected at either 
10 or 16 weeks of age in order to determine whether the degree of underlying 
pathology at the time of injection influenced the severity of the sickness response. The 
previous chapter described the disease-associated trajectory of P301S mice compared 
with control mice, in terms of both behaviour and pathology, and identified the 
horizontal bar task as a suitable tool to follow the trajectory of the disease. In this 
chapter mice completed the horizontal bar task weekly until they were sacrificed at 
end stage in order to determine whether a superimposed single acute systemic 




The hypotheses being tested in these experiments are: 
• There will be an exaggerated acute behavioural response to systemic inflammation in 
P301S mice compared with controls. 
• The degree of underlying pathology at the time of injection will determine the 
magnitude of this acute response to systemic inflammation; specifically, there will be 
an exaggerated acute response in mice injected at 16 weeks of age compared with mice 
injected at 10 weeks of age 
• The systemic inflammation will influence the chronic end stage trajectory of the 
disease. This might be impacted by the age at the time of injection – 10 or 16 weeks of 
age. 
4.2 Methods 
4.2.1 Experimental design 
In order to determine the impact of systemic inflammation on P301S mice, 
intraperitoneal injection of LPS was used to mimic a bacterial infection (details 
below).  
To our knowledge, this is the first study involving LPS-injection into P301S mice and 
hence cohort 1, injected at 10 weeks of age, was used as a pilot study to inform future 
experimental designs. This pilot study generated new information regarding the 
severity and duration of the sickness response in P301S mice and controls, and thus 
informed the timing and the type of behavioural experiments used in future studies. 
In the pilot study, only horizontal bar performance was assessed. However, in all 
follow up experiments, in addition to horizontal bar performance, during the acute 
phase mice were weighed, their temperature recorded, their open field activity 
assessed and an acute sickness score was completed as per the schematics in Figure 
10 and Figure 13.  
Based on behavioural data from Chapter 3, mice were group housed in cages of equal 
size where possible. Animals were caged according to the four treatment groups: 
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C57BL/6 injected with saline; C57BL/6 injected with LPS; P301S injected with saline; 
and P301S injected with LPS (numbers in Table 13). Experimental cages were placed 
on a separate cage rack in the home cage room and I exclusively cared for these mice 
myself. Their food, bedding and water was changed weekly after behavioural testing 
to minimise the impact of disturbances affecting behavioural results. 
Table 13- Behavioural cohorts used in chapter 4 
4.2.2 LPS Intraperitoneal Injection 
Lipopolysaccharide (LPS; from Salmonella enterica serotype abortus equi, Sigma 
L5886, Poole, UK) was dissolved in 0.9% NaCl2 solution to yield a 1mg/ml LPS stock 
solution which was aliquoted and frozen. On the day of injection stock solution was 
diluted further in 0.9% NaCl2 to yield a final concentration of 0.05mg/ml. Mice were 
scruffed and injected intraperitoneally with 500 μg LPS per kg animal’s weight or an 
equivalent volume of saline solution and were then returned to their cage. The chosen 
dose 500 µg/kg body weight is sufficient to elicit a significant sickness response 
without inducing sepsis in alternative animal models (Cunningham et al., 2005), 
however it remained to be seen how this response would manifest in P301S mice. 
They were monitored for signs of acute sickness.  
4.2.3 Acute Sickness Score 
While monitoring the acute sickness response of cohort 1 observations were recorded 
which included: hunched posture, piloerection, decreased responsiveness, and the 








Mice Injected at 10 weeks 
Cohort 1 4 4 4 4 
Cohort 2 5 5 5 5 
Cohort 3 5 5 3 4 
Mice Injected at 16 weeks 
Cohort 4 
8 (2 cages 
of 4) 
8 (2 cages 
of 4) 
8 (2 cages 
of 4) 




presence of a film of white ocular discharge. The time of onset for each of these criteria 
was recorded for cohort 2 and the severity scored, which enabled generation of a new 
chronological scoring system (Table 14). This Acute Sickness Scoring System was then 
applied to all future cohorts. Mice were scored at -1, 2, 4, 6, 12, 24 and 36 hours relative 
to i.p. injection. 
Score Appearance 
0 Normal for a mouse of that phenotype 
1 Slightly hunched posture when undisturbed. 
Slow to respond. 
2 Hunched posture. 
Slow to Respond. 
Piloerection. 
Possible mild ocular discharge 
3 Hunched posture. 
Slow to Respond. 
Piloerection. 
Film of white ocular discharge has developed 
around the eyes. 
4 Hunched posture. 
Unresponsive – can touch the mouse with very 
minimal reaction; barely tries to move. 
Piloerection. 
Thick coating of ocular discharge. 
Diarrhoea. 
Table 14 – Acute Sickness Score 
 Statistics 
The score was plotted and the area under the curve (AUC) was calculated for 
individual mice and mixed effects linear regression of AUC data was used to compare 
the impact of LPS on P301S mice and controls at all time-points assessed. 
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4.2.4 Open field Activity - as a measure of acute sickness 
 Apparatus 
Apparatus consisted of a purpose-built, circular, white acrylic open field chamber 
measuring 1 m in diameter, with walls 30 cm high. A digital camera was suspended 
above the open field chamber and was linked to Actimetrics Limelight 3 tracking 
software on a laptop. 
 Protocol 
Mice were placed in the centre of the chamber, always facing the same direction and 
were allowed to explore for 3 minutes. Their activity was recorded via the digital 
camera using Actimetrics Limelight 3 tracking software, which traced the movement 
of mice and recorded their distance travelled. Mice were returned to their home cage 
after 3 minutes and the open field chamber was cleaned with ethanol and dried. Mice 
were tested 24-hours prior to injection and then 4-hours, and 24-hours post-injection 
in order to capture the acute response. The distance travelled was recorded for each 
mouse.  
 Statistics  
The average distance travelled by saline-injected groups was determined. The 
distance travelled by individual LPS-injected mice was then expressed as a 
percentage of the average distance travelled by saline-injected counterparts and 
average was calculated for each group as shown below. 
= (∑ (
𝐷𝑖𝑠𝑡. 𝑇𝑟𝑎𝑣𝑒𝑙𝑙𝑒𝑑
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐷𝑖𝑠𝑡. 𝑇𝑟𝑎𝑣𝑒𝑙𝑙𝑒𝑑 𝑏𝑦 𝑆𝑎𝑙𝑖𝑛𝑒 𝐶𝑜𝑢𝑛𝑡𝑒𝑟𝑝𝑎𝑟𝑡
)  𝑥 100) /𝑛 
The “percentage open field activity” data was used in statistical analysis. Mixed 
effects linear regression with random intercept for ID was used to compare within-
time-point data.  
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4.2.5 Weight  
Mice were weighed using a Sartorius Entris 8201i-1S Toploader Balance. Mice were 
weighed 24-hours, 12-hours and 1-hour prior to injection and 2, 4, 6, 12, 24 and 36-
hours post-injection. 
 Statistics 
The average pre-injection baseline weight for each mouse was determined by 
averaging the 3 recordings prior to injection. For every time point post-injection the 
weight (g) of each mouse was converted to a percentage of its own baseline weight. 
These “percentage of baseline weight” data were used in statistical analysis. Mixed 
effects linear regression with random intercept for ID was used to compare groups. 
4.2.6 Body Temperature 
Unfortunately, use of a rectal temperature probe or biometric chip was not stipulated 
in our project licence and hence temperature recordings were taken using a GM300 
Digital Infrared IR Thermometer Temperature Laser Point Gun. Mice were scruffed 
and the temperature probe held at a consistent angle relative to the direction of the 
fur and at a consistent distance from the mouse. The mammary glands were used as 
a landmark to ensure recordings were taken from the same area each time. The 
average of three measurements was recorded. Temperature fluctuates throughout the 
course of the day, hence in order to see the effect of LPS the temperature for LPS-
injected mice is expressed as a percentage of that of saline-injected counterparts. 
Temperature recordings were taken 24-hours prior to injection and then 4, 6 and 12-
hours post-injection (in mice injected at 16-weeks temperature was recorded at 24-




The temperature data were used to calculate the AUC for individual mice and mixed 
effects linear regression with random intercept for ID was used to compare groups. 
4.2.7 Horizontal Bar Task 
The horizontal bar task was conducted as described in section 2.2.3. Mice were trained 
from 6 weeks of age and their activity on the horizontal bar recorded from 8 weeks of 
age onwards in order to establish a steady baseline prior to injection.  
On the week of LPS injection (10 or 16 weeks of age) mice were assessed 24-hours and 
1-hour prior to injection and again 6-hours and 24-hours post-injection in order to 
capture the acute response to injection. Mice injected at 16 weeks of age had not all 
recovered by 24-hours post-injection hence horizontal bar performance was also 
assessed 36-hours post-injection. 
As well as piecewise linear regression to compare the trajectory of decline in the stable 
and chronic phases additional statistical tests were required to probe the acute phase: 
mixed effects linear regression with random intercept for ID was used for within time 
point comparisons of the four groups 24-hours prior to injection and 6-hours, 24-
hours and where required 36-hours post-injection. 
4.3 Results 
4.3.1 Early systemic inflammation 
P301S and C57BL/6 mice were injected with LPS or saline solution at 10 weeks of age 
when there is mild cortical astrogliosis but cortical neuronal loss has not yet become 
apparent, importantly there is significant astrogliosis and microgliosis in lamina 9 of 
the spinal cord hence at 10 weeks of age subtle disease pathology has begun but mice 
are not symptomatic and they are on the precipice of neurodegeneration (see Chapter 
3). Mice were closely monitored around the time of injection; locomotor activity in 
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the open field was assessed, observations were recorded enabling generation of an 
Acute Sickness Score, and weight and temperature were recorded during the hours 
and days around the time of injection as per the schematic in Figure 10.  Horizontal 
bar performance was assessed weekly across the lifespan and multiple times during 
the acute sickness. 
P301S mice showed an exaggerated sickness response to LPS compared with C57BL/6 
mice; this was apparent by observation but was also reflected by the data from 
behavioural tasks, as follows.  
 
Figure 10 – Early systemic inflammation - Experimental design schematic. C57BL/6 and P301S mice were 
tested on the horizontal bar weekly. They were injected with either Saline or LPS at 10 weeks of age and during the 
acute phase were tested on the horizontal bar and distance travelled in open-field, Acute Sickness Score, weight and 




 Exaggerated Acute Sickness Response in P301S mice  
 Prolonged reduction in locomotion in LPS treated P301S mice 
The open field task is a simple task that records the innate exploratory behaviour of 
rodents with no need for training. Mice often display decreased locomotion during 
acute sickness (Bolivar, 2009). Mice were placed in the open field arena and their 
movement recorded 24-hours prior to injection, and then 4, 24 and 36-hours post-
injection (Figure 10).  
P301S mice are known to travel further than C57BL/6 mice in the open field (Scattoni 
et al., 2010) and when mice are repeatedly retested in an open field arena there is 
habituation – mice travel less as they become accustomed to the environment – this is 
true of even non-injected control mice. Therefore, to determine the influence of LPS 
on mice, without the variation due to genotype or re-testing, the distance travelled 
(cm) by LPS-injected mice was expressed as a percentage of within-genotype within-
time-point saline-injected activity. 
As expected 24-hours prior to injection there was no difference between saline and 
LPS treatment groups (C57BL/6 + LPS vs C57BL/6 + Saline: +19.6%; p=0.180; 95% CI -
9.51 to 48.6; and P301S + LPS vs P301S + Saline: -7.4%; p=0.652; 95% CI -41.5 to 26.8) 
(Figure 11 A). 
4-hours post-LPS-injection there was a 54.9% reduction in the distance covered by 
C57BL/6 mice compared with saline-injected counterparts (p=0.001; 95% CI -85.1 to -
24.8). LPS-injected P301S mice travelled 88.0% less than their saline-injected 
counterparts (p<0.001; 95% CI -121.3 to -54.8). When formally tested the differential 
effect of LPS on P301S mice was not significant (-33.1%; p=0.139; 95% CI -77.7 to 11.4) 
(Figure 11 A). 
By 24-hours post-LPS-injection C57BL/6 mice had recovered relative to saline-injected 
counterparts (-10.6%; p=0.534; 95% CI; -44.8 to 23.6). LPS-injected P301S mice, 
however, had still not yet recovered to the same activity as saline-injected 
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counterparts (-51.0; p=0.039; 95% CI -99.0 to -3.0) (Figure 11). When formally tested, 
the differential effect of LPS on P301S mice was not significant (-40.4%; p=0.113; 95% 
CI -90.9 to 10.1). 
By 36-hours post-injection both LPS-injected groups had recovered compared to their 
saline-injected counterparts (C57BL/6 + LPS vs C57BL/6 + Saline: -20.6%; p=0.444; 95% 
CI -74.8 to 33.6; P301S + LPS vs P301S + Saline: -27.6%; p=0.374; 95% CI -91.4 to 36.2) 
(Figure 11 A). 
Hence the open field task highlighted a potentially longer-lasting LPS-induced 
hypoactive sickness response in P301S mice compared with LPS-injected C57BL/6 
mice. 
 Elevated Acute Sickness Score in P301S mice following LPS injection 
LPS-injected mice were visibly unwell. Observations were recorded in chronological 
order and from this developed an Acute Sickness Score described in Table 14. Similar 
scoring techniques are used in the pharmaceutical industry to assess sickness in 
animal models (Irwin, 1968). 
P301S and C57BL/6 mice that received a saline injection appeared “normal for their 
phenotype” and scored 0 throughout the experiment (Figure 11 B).  
LPS-injected C57BL/6 mice were still phenotypically normal 2-hours post-injection 
but at 4-hours post-injection some had become hunched and slower to respond, 
scoring 1 on the acute sickness scale. This persisted until 12-hours post-injection but 
all C57BL/6 mice had recovered to normal activity by 24-hours post-injection (Figure 
11 B).  
LPS-injected P301S mice were phenotypically normal 2-hours post-injection but by 4-
hours post-injection all the P301S mice scored 1 on the Acute Sickness Scale. By 6-
hours P301S mice were hunched up and very slow to respond, their coats were 
unkempt and showing signs of piloerection and they showed signs of ocular 
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discharge. At 12-hours the inflammatory response had progressed to a thick coating 
of discharge around the eyes and in some cases mice showed signs of diarrhoea. 24-
hours post-injection P301S mice were still slow to respond but by 36-hours post-
injection P301S mice had fully recovered and appeared normal for their phenotype 
(Figure 11 B).  
The area under the curve data indicated that LPS-injected P301S mice had a 
significantly more severe response than C57BL/6 mice overall (C57BL/6 + LPS: 1.9; 
p=0.006; 95% CI 0.6 to 3.2; P301S + LPS: 6.9; p<0.001; 95% CI 5.7 to 8.1). The differential 
effect of LPS was also greater in P301S mice than C57BL/6 mice when formally tested 
(differential 5.0; p < 0.001; 95% CI 3.0 to 6.9) (Figure 11 B). 
 Equivalent LPS-induced weight loss in P301S and C57BL/6 mice 
Mice were weighed 24, 12 and 1-hour(s) prior to intraperitoneal injections (averaged 
to generate baseline weight) and 2, 4, 6, 12, 24 and 36-hours after injections (Figure 
10). C57BL/6 mice weigh more than P301S mice hence the weight in grams was 
converted to weight as a percentage of baseline weight for each mouse.  
There was subtle weight loss in saline-injected C57BL/6 (hourly change -0.1%; 
p=0.008; 95% CI -0.2 to 0.0) and P301S mice over time (additional 0.0%; p=0.876; 95% 
CI -0.1 to 0.1) (Figure 11 C). LPS induced an additional hourly loss of 0.3% of baseline 
body weight in C57BL/6 mice (additional -0.3%; p<0.001; 95% CI -0.4 to -0.2) which 
equates to approximately 10% of total body weight over the 36-hour recorded time- 
period. LPS induced an hourly loss of 0.2% of baseline body weight in P301S mice 
compared with saline-injected counterparts (-0.2%; p<0.001; 95% CI -0.3 to -0.1). There 
was no differential effect of LPS in P301S mice compared with C57BL/6 mice 
(additional 0.0%; p=0.671; 95% CI -0.1 to 0.2) (Figure 11 C). 
 LPS-induced Hypothermia in P301S mice 
Temperature recordings were taken 24-hours prior to injection, and then 4, 6 and 12-
hours post-injection. While the temperature of C57BL/6 mice appeared relatively 
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stable across the time-period of the experiment the temperature of P301S mice 
injected with LPS dipped at 4-hours and remained low at 6-hours before recovering 
at 24-hours. The area under the curve (AUC) was calculated for individual mice to 
compare their overall experience of temperature fluctuations during the experiment. 
Mixed effects linear regression of AUC data indicated that P301S mice were colder 
than C57BL/6 mice (ΔAUC: -4.4; p=0.008; 95% CI -7.5 to -1.4) (Figure 11 D). LPS did 
not impact the temperature of C57BL/6 mice (ΔAUC: -1.7; p=0.186; 95% CI -4.3 to 0.9) 
but LPS did cause a further decrease in temperature in P301S mice compared with 
saline-injected counterparts (ΔAUC: -4.4; p=0.026; 95% CI -7.9 to -0.8). The differential 





Figure 11 - Exaggerated impact of intraperitoneal LPS-injection in P301S mice compared with control 
mice. A) Open field - distance travelled in an open field arena by C57BL/6 (blue) and P301S mice (red) was 
recorded 24h pre- and 4-, 24- and 36-hours post-injection with either saline or LPS. Distance travelled by LPS-
injected mice is expressed as a percentage of distance travelled by saline-injected counterparts. 24h pre-injection 
groups travelled the same distance as their saline-injected counterparts. 4h post-injection LPS impacted open field 
activity of C57BL/6 and P301S mice (mixed effects linear regression, indicated by **p<0.001, **p<0.0001). 24-
hours post-injection LPS-injected C57BL/6 mice had recovered compared with saline-injected counterparts, LPS 
injected P301S mice had not (indicated by *p<0.05). 36h post-injection all groups had recovered compared with 
saline-injected counterparts.  B) Acute Sickness Score – the severity of the sickness response of C57BL/6 and P301S 
mice was scored regularly post-injection with saline or LPS (defined Table 14). The area under the curve (AUC) 
was calculated for individuals and mixed effects linear regression showed that LPS impacted C57BL/6 and P301S 
mice (indicated by * p<0.05, ** p<0.0001 respectively). C) Weight loss – P301S and control mice were weighed 
regularly following injection. LPS induced equivalent weight loss in C57BL/6 and P301S mice over the 24-hours 
post-injection (mixed effects linear regression). (A-C: C57BL/6 + Saline n=10, C57BL/6 + LPS n=10, P301S + 
Saline n=8, P301S + LPS n=9) D) External temperature – an infrared thermometer laser pointer gun was used to 
record temperature of C57BL/6 and P301S mice 24-hours pre-injection and 4-, 6- and 12-hours post-injection with 
either saline or LPS. The area under the curve (AUC) was calculated for individuals and mixed effects linear 
regression showed that P301S mice were colder overall (p<0.01) and LPS did not impact the temperature of 
C57BL/6 mice but caused a decrease in temperature in P301S mice compared with saline injected counterparts 




 Exaggerated Acute Horizontal Bar Deficit in P301S mice 
Prior to injection there was no initial difference in horizontal bar performance 
between genotypes or intervention groups and performance was stable throughout 








Intercept     
Reference baseline score 
(C57BL/6 + Saline) 
9.9 0.000 9.1 10.8 
Δ Baseline P301S -0.2 0.164 -0.6 0.1 
Δ Baseline LPS -0.2 0.138 -0.6 0.1 
Δ Baseline P301S + LPS 
(interaction term) 
-0.1 0.749 -0.5 0.4 
Weekly rate of change     
Reference weekly change 
(C57BL/6 + Saline) 
0.0 0.522 0.1 0.2 
Δ Weekly change P301S  0.0 0.731 -0.1 0.2 
Δ Weekly change LPS 0.0 0.863 -0.2 0.1 
Δ Weekly change P301S + 
LPS (interaction term) 
0.0 0.795 -0.2 0.2 
Table 15 – Baseline horizontal bar score prior to injection (8-10 weeks) The first term represents baseline 
performance for the C57BL/6 group receiving saline. The following two terms test for an independent effect of 
genotype and intervention. The fourth term tests for a difference in the independent effect of LPS between 
genotypes. The last four terms can be interpreted in the same way but show differences in the weekly rate of change 
in performance.  
On the week of injection mice were assessed 24-hours and 1-hour prior to injection 
and then 6-hours and 24-hours post-injection. Within time-point comparisons 
demonstrated the following. 
24-hours prior to injection: All groups were at peak performance. There were no 
differences between genotype or LPS groups (See Figure 12 and Table 16 for details).  
6-hours post-injection: Saline-injection had no effect on acute horizontal bar 
performance in P301S mice or controls; 6-hours post saline-injection C57BL/6 mice 
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could maintain a high score of 10.0 and saline-injected P301S mice were not 
significantly different (see Figure 12 and Table 16 for details). LPS injection did, 
however, influence horizontal bar performance; all LPS-injected C57BL/6 mice 
successfully completed the task but they were slower to complete the task and this 
was reflected in the score (see Figure 12 and Table 16 for details). Horizontal bar 
performance of LPS-injected P301S mice was also impaired; four of thirteen LPS-
injected P301S mice failed the task at least twice thus LPS-injected P301S mice scored 
significantly less than saline-injected counterparts (-4.3; p<0.001; 95% CI -5.5 to -3.2). 
P301S mice also had a much more severe acute sickness response compared with LPS-
injected C57BL/6 mice and this differential effect was reflected by interaction term 
(see Figure 12 and Table 16 for details). 
24-hours post-injection: LPS-injected C57BL/6 mice had recovered to baseline 
performance 24-hours after injection (see Figure 12 and Table 16 for details). LPS-
injected P301S mice had almost but not fully recovered by this time compared with 
saline-injected counterparts (-0.5; p=0.014; 95% CI -0.9 to -0.1). The interaction term 
which formally tests the difference in the independent effect of LPS on C57BL/6 and 







































































































































































































































































































































































































































































































Figure 12 - Exaggerated impact of intraperitoneal LPS-injection on horizontal bar performance of  P301S 
mice compared with control mice. Horizontal bar task - performance of C57BL/6 (blue) and P301S mice (red) 
was tested weekly before and after intraperitoneal LPS (500 μg/kg) (triangle) or saline (circle) administration. 
During the acute period mice were tested 24-hours and 1-hour prior to injection and 6- and 24- hours post-injection 
(indicated by the grey area). 6-hours post-i.p.-injection LPS significantly impacted horizontal bar performance of 
C57BL/6 and P301S mice (mixed effects linear regression, indicated by *p<0.05, **p<0.0001). The impact of LPS 
on P301S horizontal bar performance was significantly greater than control mice (p<0.0001). All mice had 
recovered to baseline by 24h post-injection and continued to perform well until 16 weeks. Piecewise mixed effects 
linear regression showed that LPS administration at 10 weeks had no lasting effect on the trajectory of decline 




 Effect of early systemic inflammation on chronic horizontal bar 
performance 
All mice had recovered to peak performance following the acute sickness response. 
C57BL/6 mice maintained that healthy baseline performance throughout the rest of 
the experiment, regardless of whether they were injected with saline or LPS at week 
10 (Figure 12). 
For P301S mice, however, there were two distinct phases:  the stable phase (phase 1; 
10-16 weeks) and the declining phase (phase 2; 16-20 weeks) (Figure 12). During the 
stable phase both P301S groups maintained the steady baseline score (Figure 12 and 
Table 17). During the declining phase saline-injected P301S mice lost on average 0.8 
points per week on the horizontal bar task (Figure 12 and Table 17). Mixed effects linear 
regression of the whole 16-to-22-week period indicates that LPS-injection at 10 weeks 
of age did not impact on the rate of decline in horizontal bar performance during the 
decline phase, however it should be noted that the first cohort of mice was sacrificed 
at 20 weeks of age and thus there was a loss of statistical power at 21 and 22 weeks of 



















































































































































































































































































































































































































































































































































































































































































































4.3.2 Late systemic inflammation 
As described in the introduction, it is likely that the degree of underlying pathology 
in the P301S mouse will influence the extent of vulnerability to subsequent 
inflammatory challenge. This might manifest as heightened or longer lasting acute 
sickness and/or larger effects on the trajectory of the disease as measured by 
horizontal bar performance. To investigate this hypothesis further, mice were 
exposed to the same dose of LPS at 16 weeks of age instead of at 10 weeks and were 
monitored as per the schematic in Figure 13. At 16 weeks of age there is significant 
neuronal loss and more advanced astrogliosis in the cortex of P301S mice, there is 
astrogliosis and microgliosis in the spinal cord. They are also on the brink of the 
decline in motor function detected on the horizontal bar task. 
 
Figure 13 – Late systemic inflammation - experimental design schematic. C57BL/6 and P301S mice were 
tested on the horizontal bar weekly. They were injected with either Saline or LPS at 16 weeks of age and during the 
acute phase were tested on the horizontal bar and distance travelled in open-field, Acute Sickness Score, weight and 




 Exaggerated Acute Sickness Response in P301S mice  
 Prolonged reduction in locomotion in LPS treated P301S mice 
24-hours prior to injection there was no difference within genotypes between LPS and 
saline groups (C57BL/6 + LPS vs C57BL/6 + Saline: -9.4%; p=0.394; 95% CI -31.7 to 12.9; 
P301S + LPS vs P301S + Saline: 12.5%; p=0.260; 95% CI -10.4 to 35.4) (Figure 14A). 
Again, LPS caused a decrease in activity in both groups of mice. At 4-hours post-
injection LPS-injected C57BL/6 mice travelled significantly less than saline-injected 
counterparts (-72.1%; p<0.001; 95% CI -92.3 to -51.8) (Figure 14A). LPS-injected P301S 
mice also travelled significantly less than saline-injected counterparts (-75.2%; 
p<0.001; 95% CI -100.0 to -50.4). There was no differential effect of LPS on P301S mice 
(-3.1%; p=0.826; 95% CI -32.2 to 25.9) (Figure 14A). 
24-hours post-LPS-injection C57BL/6 mice had recovered to normal activity 
compared with saline-injected counterparts (-0.5%; p=0.983; 95% CI -43.1 to 42.2). 
Whereas P301S mice had not (-43.9%; p=0.051; 95% CI -88.0 to 0.3) however when 
formally tested this differential effect of LPS on P301S mice was not significant 
(-43.4%; p=0.158; 95% CI -104.8 to 18.0) (Figure 14A). 
By 36-hours post-LPS-injection both C57BL/6 mice and P301S mice had recovered to 
similar levels to saline-injected counterparts (C57BL/6 + LPS vs C57BL/6 + Saline: 
0.0%; p=1.000; 95% CI -48.2 to 48.2; P301S + LPS vs P301S + Saline: 0.0%; p=1.000; 95% 
CI -51.4 to 51.4) (Figure 14A). 
Comparison of open field data from mice injected at 10 weeks of age with mice 
injected at 16 weeks of age indicated that the LPS-induced decrease in locomotor 
activity 4-hours post-injection was not affected by the age of injection (16 week 
C57BL/6 + LPS vs 10 week C57BL/6 + LPS: -17.1%; p=0.363; 95% CI -54.6 to 20.3; 16 
week P301S + LPS vs 10 week P301S + LPS: 12.8%; p=0.522; 95% CI -27.8 to 53.5) 
(Figure 11A and Figure 14A). This, and all future comparisons come with the caveat 
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that animals injected at 10 weeks and 16 weeks of age were not treated with LPS at 
the same time and so comparisons are across different experiments on different days. 
The delayed recovery from LPS-injection measured 24-hours post-injection was also 
equivalent in mice injected at 16 weeks of age compared with mice injected at 10 
weeks of age (16 week C57BL/6 + LPS vs 10 week C57BL/6 + LPS: 10.1%; p=0.704; 95% 
CI -42.8 to 63.0; 16 week P301S + LPS vs 10 week P301S + LPS: 7.1%; p=0.819; 95% CI 
-55.8 to 70.1) (Figure 11A and Figure 14A). 
 Elevated Acute Sickness Score in P301S mice following LPS injection 
Mice were scored according to the Acute Sickness Scale (Table 14). As before saline-
injected C57BL/6 and P301S mice were normal throughout the experiment and scored 
0 (Figure 14B).  
At 4 and 6-hours post-injection C57BL/6 mice injected with LPS were all hunched and 
slow to respond, scoring 1 on the acute sickness scale; at 12-hours post-injection they 
showed signs of piloerection and by 24-hours post-injection C57BL/6 mice had fully 
recovered (Figure 14B). 
At 4-hours post-LPS injection P301S mice reacted the same as control mice, however 
by 6-hours post-injection P301S mice were extremely unwell and 7 of 8 mice scored a 
4 – they were hunched and unresponsive when disturbed and showed signs of 
piloerection, inflammatory eye reaction and diarrhoea. This persisted at 12-hours 
post-injection. By 24-hours post-LPS-injection P301S mice had improved but still 
showed signs of an inflammatory response in the eye, piloerection and were slow to 
respond. By 36-hours post-injection LPS-injected P301S mice had still not fully 
recovered (Figure 14B).  
Mixed effects linear regression comparing area under the curve data indicated that 
LPS-injected P301S mice had a significantly greater response than LPS-injected 
C57BL/6 mice (C57BL/6 + LPS: 3.9; p=0.001; 95% CI 1.7 to 6.1; P301S + LPS: 10.5; 
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p<0.001; 95% CI 7.3 to 13.7). The effect of LPS was also greater in P301S mice than 
C57BL/6 mice when formally tested (differential 6.6; p < 0.001; 95% CI 3.5 to 9.7). 
Comparison of AUC data from mice injected at 16 weeks of age with those injected at 
10 weeks of age indicated no differential LPS-induced acute sickness response in 
C57BL/6 mice (16 week C57BL/6 + LPS vs 10 week C57BL/6 + LPS: 2.0; p=0.106; 95% 
CI -0.4 to 4.4) but 16 week old P301S mice had a significantly worse experience than 
those injected at 10 weeks of age (16 week P301S + LPS vs 10 week P301S + LPS: 
additional 3.6; p=0.029; 95% CI 0.4 to 6.8) (Figure 11B and Figure 14 B). 
 Exaggerated LPS-induced weight loss in P301S compared with C57BL/6 
mice 
Mice were weighed 24, 12 and 1-hour(s) prior to injection (these were averaged to 
determine baseline weight) and 2, 4, 6, 12, 24 and 36-hours post-injection (Figure 14C). 
Mixed effects linear regression indicated that saline-injected C57BL/6 mice and P301S 
mice maintained their body weight over the 36-hour period (C57BL/6 + saline hourly 
change: -0.1%; p=0.133; 95% CI -0.2 to 0.0; P301S + saline hourly change: 0.1%; p=0.352; 
95% CI -01 to 0.2). 
LPS-injected C57BL/6 mice lost 0.4% of their baseline body weight every hour 
(additional hourly change: -0.3%; p<0.001; 95% CI -0.5 to -0.2). LPS-injected P301S 
mice lost on average 0.6% of their body weight every hour (additional hourly change 
vs P301S + saline: -0.6; p<0.001; 95% CI -0.8 to -0.4). The differential effect of LPS on 
P301S mice was significant when formally tested (-0.3; p=0.029; 95% CI -0.05 to 0.0) 
(Figure 14C).  
Comparison of data from mice injected at 16 weeks of age with those injected at 10 
weeks of age indicated no difference in the LPS-induced weight loss in C57BL/6 mice 
(additional hourly change 16 week C57BL/6 + LPS vs 10 week C57BL/6 + LPS:  0.0%; 
p=0.646; 95% CI -0.3 to 0.2) however there was an additional LPS-induced weight loss 
in P301S mice injected at 16 weeks compared with those injected at 10 weeks of age 
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(additional hourly change 16 week P301S + LPS vs 10 week P301S + LPS: -0.3; p=0.018; 
95% CI -0.4 to 0.0).  
 Failure to detect LPS-induced hypothermia 
External body temperature recordings were taken 24 hours prior to injection, as well 
as 4, 6 and 24-hours post-injection (Figure 14D). Comparison of AUC data for 
individual mice indicated that P301S mice might be slightly colder than C57BL/6 
mice, although this did not reach significance at α= 0.05 (ΔAUC: -5.0; p=0.091; 95% CI 
-10.8 to 0.8). LPS had no significant impact on C57BL/6 mice (ΔAUC: -4.2; p=0.155; 
95% CI -10.0 to 1.7) or on P301S mice (ΔAUC: -4.6; p=0.253; 95% CI -12.9 to 3.7) and 
there was no differential effect of LPS on P301S mice (ΔAUC: -0.5; p=0.910; 95% CI -
8.7 to 7.8) (Figure 14D).  
Comparison of temperature AUC data from mice injected at 16 weeks of age with that 
of mice injected at 10 weeks of age indicated no significant differences in the LPS-
induced hypothermic response in control mice (16 week C57BL/6 + LPS vs 10 week 
C57BL/6 + LPS: -2.5; p=0.529; 95% CI -10.3 to 5.4) or P301S mice (16 week P301S + LPS 





Figure 14 - Exaggerated impact of intraperitoneal LPS injection in P301S mice compared with control 
mice. A) Open field - distance travelled in an open field arena by C57BL/6 (blue) and P301S mice (red) was 
recorded 24h pre-injection and 4- and 24- hours post-injection with either saline or LPS. Distance travelled by 
LPS-injected mice is expressed as a percentage of distance travelled by saline-injected counterparts. 24h pre-
injection groups travelled the same distance as their saline-injected counterparts. 4-hours post-injection LPS 
impacted open field activity of C57BL/6 and P301S mice (indicated by **p<0.0001). 24h- post-injection LPS-
injected C57BL/6 mice had recovered compared with saline-injected counterparts, LPS-injected P301S mice had 
not (indicated by *p<0.05). By 36h post-injection all groups had recovered compared with saline-injected 
counterparts. B) Acute Sickness Score – the severity of the sickness response of C57BL/6 and P301S mice was 
scored regularly post-injection with saline or LPS (defined Table 14). The area under the curve (AUC) was 
calculated for individuals and mixed effects linear regression showed that LPS had a significant impact on C57BL/6 
and P301S mice (indicated by * p≤0.001 and ** p<0.0001 respectively). C) Weight loss – P301S and control mice 
were weighed regularly following injection. LPS induced weight loss in C57BL/6 and P301S mice over the 24-
hours post-injection. LPS had a very slightly, but significantly, greater effect on P301S mice compared with 
controls (mixed effects linear regression, see results for more details). D) External temperature – an infrared 
thermometer laser pointer gun was used to record temperature of C57BL/6 and P301S mice 24-hours pre-injection 
and 4-, 6- and 12- hours post-injection with either saline or LPS. The area under the curve (AUC) was calculated 
for individuals and mixed effects linear regression showed that LPS had no significant effect on external 
temperature of C57BL/6 or P301S mice (A-D: C57BL/6 + Saline n=8, C57BL/6 + LPS n=8, P301S + Saline n=8, 





 Exaggerated Acute Horizontal Bar Deficit in P301S mice 
As before all groups could achieve and maintain a steady baseline performance in the 
weeks prior to i.p. injection (see Figure 15 and Table 18 for details). There was no 







Intercept    
Reference baseline (C57BL/6 
+ Saline) 
9.9 0.000 9.8 10.0 
Δ Baseline P301S -0.1 0.118 -0.3 0.0 
Δ Baseline LPS 0.0 0.904 -0.2 0.2 
Δ Baseline P301S + LPS 
(interaction term) 
0.1 0.342 -0.1 0.4 
Weekly rate of change     
Reference weekly change 
(C57BL/6 + Saline) 
0.0 0.397 0.0 0.0 
Δ Weekly change P301S  0.0 0.369 0.0 0.0 
Δ Weekly change LPS 0.0 0.842 0.0 0.0 
Δ Weekly rate of change 
P301S + LPS (interaction 
term) 
0.0 0.682 0.0 0.0 
Table 18 - Baseline Horizontal bar performance prior to injection (8-10 weeks) The first term represents baseline 
performance for the C57BL/6 group receiving saline. The following two terms test for an independent effect of 
genotype and intervention. The fourth term tests for a difference in the independent effect of LPS between 
genotypes. The last four terms can be interpreted in the same way but show differences in the weekly rate of change 
in performance.  
On the week of injection mice were assessed 24-hours and 1-hour prior to injection 
and then 6-hours, 24-hours and 36-hours post-injection. Within time-point 
comparisons demonstrated the following. 
24-hours prior to injection: All groups were at peak performance. There were no 
differences between genotype or LPS groups (Figure 15 and Table 19).  
6-hours post-injection: Saline-injection did not influence horizontal bar performance 
of C57BL/6 or P301S mice at 6-hours post-injection (Figure 15 and Table 19). LPS-
174 
 
injection at 16 weeks impaired horizontal bar performance of C57BL/6 mice 6-hours 
post-injection. As before, all the LPS-injected C57BL/6 mice successfully reached the 
platform but they were slower to do so than saline-injected counterparts and thus 
they scored significantly less (Figure 15 and Table 19). LPS-injection at 16-weeks had a 
more severe effect on P301S mice than on C57BL/6 mice. Just one of seven mice 
completed the task without falling from the bar, five of seven mice fell off twice or 
more and of the successful attempts, the average time taken to reach the platform was 
31.8 seconds. Hence at 6-hours post-LPS-injection P301S mice scored significantly less 
than saline-injected counterparts (-5.1; p<0.001; 95% CI -6.0 to -4.1) and the differential 
effect of LPS was greater in P301S mice than C57BL/6 mice when formally tested 
(Figure 15 and Table 19). 
24-hours post-injection: LPS-injected C57BL/6 mice had fully recovered compared 
with saline-injected counterparts by 24-hours post-injection whereas P301S mice had 
not (Figure 15 and Table 19); three of seven LPS-injected P301S mice fell from the bar 
at least once. Hence 24-hours post-injection LPS-injected P301S mice scored 
significantly less than saline-injected counterparts (-3.0; p=0.018; 95% CI -5.4 to -0.6). 
The differential effect of LPS on P301S mice compared to C57BL/6 mice was 
significant (Figure 15 and Table 19). 
36-hours post-injection: All groups had recovered to baseline performance; there 
were no impacts of genotype or LPS exposure (Figure 15 and Table 19). 
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Figure 15 - Exaggerated impact of intraperitoneal LPS-injection on acute horizontal bar performance 
P301S mice compared with control mice and chronic performance compared with saline-injected group. 
Horizontal bar task - performance of C57BL/6 (blue) and P301S mice (red) was tested weekly before and after 
intraperitoneal LPS (500 μg/kg) (triangle) or saline (circle) administration. During the acute period mice were 
tested 24 hours and 1 hour prior to injection and 6- 24- and 36- hours post-injection (indicated by the grey area). 
6h post-injection LPS significantly impacted C57BL/6 and P301S horizontal bar performance (mixed effects linear 
regression, *p<0.05, **p<0.0001). The impact of LPS on P301S horizontal bar performance was significantly 
greater than control mice (p<0.0001). 24h post LPS-injection C57BL/6 mice had recovered but P301S mice had 
still not recovered to baseline performance (*p<0.05). By 36h post-injection all mice had recovered to baseline 
performance. Mixed effects linear regression showed that LPS administration at 16 weeks advances the decline in 
performance during the chronic phase (16-22 weeks) (p<0.001). (C57BL/6 + Saline n=8, C57BL/6 + LPS n=8, 

































































































































































































































































































































































































































































































































































































6-hours post-injection: The impact of LPS-injection on horizontal bar performance 
was not different when mice were injected at 16 weeks of age compared with mice 
injected at 10 weeks of age for C57BL/6 mice or P301S mice (16 week C57BL/6 + LPS 
vs 10 week C57BL/6 + LPS: 0.2; p=0.733; 95% CI -1.0 to 1.4; 16 week P301S + LPS vs 10 
week P301S + LPS: -0.7; p=0.374; 95% CI -2.3 to 0.9) (Figure 16).  
24-hours post-injection: P301S mice injected with LPS at 10 weeks of age had fully 
recovered whereas P301S mice injected with LPS at 16 weeks of age had not, hence 
there was a differential impact of age of injection for P301S mice but not C57BL/6 mice 
(16 week C57BL/6 + LPS vs 10 week C57BL/6 + LPS: 0.1; p=0.822; 95% CI -1.1 to 1.3; 16 
week P301S + LPS vs 10 week P301S + LPS: -2.5; p=0.006; 95% CI -4.2 to -0.7) (Figure 
16).  
  
Figure 16 – Longer lasting impact of intraperitoneal LPS-injection on horizontal bar performance in 16 
week old P301S mice compared with 10 week old mice. C57BL/6 (blue) and P301S mice (red) were injected 
with LPS (i.p., 500 μg/kg) (triangle) or saline (circle) at 10 (dotted line) or 16 (solid line) weeks of age. Horizontal 
bar task - performance was tested 24-hours and 1-hour prior to injection and 6-, 24-, and 36- hours after injection. 
6-hours post-injection the impact of LPS-injection on horizontal bar performance of P301S mice was not affected 
by age of injection. However, 24-hours post-LPS-injection there was a differential impact of age of injection for 
P301S mice (mixed effects linear regression, p<0.01). By 36-hours post-injection all mice had recovered to baseline 
performance. (10 week: C57BL/6 + LPS n=14, P301S + Saline n=11, P301S + LPS n=13, 16 week: C57BL/6 + LPS 
n=8, P301S + Saline n=8, P301S + LPS n=7). 
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 Effect of systemic inflammation on chronic horizontal bar 
performance 
All groups fully recovered following the acute sickness response. C57BL/6 mice 
maintained a steady baseline for the remainder of the experiment regardless of 
whether they were exposed to saline or LPS at 16 weeks of age (Figure 15 and Table 
20). P301S mice however showed a progressive decline from 16 to 22 weeks of age. 
On average during the chronic phase saline-injected P301S mice lost 1 point per week. 
LPS-injection significantly increased the rate of decline in P301S mice (Figure 15 and 
Table 20). The differential effect of LPS was greater in P301S mice than C57BL/6 mice 
when formally tested.  
 Estimated 
mean 
p  95% Confidence 
Interval 
Intercept     
Reference baseline (C57BL/6 
+ Saline) 
9.9 0.000 9.1 10.8 
Δ Baseline P301S -0.2 0.675 -1.4 0.9 
Δ Baseline LPS -0.1 0.931 -1.2 1.1 
Δ Baseline P301S + LPS 
(interaction term) 
-0.3 0.747 -2.0 1.4 
Weekly rate of change     
Reference weekly change 
(C57BL/6 + Saline) 
0.0 0.936 -0.1 0.1 
Δ Weekly change P301S  -1.0 0.000 -1.2 -0.9 
Δ Weekly change LPS 0.0 0.985 -0.2 0.2 
Δ Weekly rate of change 
P301S + LPS (interaction 
term) 
-0.4 0.001 -0.6 -0.2 
Table 20 -  Horizontal bar performance during the declining phase. The first term represents baseline performance 
for the C57BL/6 group receiving saline. The following two terms test for an independent effect of genotype and 
intervention. The fourth term tests for a difference in the independent effect of LPS between genotypes. The last 
four terms can be interpreted in the same way but show differences in the weekly rate of change in performance
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The chronic decline in horizontal bar performance of P301S mice injected at 10 weeks 
of age was compared with that of mice injected at 16 weeks. Mixed effects linear 
regression demonstrated no differences between any of the C57BL/6 groups 
regardless of age of injection or LPS exposure. There was no difference in the rate of 
decline of horizontal bar performance of saline-injected P301S mice between cohorts 
(16 week P301S + Saline vs 10 week P301S + Saline: additional weekly change -0.2; 
p=0.148; 95% CI -0.5 to 0.1). LPS-injection into 16-week-old, but not 10-week-old, 
P301S mice increased the rate of decline of horizontal bar performance compared with 
saline-injected counterparts, however, when formally tested, the differential impact 
of the age of LPS-injection was not significant at α=0.05 (additional weekly change -
0.4; p=0.062; 95% CI -0.8 to 0.0) (see Figure 17).  
Figure 17 - LPS-injection into 16-week-old, but not 10-week-old, P301S mice increased the rate of decline 
of horizontal bar performance but the differential impact of age of LPS-injection was not significant. 
C57BL/6 (blue) and P301S mice (red) were injected with LPS (i.p., 500 μg/kg) (triangle) or saline (circle) at 10 
(dotted line) or 16 (solid line) weeks of age. Horizontal bar task performance was tested weekly from 16-22 weeks 
of age. Mixed effects linear regression showed that LPS injection at 16 weeks, but not 10 weeks of age, advances the 
decline in performance during the chronic phase (16-22 weeks) but when formally tested the differential impact of 
age of injection was not significant (p=0.062). (For details of 10 week n’s see Figure 12; 16 week: C57BL/6 + LPS 
n=8, P301S + Saline n=8, P301S + LPS n=7). 
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4.4 Results Summary 
The measures of the acute response to LPS discussed above are summarised in Table 
21. The Acute Sickness Score indicated that P301S mice suffered more severe and 
longer lasting symptoms of LPS-induced sickness than C57BL/6 mice. They also took 
longer to return to normal open field activity compared with C57BL/6 mice, and while 
P301S mice injected at 10 weeks of age showed no difference in percentage weight 
loss compared with control mice, P301S mice injected at 16 weeks of age showed 
additional weight loss compared with age matched C57BL/6 mice or younger P301S 
mice. P301S mice injected at 10 weeks of age also showed signs of exaggerated 
hypothermia compared with C57BL/6 mice. The cause for the exaggerated response 
to LPS in P301S mice remains to be determined. 
 















activity @4h (% 
saline injected 
counterpart) 






100.0 -10.6 100.0 40.4 10.1 7.1 
Acute Sickness 
Score (AUC) 
0.0 1.9 0.0 5.0 2.0 3.6 
Hourly weight 
loss (as % 
baseline) 
-0.1 -0.3 0.0 0.0 0.0 -0.3 
Hypothermia 
(AUC) 
120.4 -1.7 -4.4 -2.7 -2.5 -0.3 
Table 21 – The acute impact of LPS on phenotype of C57BL/6 and P301S mice at 10 and 16 weeks of age 
- summary table: The Reference column shows the open field activity at 4- and 24-hours post-injection, Acute 
Sickness Score (AUC), hourly weight loss and temperature (AUC) of C57BL/6 mice injected with saline. The 
following two columns test for an independent effect of LPS or genotype on each of those measures. The fourth term 
tests for a difference in the independent effect of LPS between genotypes. The 5th column tests for a difference in 
the independent effect of LPS between 10 week and 16 week old C57BL/6 mice. The 6th term tests for a differential 
effect of LPS in P301S mice injected at 16 weeks compared with P301S mice injected at 10 weeks. Bold and 




The current study demonstrates that an early systemic inflammatory insult in pre-
symptomatic P301S tau mice (i.e. at 10 weeks of age) caused an exaggerated acute 
sickness response compared with age-matched control mice; LPS-injected P301S mice 
had a significantly higher sickness score than LPS-injected C57BL/6 mice (Figure 11 
B). Importantly, exaggerated acute symptoms extended beyond those typically 
associated with the sickness behaviour; LPS induced an exaggerated acute 
impairment of horizontal bar performance (Figure 12) in P301S mice compared with 
controls –  a function which is known to be impaired in P301S mice later in disease 
and is associated with underlying disease pathology. These data suggest an 
interaction between acute inflammation and existing CNS vulnerability that brings 
about acute neurological dysfunction that is not a feature observed in sickness in a 
normal animal. 
Additionally, the degree of underlying pathology at the time of injection seems to be 
important in determining the magnitude and duration of acute impairments. 
Although LPS-injection at 16 weeks of age had the same effect on C57BL/6 mice as 
injection at 10 weeks of age according to all observed outcomes, P301S mice injected 
at 16 weeks of age had a significantly higher Acute Sickness Score than those injected 
at 10 weeks of age (Figure 14 B). In addition, the acute horizontal bar performance of 
P301S mice injected with LPS at 16 weeks of age was significantly more impaired than 
LPS-injected C57BL/6 mice 6-hours post-injection, and unlike those injected at 10 
weeks of age, LPS-injected P301S mice had still not recovered to baseline horizontal 
bar performance 24-hours post-injection (Figure 15). These data are consistent with 
clinical studies showing that increased age and the presence of dementia confer 
greater vulnerability to delirium (Ahmed et al., 2014). 
Furthermore, these data go on to demonstrate that an acute inflammatory event in 
pre-symptomatic mice with the P301S tau mutation was sufficient to negatively 
impact the disease-associated decline in performance of P301S mice and this effect 
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was greater in P301S mice injected at 16 weeks of age rather than at 10 weeks of age. 
Again, these data are consistent with clinical studies showing that episodes of 
delirium are a risk factor for chronic cognitive decline, and that prior 
neurodegeneration increases the strength of this relationship (Davis et al., 2017).  
4.5.1 Exaggerated acute sickness response 
Illness and infection induce well-characterised physiological and behavioural 
changes that are conserved in vertebrates; together they comprise an evolved, 
adaptive strategy that is beneficial in fighting infection. These coordinated behaviours 
exist to conserve energy required to mount an immune response and limit the spread 
of infection.  
Mice were injected with LPS (500 µg/kg) or saline and were monitored over the 
following hours and days.  During the pilot study observations were recorded in 
chronological order, allowing development of a semi-quantitative Acute Sickness 
Scoring System (see Table 14), which was then applied to all future cohorts at regular 
intervals. Recorded observations included hunched posture, piloerection, ocular 
discharge, diarrhoea and the degree of responsiveness when disturbed (Irwin, 1968, 
Grossberg, 2011).  
The Acute Sickness Score demonstrated that P301S mice had a significantly more 
severe response than C57BL/6 mice (Figure 11B). At 10 weeks of age at the peak of 
sickness behaviour LPS-injected C57BL/6 mice had hunched posture and were slower 
to respond when disturbed, however these observations were short-lived, whereas 
P301S mice were significantly more affected than control mice and exhibited all the 
symptoms described above. The acute effects of LPS also persisted in P301S mice for 
longer than in control mice.  
This impact of LPS on P301S mice Acute Sickness Score was even worse still when 
mice were injected at 16 weeks of age: P301S mice had still not fully recovered at the 
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final time point 36-hours post-injection. In hindsight, observations ought to have been 
carried out until mice had fully recovered.  
It should be noted that the Acute Sickness Score is a semi-quantitative measurement 
based on subjective observations and blinding to genotype was not possible since 
mice are different colours. Blinding to treatment was also unrealistic since it was 
abundantly clear which mice had been exposed to saline versus LPS, nor age at which 
mice were injected since experiments were not run in parallel. Ideally Acute Sickness 
Scoring would have been conducted by an independent observer blind to all variables 
tested. This scoring method is in principle similar to the Grading System for Clinical 
Assessment of EAE (Fuller et al., 2004) whereby there is a chronological progression 
of symptoms which determines the severity of the score. Since the symptoms 
associated with sickness behaviour are not as chronologically conserved it might be 
worth modifying the scoring method to something more similar in structure to the 
Irwin Neurological Test Battery whereby criteria are rated independently based on 
presence or absence and in some cases severity and all the scores are added up.  
Hypoactivity is another typically observed sickness behaviour, hence, the distance 
travelled by mice in an open field chamber was recorded at multiple time points 
following injection in order to identify any differences in activity (Figure 11A and 
Figure 14A). It has previously been demonstrated that 1) P301S mice have increased 
exploratory behaviour in the open field compared with control mice (Scattoni et al., 
2010, Torvell et al., 2013), 2) regardless of genotype there is a significant experience-
dependent decrease in distance travelled when mice are repeatedly retested in the 
open field arena; this happens as mice become habituated to this environment 
(Bolivar, 2009), and 3) open field activity fluctuates across the day (Gould et al., 2009). 
Hence here the distance travelled by LPS-injected mice was expressed as a percentage 
of the distance travelled by saline-injected counterparts at that time point.  
LPS-injection induced equivalent hypoactivity in P301S and C57BL/6 mice compared 
with their saline-injected counterparts 4-hours post LPS-injection. This result is 
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typical of a 500 µg/kg dose of LPS (Combrinck et al., 2002), however by 24-hours post 
LPS injection C57BL/6 mice had recovered to equivalent activity compared with their 
saline-injected counterparts whereas P301S mice had not. This was true of mice 
injected at 10 or 16 weeks of age (Figure 11 A and Figure 14A). 
It is plausible that decreased activity in the open field chamber might either reflect 
neurological motor impairments or alternatively decreased motivation to engage in 
non-essential activities and since P301S mice injected at 10 weeks of age demonstrated 
normal horizontal bar performance 24-hours post-injection it is likely that the 
decreased open field activity in P301S mice at this time point is a reflection of 
decreased motivation – a known characteristic of the sickness response. Hypoactivity 
is a known feature of sickness behaviours in rodents (Irwin, 1968, Combrinck et al., 
2002) which aims to minimize muscle usage and thus conserve energy required to 
mount an immune response (Hart, 1988).   
Anorexia is another known feature of sickness behaviours in rodents (Kluger, 1991) 
hence mice were weighed at regular intervals following injection. P301S mice and 
C57BL/6 mice injected with LPS at 10 weeks of age displayed equivalent weight loss 
throughout the experiment (Figure 11 C). In hindsight mice ought to have been 
weighed until full recovery (which in C57BL/6 mice given this dose of LPS ought to 
be approximately 5 days (Weiland et al., 2007)) in case there was a difference in the 
trajectory of recovery. However, the data here indicate no difference in LPS-induced 
weight loss between P301S and C57BL/6 mice in the first 36-hours. P301S mice 
injected at 16 weeks of age showed a subtle but significant additional weight loss 
compared with LPS-injected C57BL/6 mice and compared with P301S mice injected 
at 10 weeks of age (Figure 14 C). 
Anorexia seems somewhat counterintuitive as an adaptive response to infection since 
fighting infection is so energetically costly. However, reduced food seeking 
behaviour in wild animals is beneficial for several reasons: decreased motivation for 
food and water facilitates decreased locomotion which minimizes risk of predation 
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and conserves energy by reduced muscular activity and reduced heat loss. Anorexia 
also reduces plasma iron and zinc levels – both elements are required by bacteria for 
replication and are sourced from host blood supplies, hence, during an infection iron 
is redistributed throughout the body (Kirby et al., 1982) and decreased food 
consumption helps reduce circulating iron levels and thus impairs replication of 
invading bacteria.  
Systemic-inflammation-induced anorexia is mediated by central proinflammatory 
cytokines IL-1, IL-6 and TNF-α (Layé et al., 2000). Peripheral LPS administration 
increases proinflammatory cytokine levels in the hypothalamus of mice. Central IL-1 
receptor agonist administration does not affect circulating cytokine levels but 
completely blocks IL-1β, IL-6 and TNF-α mRNA expression in the hypothalamus and 
is sufficient to partially abrogate LPS-induced anorexia (Layé et al., 2000).  It is 
plausible that the increased weight loss in P301S mice exposed to LPS at 16 weeks of 
age related to disease-associated neuroinflammation.  
LPS is known to cause hypothermia in C57BL/6 mice at ambient temperatures (Greer 
et al., 1978). Here I demonstrate an exaggerated LPS-induced hypothermia in P301S 
mice compared with LPS-injected C57BL/6 mice when mice were injected at 10 weeks 
of age (Figure 11 D) but not when they were injected at 16 weeks of age (Figure 14 D).  
Multiple pro-inflammatory molecules have been implicated in mediating LPS-
induced thermoregulatory responses, including key cytokines (IL-1β, TNF-α and IL-
6) and prostaglandins (PGE2, PGD2) (Ueno et al., 1982, Derijk et al., 1994, Chai et al., 
1996, Leon et al., 1998, Quan et al., 1999)  and the anti-inflammatory cytokine IL-10 
regulates the intensity and duration of the LPS-induced thermoregulatory response – 
IL-10 deficient mice have exaggerated and prolonged fever compared with wild type 
mice (Leon et al., 1999). It is conceivable that disease-associated dysregulation of these 
proinflammatory mediators are pivotal in producing an exaggerated hypothermic 
response in P301S mice. 
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Previous studies demonstrated an exaggerated hypothermic response to LPS (500 
µg/kg) in the ME7 prion disease model of neurodegeneration (Combrinck et al., 2002, 
Teeling et al., 2010, Murray et al., 2011), which was reversed by blocking NFκB-
dependent transcription of IL-1β and IL-6 with synthetic glucocorticoid 
dexamethasone-21-phopshate (Murray et al., 2011).  
The downstream consequences of exaggerated hypothermia could be biologically 
significant in determining the severity of the acute response and the longer-term 
impacts of this acute insult. Hypothermia prolongs the activation of NFκB and 
increases production of pro-inflammatory cytokines IL-1β and TNF-α (Fairchild et 
al., 2004) which are key in determining the magnitude of the LPS-induced acute 
sickness response. Hypothermia is also associated with increased tau 
hyperphosphorylation through inhibition of phosphatase activity which persists 1 
week later (Planel et al., 2007, Planel et al., 2009) and thus in a model of tauopathy it 
is plausible that LPS-induced hypothermia might increase tau pathology and thus 
influence the trajectory of the disease. 
One major limitation of this experiment was that use of a rectal temperature probe 
was not permitted on our licence hence a non-contact infrared (IR) temperature point 
gun was used to record temperature of mice following i.p. injection of saline or LPS. 
The temperature changes typically associated with LPS-induced hypothermia in 
C57BL/6 mice are very small when measured using a rectal temperature probe; even 
the exaggerated hypothermic response of ME7 prion diseased mice saw temperatures 
of ~37.0°C in LPS-injected ME7 mice compared with  ~37.6°C in saline-injected 
counterparts (Combrinck et al., 2002). In the current study, however, the recorded 
temperature prior to injection ranged from ~29 – 31°C and dropped to approximately 
26°C following LPS. These absolute temperatures are comparable to those cited in the 
literature for the IR temperature probes compared with rectal or implanted 
temperature transponders (Stephens Devalle, 2005). IR thermometers detect the 
infrared radiation emitted from an object and deduce the surface temperature using 
Boltzmann’s law which relates wavelengths of electromagnetic radiation to the 
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temperature; thus, IR thermometers detect only the surface body heat which is 
emitted through the fur rather than the true body temperature which explains why 
the temperatures recorded were so low. Not only this but emissivity of an object 
varies with colour and texture, hence coat colour and direction of fur might have 
introduced variability. In fact, it is plausible that coat colour may account for the 
observed temperature difference between saline-injected P301S mice and controls. 
External emitted temperature is also subject to changes in ambient temperature, 
altered vasodilation and cold-/warmth-seeking behaviours. It is because of the 
apparent flaws in the method of data collection that the AUC data rather than the 
absolute figures were analysed.  
There were no significant differences in the AUC data between any of the groups 
injected at 16 weeks of age (Figure 14 D). The data suggest a dramatic hypothermic 
response in saline-injected mice as well as in LPS-injected mice. While it is known that 
there are stress-related thermoregulatory changes in mice following intraperitoneal 
injection per se, this generally manifests as a hyperthermic response and tends to last 
30-120 minutes (Rudaya et al., 2005) and hence cannot explain the hypothermic 
response seen here at 4- and 6-hours post-saline-injection. This is likely due to use of 
an IR thermometer.  
The data from the mice injected at 10 weeks suggest it is worth pursuing more 
accurate temperature recordings in the future. Alternative methods for monitoring 
the hypothermic response include: use of a rectal probe, however this method can 
cause stress-related temperature fluctuations which mask hypothermic responses 
(Dallmann et al., 2006); tympanic thermometers do not cause stress-related impacts 
on core body temperature, however there are contradictory results regarding the 
reliability (Stephens Devalle, 2005, Quimby et al., 2009). An implanted telemetry chip 
would be ideal in future experiments to ensure accurate recording of core body 
temperature –these devices, although expensive, can be transplanted in advance to 
avoid stress-related temperature changes interfering with data collection, by constant 
monitoring can allow detection of the peak temperature response and reflect core 
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body temperature rather than radiated temperature (Stephens Devalle, 2005, Quimby 
et al., 2009). 
Peripheral LPS-induced inflammation communicates with the brain to initiate the 
conserved sickness behaviours via multiple routes. LPS is recognised in the periphery 
by local pattern recognition receptors expressed on monocytes, macrophages and 
liver Kupffer’s cells (Dantzer, 2009), which induces NFκB-mediated transcription of 
pro-inflammatory cytokines (Dantzer, 2001, Dantzer, 2009). These cytokines are large 
hydrophilic peptides and cannot diffuse through the BBB, however they can influence 
the brain in several ways: 1) by stimulating afferent nerves, e.g. the vagal afferents 
which activate the brainstem, hypothalamus, and limbic structures (Goehler et al., 
1997, Romanovsky, 2004); 2) circulating cytokines, or LPS itself, may act on 
endothelial cells of the BBB to induce active transport (Gutierrez et al., 1993, Gutierrez 
et al., 1994) or alternatively they stimulate synthesis of downstream mediators by 
endothelial cells themselves (Laflamme et al., 1999, Terrando et al., 2011); 3) cytokines 
may bypass the BBB entirely and act on macrophage-like cells via the 
circumventricular organs (CMVOs) which lack the tight junctions of the BBB (Blatteis 
et al., 1983, Dantzer et al., 2008). Electrical stimulation of the vagus nerve and cytokine 
signalling to endothelial cells and local macrophages then cause increased 
downstream production of cytokines and proinflammatory mediators such as nitric 
oxide (NO) and prostaglandins of the E2 series (PGE2) by inducible cyclooxygenase -
2 (COX2) enzyme (Hosoi et al., 2000, Romanovsky, 2000). Cytokines and 
prostaglandins then enter the brain parenchyma by volume diffusion and act on the 
brain (Dantzer et al., 2008). This results in production of more proinflammatory 
mediators in the CNS by microglia; primarily IL-1α, IL-1β, IL-6 and TNF-α, as is seen 
in the periphery. Cytokines and other proinflammatory mediators work together to 
initiate sickness behaviours; use of cytokine receptor agonists and knock-out mice has 
shown that proinflammatory cytokines have overlapping functions, they potentiate 
and compensate for each other.  
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Sickness behaviours comprise conserved and coordinated behavioural responses to 
infection which aim to limit replication of the pathogen and conserve energy required 
by the host to fight infection. In this way sickness behaviours are a healthy and 
adaptive part of restoring homeostasis – the sickness response can however become 
maladaptive when it is exaggerated in intensity or duration. This can occur when: (1) 
there is over-production of proinflammatory cytokines, or cytokine production 
persists for longer than normal; (2) pro-inflammatory cytokines and cells are not 
downregulated in the usual way or; (3) the neuronal circuits that mediate sickness 
behaviour become sensitized.  
Previous studies have shown exaggerated sickness behaviour in aged animals 
compared with young, associated with exaggerated neuroinflammation (Godbout et 
al., 2005) as well as in the ME7 prion disease model of neurodegeneration (Combrinck 
et al., 2002). In both instances the microglia were primed such that subsequent 
inflammatory challenge caused over-production of central proinflammatory 
cytokines including IL-1β, which is key in coordinating sickness behaviours. The 
over-zealous proinflammatory response in the CNS was deleterious in ME7 mice; it 
caused increased apoptosis, and exacerbated and accelerated the disease-associated 
decline in motor function (Cunningham et al., 2009).  
Alternatively, rather than an over-zealous central inflammatory response in the CNS 
there might be an equivalent central inflammatory response but the neurons are in 
some way sensitised by the over-expression of mutant-tau such that they are unable 
to respond appropriately to an equivalent central cytokine response or there might 
be an exaggerated peripheral immune response in P301S mice with downstream 
effects on CNS inflammation. Thorough analysis of central and circulating pro- and 
anti-inflammatory markers following LPS-injection is required in order to better 
understand the cause of the exaggerated sickness response in P301S mice compared 
with control animals.  
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4.5.2 Exaggerated acute neurological deficit 
The exaggerated acute deficits seen in the present experiments extend beyond those 
typically associated with sickness behaviours. In alternative models of 
neurodegeneration systemic inflammation appears to cause acute dysfunction in the 
already vulnerable neurocircuitry of the CNS, apparently propagated by microglia 
primed by the disease (Cunningham et al., 2005, Cunningham et al., 2009). This 
interaction of systemic inflammation and disease pathology results in acute deficits 
in disease-relevant faculties. In P301S mice there is a disease associated progressive 
decline in horizontal bar performance, hence this task was used to detect LPS-
induced, acute, exaggerated neurological deficits in P301S mice compared with 
C57BL/6 mice, caused by an interaction between systemic inflammation and the 
underlying disease-pathology. LPS induced an exaggerated acute deficit in horizontal 
bar performance of P301S mice compared with C57BL/6 mice (Figure 12 and Figure 
15). 6-hours post-injection LPS-injected C57BL/6 mice took longer to reach the 
platform than saline-injected counterparts, however all C57BL/6 mice successfully 
completed the task in under 30 seconds, whereas, in P301S mice LPS induced an 
exaggerated acute deficit in horizontal bar performance; several mice repeatedly 
failed the task and those that succeeded regularly took upwards of 30 seconds to reach 
the platform. 
Furthermore, P301S mice injected at 16 weeks of age were more acutely impaired on 
the horizontal bar task than those injected at 10 weeks of age: mice injected at 16 
weeks of age had still not recovered back to normal baseline performance by 24-hours 
post LPS injection whereas mice injected at 10 weeks of age had fully recovered by 
this time point (Figure 12 and Figure 15). The fact that LPS had a greater, longer 
lasting impact on horizontal bar performance of older P301S mice than younger mice, 
despite the mild response in C57BL/6 mice which was consistent regardless of age, 
supports the notion that the degree of underlying disease pathology predicts the 
magnitude of the observed exaggerated acute neurological deficits in P301S mice.  
191 
 
In epidemiological studies, dementia has often been treated as a binary condition; 
patients either have dementia or they do not. However, a recent study demonstrated 
that in humans, worse prior cognitive impairment, determined by Mini-Mental State 
Exam (MMSE), predicted increased susceptibility to acute deficits which manifest as 
delirium and in mice, worse disease pathology predicted the severity of the acute 
response to intraperitoneal LPS injection (Davis et al., 2015).  
ME7 prion disease mice present with an exaggerated sickness response compared 
with wild-type mice when injected with LPS (Combrinck et al., 2002, Cunningham et 
al., 2005, Cunningham et al., 2009, Davis et al., 2015) and it has been suggested that 
the exaggerated response is underpinned by microglial priming (discussed in section 
1.2.9). In ME7 prion diseased mice the pathology and primed microglial cells exist in 
the hippocampus and limbic system hence pathology is associated with functional 
deficits in tasks associated with these regions e.g. impaired T-maze performance (a 
predominantly hippocampal dependent task) (Betmouni et al., 1996, Guenther et al., 
2001, Cunningham et al., 2005).  
Since the neurocircuitry involved in T-maze alternation is known to be vulnerable in 
ME7 mice this task was used to demonstrate exaggerated acute hippocampal 
dependent cognitive deficits in the ME7 prion disease model following a systemic 
inflammatory event (Cunningham et al., 2009). These authors used this and other 
tasks to show that LPS induced a reversible, “acute onset, fluctuating, change in 
cognition not better accounted for by dementia” thus meeting the DSM-IV criteria for 
delirium (Davis et al., 2015). In animal models where there is microglial priming in 
the hippocampus and limbic systems, LPS appears to induce exaggerated deficits in 
hippocampal dependent tasks such as burrowing and impaired spatial memory in 
the underwater radial arm maze, Morris water maze and the “paddling” Y-maze task 
(Chen et al., 2008, Cunningham et al., 2009, Field et al., 2010, Sy et al., 2011, Davis et 
al., 2012).  
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However, P301S mice do not demonstrate disease-associated impairment of 
spontaneous-alternation in the T-maze with age. That does not necessarily mean that 
there is no disease-associated pathology in the region, and in any case the 
hippocampus receives cortical and sub-cortical inputs from regions with pathology 
(including the medial septum and amygdala) in the P301S mouse hence T-maze 
alternation during the acute phase might be an appropriate task for detecting 
exaggerated acute cognitive deficits in the P301S mouse. As of yet, no clear cognitive 
deficits have been identified in the P301S model of tauopathy. Disease pathology 
dominates in the spinal cord and the acute impairment of horizontal bar performance 
reflects this.  
The horizontal bar task is used as a test of motor strength and coordination. It is 
possible that the exaggerated deficit in horizontal bar performance observed in P301S 
mice is not neurological, but might be the result of an exaggerated sickness response 
because this task does not allow distinction between malaise vs. motor dysfunction. 
However, inhibition of locomotion in the openfield was not significantly different 
between LPS-injected control mice and LPS-injected P301S mice and mice appeared 
to be trying hard to complete the horizontal bar task but were physically unable. 
Based on these observations and experience of watching mice during the chronic 
decline phase of disease I am inclined to speculate that this exaggerated acute deficit 
in horizontal bar task performance in P301S mice reflects an acute LPS-induced 
neurological impairment, rather than malaise.  
In a case-controlled study of 60 patients with delirium or dementia, or both or neither 
(fifteen per group) patients had serial evaluations of motor control (Trunk Control 
Test – TCT) at 4 different time points. Results showed that delirium was associated 
with fluctuating motor performance whereas dementia was not (Bellelli et al., 2011). 
Delirium is also known to be associated with increased risk of falls; though there are 
multiple potential reasons for this, acute motor incoordination occurring as part of 
the syndrome is one plausible explanation (Babine et al., 2016). 
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It is unclear whether this neurological impairment might be due to increased 
production of proinflammatory mediators by microglia, as is the case in aged animals 
and prion diseased mice (Combrinck et al., 2002, Godbout et al., 2005), or whether 
this exaggerated response might be attributed to increased sensitivity of neurons in 
P301S mice. Indeed previous studies investigating inflammatory markers in P301S 
mice found IL-1β stained cells of neuronal morphology in the brainstem and spinal 
cord (Bellucci et al., 2004) hence it is plausible that P301S tau expression sensitizes 
neurons such that they respond differently to equivalent cytokine levels.  
Regardless of the mechanism, these data indicate that there is an exaggerated acute 
deficit in the already vulnerable circuitry involved in horizontal bar performance in 
P301S mice, and worse disease pathology predicts increased vulnerability to the 
effects of LPS-induced systemic inflammation. 
4.5.3 Long term impacts of systemic inflammation 
There was no difference in the decline in horizontal bar performance of P301S mice 
injected with saline at 10 vs 16 weeks of age. P301S mice injected with LPS at 10 weeks 
of age showed no significant difference in the rate of decline compared with saline-
injected counterparts, however the first pilot cohort of mice were sacrificed at 20 
weeks of age, hence there is a loss of statistical power in the last two weeks which 
might have impacted on this result (see numbers in Figure 12). P301S mice who were 
injected with LPS at 16 weeks of age, however, showed an accelerated and 
exacerbated decline in horizontal bar performance compared with saline-injected 
counterparts. These data, therefore, show that a single 500 μg/kg dose of LPS is 
capable of increasing the rate of disease-associated decline in motor function in P301S 
mice associated with permanent neurological dysfunction. Furthermore, the degree 
of pathology at the time of injection also affects the impact of LPS on the 
neurodegenerative decline such that worse disease pathology at the time of injection 
advances the decline. 
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The biological mechanism behind this altered trajectory of decline in horizontal bar 
performance remains to be determined. There is a known 49% reduction in motor 
neurons in the spinal cord of P301S mice at end stage (Allen et al., 2002) however the 
trajectory of that neuronal loss is unknown. Since tau protein is a microtubule 
associated protein found predominantly in the axon and tau pathology leads to 
microtubule destabilisation, declining horizontal bar performance might be 
associated with axonal degeneration or synaptic dysfunction (Spittaels et al., 1999). 
There is also progressive reactive astrogliosis and microgliosis in the P301S mouse 
which are thought to contribute to disease pathology through loss of neuroprotective 
and neurotrophic roles (Hampton et al., 2010) and gain of neuroinflammatory roles 
(Bellucci et al., 2004). 
There are several ways in which LPS might exacerbate disease pathology and thus 
advance the decline in horizontal bar performance of P301S mice. LPS is also known 
to exacerbate tau pathology in mice. Evidence from triple transgenic 3xTgAD mice 
shows that a chronic systemic LPS regime increases tau pathology 24h and 48h post-
injection (Kitazawa et al., 2005, Sy et al., 2011) and intracerebral mouse hepatitis virus 
(MHV) exacerbates tau pathology 2 and 4 weeks post-injection (Sy et al., 2011). 
Intracerebral LPS in the rTg4510 model of pure tauopathy caused an increase in tau 
pathology which persisted 1 week later (Lee et al., 2010). Systemic LPS also caused 
exacerbated tau pathology in the hTau mouse 24-hours post LPS which was further 
exacerbated in Cx3cr1 deficient hTau mice. Since CX3CR1 is involved in dampening 
the microglial response these data thus implicate microglial activation in the 
exacerbation of acute tau pathology (Bhaskar et al., 2010). 
There is evidence that LPS can trigger a phenotypic switch in microglia and astrocytes 
away from neuroprotective and neurotrophic functions and towards a neurotoxic 
proinflammatory profile (Zamanian et al., 2012, Holtman et al., 2015, Liddelow et al., 
2017). In an animal where there is mutant-tau-induced neuronal dysfunction and cell 
death, loss of neuroprotective function and gain of neurotoxic function is likely to be 
deleterious. As discussed, disease pathology might cause microglial priming such 
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that subsequent inflammatory LPS challenge causes exaggerated cytokine 
production. LPS is capable of inducing neuronal apoptosis (Semmler et al., 2005) e.g. 
via IL-1β induced p38-MAPK and JNK signalling (Lee et al., 2002, Xie et al., 2004). 
Apoptosis is a carefully controlled mechanism which depends on integration of pro- 
and anti-apoptotic signals – hence the expression of mutant tau under the Thy1.2 
promoter might sensitise neurons such that they are more vulnerable to the effects of 
an inflammatory stimulus. All of these are mechanisms through which LPS might 
contribute to the observed advance in the decline of horizontal bar performance. 
These pathological correlates will be explored in more detail in Chapter 5. 
4.6 Conclusion 
The P301S mouse is a well-established model of progressive neurodegeneration 
which recapitulates key hallmarks of tauopathy dementia and by intraperitoneal 
injection of LPS it was possible to induce an acute and reversible sickness response.  
In addition to typically observed sickness behaviours, the current study demonstrates 
that: 1) a single dose of LPS early in disease is sufficient to induce exaggerated acute 
impairments of motor strength and coordination in P301S tau mice compared with 
LPS-injected control mice; 2) acute motor function impairments were reversible and 
recovered with resolution of inflammation; 3) P301S mice injected at 16 weeks of age 
were more impaired and took longer to recover from the systemic inflammatory 
insult compared with mice injected with the same dose of LPS at 10 weeks of age; 4) 
importantly in P301S mice injected at 16 weeks systemic inflammation was sufficient 








5 Chapter 5 – Acute and chronic pathological 
consequences of systemic inflammation in the P301S 
mouse 
5.1 Introduction 
As shown in experiments described in Chapter 4, P301S mice were more vulnerable 
to the acute effects of LPS compared with C57BL/6 mice. Symptoms extended beyond 
those usually associated with sickness behaviours – LPS-injected P301S mice showed 
exaggerated acute impairments of motor strength and coordination as measured by 
horizontal bar performance. The acute systemic inflammatory insult was also 
sufficient to exacerbate the trajectory of chronic decline in horizontal bar performance 
associated with neuronal dysfunction and neurodegeneration in the P301S mouse.  
The exaggerated acute behavioural response seen in alternative animal models of 
neurodegeneration exposed to systemic LPS is suggested to be a consequence of 
microglial priming (Cunningham et al., 2005, Godbout et al., 2005). This is the 
phenomenon whereby microglia are in some way stimulated or disinhibited by 
ageing or disease such that subsequent inflammatory insult causes an exaggerated 
pro-inflammatory response typically with exaggerated production of cytokines, 
predominantly IL-1β (discussed in section 1.2.9).  
The P301S mouse develops progressive neuronal loss and astrogliosis in the cortex in 
the absence of readily detectable microgliosis, and progressive astrogliosis and 
microgliosis in the spinal cord (Chapter 3). On that background this chapter aims to 
investigate the acute consequences of a systemic inflammatory challenge on key 
disease-relevant pathological hallmarks in the P301S mouse as well as those 
remaining at end stage. 
P301S mice injected at 16 weeks of age were more vulnerable to the acute effects of 
LPS and the longer-term impacts on the decline in horizontal bar performance than 
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mice injected at 10 weeks of age which informed the decision to focus on the cohort 
of mice injected with LPS at 16 weeks in the following pathological studies. 
5.2 Methods 
In order to determine the acute and long term consequences of systemic inflammation 
on disease pathology mice injected intraperitoneally at 16 weeks of age with saline or 
LPS (500µg/kg – as previously described in section 4.2.2) were sacrificed 4-hours post-
injection for qPCR, or 24-hours post-injection or at 22 weeks of age, for 
immunohistochemical pathological studies. 
In every experiment, all of the tissue – acute and chronic tissue from C57BL/6 and 
P301S mice, exposed to either saline or LPS –  was stained and imaged in a single 
batch. 
5.2.1 Tissue Collection and Fluorescent staining 
Fixed brain and spinal cord tissue was collected and processed as previously 
described in section 1.3.1. Numbers of animals quantified with each label are given in 
relevant sections. 
Immunohistochemistry was performed for GFAP-positive astrocytes, IBA-1-positive 
microglia, AT8-positive hyperphosphorylated tau and NeuN-positive neurons as 
described in section 2.3.3 and using antibodies described in Table 22. 
5.2.2 Imaging and Quantification 
 Astrogliosis in the motor cortex  
 Imaging 
Fluorescent images of the motor cortex from GFAP-stained brain were taken as 
previously described in section 1.4, with 20x objective and 2300 ms exposure. Four 
hemispheres per animal were imaged and, as before, the camera was aligned with the 











































































































































































































































































































































































































































































































































































































































 Quantification by manual cell counts 
GFAP-positive cell counts were counted manually using Zen 2011 software. An area 
150 μm (sub-pial depth) x 300 μm length was pasted onto all images and counts 
conducted therein using the “Events” tool to quantify. Cell counts were converted to 
cells per mm2 using Microsoft Excel™. 
 Automated quantification of percentage area containing GFAP signal 
Fiji Image J software was used to determine the percentage of the selected area 
containing positive signal as described in section 2.5, with the following parameters: 
subtract background with rolling ball radius 50 pixels; set threshold (16, 255); select 
an area 150 μm by 333 μm; measure percentage area containing GFAP signal.  
Statistical analyses are described in section 5.2.4. Acute tissue: C57BL/6 + Saline n=5, 
C57BL/6 + LPS n=5, P301S + Saline n=6, P301S + LPS n=6. Chronic tissue: C57BL/6 + 
Saline n=8, C57BL/6 + LPS n=8, P301S + Saline n=8, P301S + LPS n=8 
 Astrogliosis in lamina 9 of the spinal cord 
 Imaging 
Fluorescent images of lamina 9 of GFAP-stained spinal cord were taken with 20x 
objective and 1200 ms exposure. Four sections per animal were imaged 
 Quantification of percentage area containing GFAP signal using Image 
J/ Fiji 
Fiji Image J software was used to determine the percentage of the selected area 
containing positive signal as described in section 2.5. There was no need to subtract 
background from the image. The intensity threshold for chronic tissue was (55, 255). 
Astrogliosis was less severe in the acute tissue and hence the intensity threshold for 
acute tissue was modified to (45, 255). 
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Statistical analyses are described in section 5.2.4. Acute tissue: C57BL/6 + Saline n=3, 
C57BL/6 + LPS n=6, P301S + Saline n=6, P301S + LPS n=6 Chronic tissue: C57BL/6 + 
Saline n=8, C57BL/6 + LPS n=8, P301S + Saline n=8, P301S + LPS n=8 
 Microgliosis in the motor cortex 
 Imaging 
Confocal z-stack images of the motor cortex from IBA1-stained brain were taken 
using a Ziess LSMZ10 confocal microscope with 15 slices per stack and 0.96 μm per 
slice. Four hemispheres were imaged per animal.  
 Quantification 
IBA1-positive cells were counted manually using Zen 2011 software in the superficial 
layers of the cortex. Two areas both 150 μm (sub-pial depth) x 150 μm were copied 
across all images and counts conducted therein.  
Cell counts were converted to cells per mm2 in Excel. Statistical analyses described in 
section 5.2.4. Acute: C57BL/6 + Saline n=4, C57BL/6 + LPS n=6, P301S + Saline n=5, 
P301S + LPS n=6 Chronic: C57BL/6 + Saline n=6, C57BL/6 + LPS n=7, P301S + Saline 
n=6, P301S + LPS n=6 
 Microgliosis in lamina 9 of the spinal cord 
 Imaging 
Fluorescent images were taken of lamina 9 and the rubrospinal (Rb) tract. When the 
Rb tract had been identified, the camera was adjusted to align the edge of the image 
with the edge of the spinal cord.  
Images were taken of IBA1-stained spinal cord tissue, with 20x objective and 
2300ms exposure.  
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 Quantification by manual cell counts 
IBA1-positive cells were counted in lamina 9 of the spinal cord using Zen 2011. An 
area 224 μm x 224 μm was copied across all images and cells counted therein. Cell 
counts were converted to cells per mm2 in Excel. 
 Microgliosis in the white matter of the spinal cord 
 IBA1-positive cell counts using Image J/ Fiji 
Automated IBA1-positive cell counts were conducted in the Rb tract using Image 
J/Fiji.  
As with previous automation of image processing, in order to automate IBA1-positive 
cell counts one or two images were manually processed to determine parameters 
required, a template macro was then modified accordingly, the macro was tested on 
a small batch of approximately 10 representative images and parameters were 
optimised and then the images were batch processed. 
As before the macro was used to: open the .tif files; duplicate images; subtract the 
background from the duplicates (rolling ball radius 25 pixels); impose an intensity 
threshold (set threshold: (22, 255)); and create a binary mask but from this point 
onwards the macro was modified to include further image-processing steps, as 
follows.  
The first step was  to “fill holes” in the binary mask. This was followed by a step to 
“despeckle” the image. According to the User Guide 
(https://imagej.nih.gov/ij/docs/guide/146-29.html) this filter “replaces each pixel with 
the median value in its 3 × 3 neighbourhood… for each pixel in the selection, the nine 
pixels in the 3 × 3 neighbourhood [are] sorted and the centre pixel replaced with the 
median value…” Once the image has been despeckled the ‘analyze particles’ function 
in ImageJ (Analyze > Analyze particles) was used to detect all objects larger than 20 
pixels. The number of IBA1-positive cells were converted to cells per mm2 in Excel.  
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 Quantification of percentage area containing IBA1 signal using Image J/ 
Fiji 
Fiji Image J software was used to determine the percentage area containing positive 
signal in lamina 9 and in the Rb Tract as described in section 2.5, with the following 
parameters: background subtraction with rolling ball radius 30 pixels; set threshold 
(18, 255); percentage area containing IBA1 signal across the whole image was 
analysed rather than a selected area.  
Statistical analyses described in section 5.2.4. Acute: C57BL/6 + Saline n=6, C57BL/6 + 
LPS n=6, P301S + Saline n=6, P301S + LPS n=6. Chronic: C57BL/6 + Saline n=8, C57BL/6 
+ LPS n=8, P301S + Saline n=8, P301S + LPS n=7 
 Hyperphosphorylation of tau in the brain 
 Quantification 
AT8-positive cell counts were conducted using the Zeiss upright A1 microscope with 
objective 20x. Cells were counted in a grid 0.5 mm width by 1 mm subpial depth using 
the graticule, with use of a cell counter to keep track. Counts were converted to cells 
per mm2 in Excel. Statistical analyses described in section 5.2.4. Acute: C57BL/6 + 
Saline n=3, C57BL/6 + LPS n=3, P301S + Saline n=6, P301S + LPS n=5 Chronic: C57BL/6 
+ Saline n=3, C57BL/6 + LPS n=3, P301S + Saline n=7, P301S + LPS n=6 
 Hyperphosphorylation of tau in the spinal cord 
 Imaging 
Fluorescent images of AT8-stained spinal cord were taken with 20x objective and 1600 
ms exposure. Four spinal sections per animal were imaged. Until now only the most 
lateral part of lamina 9 has been imaged. Here images were taken of the most lateral 
part of lamina 9 as previously described; the medial ventral horn which includes 
lamina 9 and lamina 8; and the area adjacent to the central canal comprised of laminae 




AT8-positive cell counts were conducted using Zen 2011 software across the whole 
image (444.2 μm x 332.8 μm). Cell counts were converted to cells per mm2 in Excel. 
Statistical analyses described in section 5.2.4. Acute: C57BL/6 + Saline n=3, C57BL/6 + 
LPS n=5, P301S + Saline n=6, P301S + LPS n=4 Chronic: C57BL/6 + Saline n=4, C57BL/6 
+ LPS n=4, P301S + Saline n=8, P301S + LPS n=5 
 Chronic Neuronal loss in the brain 
 Quantification 
NeuN-positive cell counts were conducted using the Zeiss Axiovision microscope at 
objective 63x using oil. Cells were counted in a grid 152 μm width by 152 μm subpial 
depth using the graticule, with use of a cell counter. Counts were converted to cells 
per mm2 using Microsoft Excel™. 
Statistical analyses described in section 5.2.4. C57BL/6 + Saline n=6, C57BL/6 + LPS 
n=7, P301S + Saline n=4, P301S + LPS n=5 
 Chronic Neuronal loss in the SC 
 Imaging 
Fluorescent images of lamina 9 of NeuN-stained spinal cord were taken with 20x 
objective and 1200 ms exposure. Four sections per animal were imaged. 
 Quantification 
NeuN-positive cell counts were conducted in lamina 9 of the spinal cord using Zen 
2011. An area 300 μm x 300 μm was copied across all images and cells counted therein. 
Cell counts were converted to cells per mm2 in Excel.  
Statistical analyses described in section 5.2.4. C57BL/6 + Saline n=8, C57BL/6 + LPS 
n=8, P301S + Saline n=8, P301S + LPS n=8 
205 
 
5.2.3 Gene expression analysis 
Brain and spinal cord tissue were collected from P301S mice and control mice 4-hours 
post-injection and gene expression analysis conducted as described in methods 
section 2.6. 
5.2.4 Statistical Analyses 
All statistical analyses were conducted in IBM SPSS Statistics Software Version 22. 
For all stains acute and chronic analysis was separated. Mixed effects linear 
regression with random intercept for animal ID was used for comparison of C57BL/6 
mice and P301S mice treated with either saline or LPS. Custom hypothesis tests were 
used to generate estimated means and SEMs for graphs. An interaction term was 





5.3.1 Acute pathology 
Having demonstrated an exaggerated acute behavioural response to LPS in P301S 
mice compared with C57BL/6 mice (see section 4.3.2.1) astrocyte and microglial status 
in the cortex and spinal cord were assessed by qPCR 4-hours post-injection and by 
immunofluorescence 24-hours post-injection. CD11b mRNA levels and IBA1 
immunofluorescence were used to assess microglial status; GFAP mRNA levels and 
immunofluorescence were used to determine the degree of reactive astrogliosis; IL-
1β mRNA levels were assessed and finally tau pathology was assessed by AT8-
positive immunofluorescence.  
 LPS exacerbates tau pathology in the P301S mouse  
In order to investigate the impact of systemic inflammation on the abundance of 
phosphorylated tau 24-hours after injection (age 16 weeks), AT8 antibody was used. 
This antibody recognises pathological phospho-epitopes P-Ser202, P-Thr205. 
There were no AT8-positive cells in the motor cortex of control mice 24-hours post-
injection regardless of LPS exposure (Figure 18). However, AT8-positive cells were 
detected in the motor cortex of P301S mice, (4.0 cells per mm2; p=0.193; 95% CI -2.6 to 
10.7) and LPS-treatment tripled the number of AT8-positive cells in the motor cortex 
24-hours post-injection (additional 9.2 cells per mm2; p=0.055; 95% CI -0.3 to 18.6) 
(Figure 18). 
As expected there were no AT8-positive cells in lamina 9 of the spinal cord of control 
mice either (Figure 18). There were AT8-positive cells in lamina 9 of the spinal cord 
of P301S mice (22.7 cells per mm2; p=0.005; 95% CI 8.9 to 36.4) and LPS exposure 
increased AT8-positive cell counts although this was not statistically significant at 
α=0.05 (additional 15.2 cells per mm2 compared with P301S + saline group; p=0.147; 





Figure 18 - Acute impact of systemic LPS on AT8-positive tau in the brain and spinal cord. A-D; 
Representative examples of AT8 stained cortical tissue collected 24h post-injection from C57BL/6 + Saline (A), 
C57BL/6 + LPS (B), P301S + Saline (C), P301S + LPS (D). E-H; Representative examples of AT8 stained spinal 
cord (lamina 9 of c5-c7) from C57BL/6 + Saline (E), C57BL/6 + LPS (F), P301S + Saline (G), P301S + LPS (H). 
Scale bar 100 μm. I) AT8-positive cell counts in the motor cortex (to sub-pial depth of 150 μm) from C57BL/6 
(blue) and P301S (red) mice collected 24-hours post-injection with either saline (no pattern) or LPS (patterned) 
indicated that LPS increased tau hyperphosphorylation detected by AT8 (mixed effects linear regression, indicated 
by †p=0.055) (C57BL/6 + Saline n=3, C57BL/6 + LPS n=5, P301S + Saline n=6, P301S + LPS n=4). J) AT8-
positive cell counts in lamina 9 of spinal cord of C57BL/6 and P301S mice suggest no significant impact of LPS on 
AT8-positive tau accumulation in the lamina 9 of the spinal cord. (C57BL/6 + Saline n=3, C57BL/6 + LPS n=5, 
P301S + Saline n=6, P301S + LPS n=4).  
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 LPS-injection did not increase cortical CD11b mRNA levels in 
C57BL/6 or P301S mice 
Cortical tissue was collected 4-hours post-injection with saline or LPS, for gene 
expression analysis. No difference in cortical CD11b mRNA levels was observed 
between groups. Following sensitivity analysis to take into account 3 outliers (see 
Figure 19): one in the C57BL/6 + Saline group (-4.7 SD from the mean), one in P301S + 
Saline group (-3.2 SD from the mean) and one in the P301S + LPS group (-3.4 SD from 
the mean) – still no independent effect was seen between the groups thus confirming 
the absence of an effect for genotype and no differential effect of LPS on the P301S 





p-value 95% CI 
Reference 
C57BL/6 + Saline 
1.0 - - - - 
LPS 1.1 +0.1 0.175 -0.1 0.3 
P301S 1.0 -0.1 0.487 -0.2 0.1 
P301S + LPS 
(interaction term) 
1.1 +0.1 0.480 -0.1 0.3 
Table 23 - Systemic LPS does not impact cortical CD11b mRNA levels. The first term represents relative 
quantity of CD11b mRNA for the reference group: C57BL/6 mice receiving saline. The following two terms test 
for an independent effect of genotype and intervention. The fourth term tests for a difference in the independent 
effect of LPS between genotypes. 
Figure 19 – Systemic LPS does not impact cortical CD11b mRNA levels. The relative quantity of CD11b 
mRNA in the motor cortex of groups compared with the C57BL/6 + Saline reference group 4h post-injection 
indicated neither genotype nor systemic LPS treatment significantly impacted CD11b mRNA in the cortex (mixed 




 LPS-injection did not increase IBA1-positive cortical microgliosis in 
C57BL/6 or P301S mice 
Tissue collected 24-hours post-injection was stained for pan-microglial marker IBA1. 
In agreement with CD11b gene expression analysis IBA1-positive cell counts in the 
superficial layers of the cortex indicated no significant difference between any of the 
groups (see Figure 20 and Table 24 for details).  
 
Figure 20 – Systemic LPS injection does not influence numbers of cortical microglia measured by IBA1. 
A-D; Representative examples of IBA1 stained cortical tissue collected 24h post-injection from C57BL/6 + Saline 
(A), C57BL/6 + LPS (B), P301S + Saline (C), P301S + LPS (D). E-H; Close-up of microglial morphology; (E), 
C57BL/6 + LPS (F), P301S + Saline (G), P301S + LPS (H). I; IBA1-positive cell counts in the superficial layers of 
the motor cortex of C57BL/6 (blue) and P301S (red) mice collected 24-hours post-injection with either saline (no 
pattern) or LPS (patterned) indicated that neither genotype nor systemic LPS treatment significantly impacted 
IBA1-positive microglial cell counts in the motor cortex (mixed effects linear regression). (C57BL/6 + Saline n=5, 




Condition Cells per 
mm2  
Δ Cells per 
mm2  
p-value 95% CI 
Reference Cells per mm2 
(C57BL/6 + Saline) 
244.6 - 0.000 179.3 309.8 
LPS 310.7 +66.1 0.145 -25.5 157.8 
P301S 251.4 +6.9 0.881 -89.7 103.4 
P301S + LPS  
(interaction term)  
287.8 -29.8 0.647 -166.0 106.4 
Table 24 - Systemic LPS injection does not influence numbers of cortical microglia measured by IBA1  
The first term represents IBA1-positive cells per mm2 for the reference group: C57BL/6 mice receiving saline. The 
following two terms test for an independent effect of genotype and intervention. The fourth term tests for a 
difference in the independent effect of LPS between genotypes. Post hoc analysis to compare P301S + LPS with 




 LPS injection results in an increase in cortical IL-1β mRNA levels  
Gene expression assay for IL-1β mRNA in the cortex showed that there was no effect 
of genotype (Figure 21 and Table 25). There was a 23-fold increase in the relative 
abundance of IL-1β in LPS-injected C57BL/6 mice (Figure 21 and Table 25). There was 
a 16-fold increase in IL-1β expression in the brain of LPS-injected P301S compared 
with saline-injected counterparts (p=0.001; 95% CI 8.3 to 21.7). The differential effect 
of LPS in P301S mice compared with LPS-injected C57BL/6 mice was significant when 





p-value 95% CI 
Reference 
C57BL/6 + Saline 
1.0 - - - - 
LPS 23.4 +22.4 <0.001 15.7 29.1 
P301S 0.8 -0.3 0.938 -7.0 6.5 
P301S + LPS 
(interaction term) 
11.8 -11.3 0.022 -20.8 -1.8 
Table 25 - Systemic LPS induces an acute increase in cortical IL-1β mRNA levels. The first term represents 
relative quantity of IL-1β mRNA for the reference group: C57BL/6 mice receiving saline. The following two terms 
test for an independent effect of genotype and intervention. The fourth term tests for a difference in the independent 
effect of LPS between genotypes. 
Figure 21 – Systemic LPS induces an acute increase in cortical IL-1β mRNA levels. The relative quantity 
of IL-1β mRNA in the motor cortex of groups compared with the C57BL/6 + Saline reference group 4h post-injection 
indicated no effect of genotype. Systemic LPS treatment significantly impacted IL-1β mRNA levels in the cortex  
(mixed effects linear regression, indicated by *p<0.05, **p<0.001). (C57BL/6 + Saline n=6, C57BL/6 + LPS n=6, 
P301S + Saline n=6, P301S + LPS n=6). 
212 
 
 LPS-injection increased CD11b mRNA levels in the spinal cord in 
C57BL/6 and P301S mice 
Whole spinal cord tissue (C5-C7) was collected 4-hours post-injection for gene 
expression analysis. LPS induced a 40% increase in CD11b mRNA levels in the 
C57BL/6 spinal cord (Figure 22 and Table 26). The effect of genotype on CD11b 
mRNA levels was not significant and there was no additional differential effect of 
LPS in P301S mice (Figure 22 and Table 26).  




p-value 95% CI 
Reference 
C57BL/6 + Saline 
1.0 - - - - 
LPS 1.4 +0.4 0.010 0.1 0.7 
P301S 1.3 +0.2 0.149 -0.1 0.6 
P301S + LPS 
(interaction term) 
1.9 +0.2 0.278 -0.2 0.7 
Table 26 - Systemic LPS induces an acute increase in CD11b mRNA levels in the spinal cord. The first term 
represents relative quantity of CD11b mRNA for the reference group: C57BL/6 mice receiving saline. The following 
two terms test for an independent effect of genotype and intervention. The fourth term tests for a difference in the 
independent effect of LPS between genotypes. 
Figure 22 - Systemic LPS induces an acute increase in CD11b mRNA levels in the spinal cord. The relative 
quantity of CD11b mRNA in c5-c7 of the spinal cord of groups compared with the C57BL/6 + Saline reference 
group 4h post-injection indicated no effect of genotype. Systemic LPS treatment significantly impacted IL-1β 
mRNA levels in the cortex (mixed effects linear regression, indicated by *p<0.05). (C57BL/6 + Saline n=6, 
C57BL/6 + LPS n=6, P301S + Saline n=5, P301S + LPS n=5). 
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The relative quantity of CD11b mRNA in the spinal cord of C57BL/6 mice was 1.5-
fold the levels found in the cortex. In the LPS-injected C57BL/6 mice CD11b levels in 
the spinal cord were 1.7-fold the levels in the cortex (Table 27). In P301S mice CD11b 
mRNA levels were 2.0-fold higher in the spinal cord than in the cortex and following 






p-value 95% CI 
C57BL/6 + Saline 1.5 +0.5 0.006 0.2 0.9 
C57BL/6 + LPS 1.7 +0.7 0.001 0.4 1.0 
P301S + Saline 2.0 +0.9 0.002 0.5 1.4 
P301S + LPS  2.6 +1.7 >0.001 1.2 2.2 
Table 27 – Regional differences in CD11b mRNA levels. The first term represents the relative quantity of 
CD11b mRNA in C5-C7 of the spinal cord of C57BL/6 compared with brain, 4-hours post-saline-injection. The 
following three terms can be interpreted the same way for each of the different groups. 
  
Figure 23 – Regional differences in CD11b mRNA levels. The relative quantity of CD11b mRNA in c5-c7 of 
the spinal cord compared with the motor cortex (C57BL/6 + Saline n=6, C57BL/6 + LPS n=6, P301S + Saline n=5, 
P301S + LPS n=5). 
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 LPS-injection increased IBA1-positive signal in the spinal cord of 
C57BL/6 and P301S mice 
Immunofluorescence for microglial marker IBA1, in lamina 9 of the spinal cord 24-
hours post-injection, confirmed the trend shown by CD11b mRNA levels. IBA1-
positive cell counts indicate the presence of microglial cells in saline-injected C57BL/6 
mice (Figure 24 and Table 28). An increase in the number of microglial cells was seen 
in P301S mice although this did not reach statistical significance. Against this, LPS 
induced an increase in IBA1-positive cell counts in both C57BL/6 mice and in P301S 
mice although post-hoc analysis indicated that this effect of LPS was not statistically 
significant in P301S mice (additional 45.7 cells per mm2; p=0.227; 95% CI -33.4 to 
124.7) (Figure 24 and Table 28). 
Densitometric analysis showed no difference in the percentage area containing IBA1 
signal between C57BL/6 mice and P301S mice (Figure 24 and Table 28). LPS induced 
a 2-fold increase in the total area containing IBA1 signal in C57BL/6 mice. Unlike the 
non-statistically significant change seen for cell counts, post hoc analysis indicated 
that LPS induced a significant increase in IBA1 signal among P301S mice (additional 




Figure 24 - Systemic LPS induces acute increase in IBA1-positive microglia in the spinal cord.  
A-D) Representative examples of IBA1 stained spinal cord (lamina 9 of c5-c7) from C57BL/6 + Saline (A), C57BL/6 
+ LPS (B), P301S + Saline (C), P301S + LPS (D). E-H) Close-up of microglial morphology; C57BL/6 + Saline (E), 
C57BL/6 + LPS (F), P301S + Saline (G), P301S + LPS (H). I) IBA1-positive cell counts in lamina 9 of the spinal 
cord indicated that there was no difference between P301S mice (red) and control mice (blue) and that LPS 
(patterned) induced an increase in IBA1-positive cells in control mice but not P301S mice (*p<0.05). J) 
Densitometric analysis of lamina 9 indicated no difference between P301S and control mice but LPS induced an 
increase in the percentage area containing IBA1-positive signal in C57BL/6 and P301S mice (mixed effects linear 
regression, indicated by *p<0.05, **p<0.005). (C57BL/6 + Saline n=6, C57BL/6 + LPS n=6, P301S + Saline n=6, 


























































































































































































































































































































































































































































































 LPS-injection increased IL-1β mRNA levels in the spinal cord of 
C57BL/6 and P301S mice 
In the spinal cord, there was no significant difference in IL-1β expression in P301S 
mice compared with C57BL/6 mice (Figure 25 and Table 29). There was an estimated 
74-fold increase in IL-1β mRNA levels in LPS-injected C57BL/6 mice compared with 
saline-injected counterparts (Table 29). As was seen in the brain, IL-1β mRNA 
production was a relatively smaller in LPS-injected P301S mice compared with LPS-
injected C57BL/6 mice, although when formally tested this differential impact was 





p-value 95% CI 
Reference 
C57BL/6 + Saline 
1.0 - - - - 
LPS 74.1 +73.0 <0.001 50.9 95.2 
P301S 2.5 +1.5 0.897 -21.7 24.6 
P301S + LPS 
(interaction term) 
46.9 -28.6 0.077 -60.7 3.4 
Table 29 - Systemic LPS induces an acute increase in IL-1β mRNA levels in the spinal cord. The first term 
represents relative quantity of IL-1β mRNA for the reference group: C57BL/6 mice receiving saline. The following 
two terms test for an independent effect of genotype and intervention. The fourth term tests for a difference in the 
independent effect of LPS between genotypes. 
Figure 25 - Systemic LPS induces an acute increase in IL-1β mRNA levels in the spinal cord. The relative 
quantity of IL-1β mRNA in c5-c7 of the spinal cord of groups compared with the C57BL/6 + Saline reference group 
4h post-injection indicated no effect of genotype. Systemic LPS treatment significantly impacted IL-1β mRNA 
levels in the spinal cord (mixed effects linear regression, indicated by *p<0.01, **p<0.001). (C57BL/6 + Saline n=6, 





IL-1β mRNA levels were equivalent in the cortex and spinal cord of saline-injected 
C57BL/6 mice (Table 30). LPS-injected C57BL/6 mice demonstrated a 3.8-fold increase 
in IL-1β mRNA levels in the spinal cord compared with the cortex (Table 30). Saline-
injected P301S mice have a 3.5-fold increase in IL-1β mRNA levels in the spinal cord 
compared to the cortex (Table 30). Following LPS-treatment there IL-1β mRNA levels 





p-value 95% CI 
C57BL/6 + Saline 1.1 +0.1 0.716 -0.3 0.4 
C57BL/6 + LPS 3.8 +2.7 0.001 1.4 4.0 
P301S + Saline 3.5 +2.5 0.019 0.5 4.5 
P301S + LPS  4.9 3.7 0.01 1.1 6.3 
Table 30 –Regional differences in IL-1β mRNA levels. The first term represents the relative quantity of IL-1β 
mRNA in C5-C7 of the spinal cord of C57BL/6 compared with brain, 4-hours post-saline-injection. The following 
three terms can be interpreted the same way for each of the different groups 
 
  
Figure 26 – Regional differences in IL-1β mRNA levels. The relative quantity of IL-1β mRNA in c5-c7 of the 
spinal cord compared with the motor cortex. (C57BL/6 + Saline n=6, C57BL/6 + LPS n=5, P301S + Saline n=5, 
P301S + LPS n=6). 
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 LPS-injection increased cortical GFAP mRNA levels in C57BL/6 and 
P301S mice 
Cortical GFAP mRNA levels were assessed 4-hours post-injection. Primary analysis 
of the complete dataset indicated no difference in the relative abundance of GFAP 
mRNA between groups (Figure 27 and Table 31). However, given the potential 
influence of an extreme outlier in the C57BL/6 + saline reference group (14 SD from 
the mean) a sensitivity analysis was performed with exclusion of that sample (Figure 
27). In this analysis, LPS induced a 2-fold increase in the relative abundance of GFAP 
mRNA in cortical brain tissue. No independent effect was seen for genotype, or any 





p-value 95% CI 
Reference 
C57BL/6 + Saline 
1.0 - - - - 
LPS 2.0 +1.0 0.001 0.5 1.4 
P301S 1.3 +0.3 0.226 -0.2 0.7 
P301S + LPS 
(interaction term) 
2.0 -0.2 0.439 -0.9 0.4 
Table 31 - Systemic LPS induces an acute increase in cortical GFAP mRNA levels. The first term represents 
relative quantity of GFAP mRNA for the reference group: C57BL/6 mice receiving saline. The following two terms 
test for an independent effect of genotype and intervention. The fourth term tests for a difference in the independent 
effect of LPS between genotypes. 
Figure 27 - Systemic LPS induces an acute increase in cortical GFAP mRNA levels. The relative quantity 
of GFAP mRNA in the cortex of groups compared with the C57BL/6 + Saline reference group 4h post-injection 
indicated no effect of genotype. Systemic LPS treatment significantly impacted GFAP mRNA levels in the cortex 
(mixed effects linear regression, indicated by *p<0.01, **p=0.001). (C57BL/6 + Saline n=5, C57BL/6 + LPS n=6, 




 GFAP immunohistochemistry indicated astrogliosis in the motor 
cortex of P301S mice but no impact of systemic LPS 
GFAP-positive cell counts in the superficial layers of the motor cortex indicated a 2-
fold increase in the number of astrocytes in P301S mice compared with C57BL/6 
(Figure 28 and Table 32). 24-hours post-injection LPS did not significantly impact the 
number of astrocytes in C57BL/6 mice and post hoc analysis indicted no impact of 
LPS in P301S mice (additional 55.0 cells per mm2; p=0.506; 95% CI 122.3 to 232.3).  
Densitometric analysis indicated little or no GFAP-positive signal in the motor cortex 
of C57BL/6 mice (Figure 28 and Table 32). The percentage area containing GFAP signal 
in P301S mice was approximately 4-fold higher than in controls. The impact of LPS 
on C57BL/6 mice was not significant (Figure 28 and Table 32). Post hoc analysis 
indicated the impact of LPS on the percentage area GFAP signal in P301S mice 
compared with saline-injected counterparts was also not quite significant (additional 





Figure 28 -Systemic LPS has no significant impact on GFAP-positive reactive astrocytes in the brain 
24-hours post-injection. A-D; Representative examples of GFAP stained cortical tissue collected 24h post-
injection from C57BL/6 + Saline (A), C57BL/6 + LPS (B), P301S + Saline (C), P301S + LPS (D). Scale bar 100 
μm. E) GFAP-positive cell counts in the motor cortex (to sub-pial depth of 150 μm) from C57BL/6 (blue) and 
P301S (red) mice 24h-post-injection with either saline (no pattern) or LPS (patterned) indicated astrogliosis in 
P301S mice compared with controls but no significant impact of LPS in either controls or P301S mice (mixed 
effects linear regression, indicated by *p<0.05). (C57BL/6 + Saline n=4, C57BL/6 + LPS n=6, P301S + Saline n=5, 
P301S + LPS n=6). F) Densitometric analysis supported these results (mixed effects linear regression, indicated by 

























































































































































































































































































































































































































































































































 No influence of LPS injection on GFAP mRNA levels 
Gene expression analysis demonstrated a 130.0% increase in the relative abundance 
of GFAP mRNA in the spinal cord of P301S mice compared with C57BL/6 mice 
(Figure 29 and Table 33). LPS had no impact on GFAP mRNA levels in the C57BL/6 
mice and although there was a 60% increase in the relative abundance of GFAP 
mRNA in LPS-injected P301S mice, the differential effect was not significant (Figure 





p-value 95% CI 
Reference 
C57BL/6 + Saline 
1.0 - - - - 
LPS 1.0 0.0 0.926 -0.9 0.8 
P301S 2.3 +1.3 0.005 0.4 2.1 
P301S + LPS 
(interaction term) 
2.9 +0.7 0.269 -0.6 2.0 
Table 33 - Systemic LPS has no significant impact on GFAP mRNA levels in the spinal cord.  The first 
term represents relative quantity of GFAP mRNA for the reference group: C57BL/6 mice receiving saline. The 
following two terms test for an independent effect of genotype and intervention. The fourth term tests for a 
difference in the independent effect of LPS between genotypes. 
 
Figure 29 – Systemic LPS has no significant impact on GFAP mRNA levels in the spinal cord. The relative 
quantity of GFAP mRNA in c5-c7 of the spinal cord of groups compared with the C57BL/6 + Saline reference 
group 4h post-injection indicated no effect of systemic LPS treatment. Genotype significantly impacted GFAP 
mRNA levels in the spinal cord (mixed effects linear regression, indicated by *p<0.01). (C57BL/6 + Saline n=6, 
C57BL/6 + LPS n=5, P301S + Saline n=5, P301S + LPS n=4). 
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 LPS increased acute GFAP-positive astrogliosis in the spinal cord of 
P301S mice 
Densitometric analysis of GFAP stained tissue detected very low levels of GFAP 
signal in lamina 9 of the spinal cord of saline-injected C57BL/6 mice (Figure 30 and 
Table 34). There was no independent effect of genotype. LPS had no effect on acute 
astrogliosis in the spinal cord of control mice. The percentage area containing GFAP 
signal was higher in LPS-injected P301S mice than all other groups; post hoc analysis 
indicated there was a significant increase in astrogliosis in LPS-injected P301S mice 
compared with saline-injected counterparts (additional 3.4%; p=0.049; 95% CI 0.0 to 
6.7) (Figure 30 and Table 34) however the differential impact of LPS on P301S mice 





Figure 30 - Systemic LPS induced significant GFAP-positive reactive astrogliosis in the spinal cord of 
P301S mice 24-hours post-injection. A-D; Representative examples of GFAP stained spinal cord (lamina 9 of 
c5-c7) from C57BL/6 + Saline (A), C57BL/6 + LPS (B), P301S + Saline (C), P301S + LPS (D). Scale bar 100 μm. 
E) Densitometric analysis of lamina 9 of the spinal cord showed no significant difference between P301S mice and 
no impact of LPS in control mice however LPS caused an increase in astrogliosis in P301S mice (mixed effects 




Condition % Area 
GFAP 
signal 
Δ % Area 
GFAP signal 
p-value 95% CI 
Reference (C57BL/6 
+ Saline) 
1.5 - 0.247 -1.1 4.0 
LPS 2.2 0.7 0.628 -2.4 3.9 
P301S 2.6 1.2 0.442 -2.0 4.3 
P301S + LPS  
(interaction term) 
6.0 2.6 0.191 -1.4 6.7 
Table 34 - Systemic LPS induced significant GFAP-positive reactive astrogliosis in the spinal cord of 
P301S mice 24-hours post-injection. The first term represents percentage area containing GFAP signal for the 
reference group: C57BL/6 mice receiving saline. The following two terms test for an independent effect of genotype 




5.3.2 Summary of acute pathology 
Acutely LPS-injection significantly increased the number of AT8-positive cells in the 
brains of P301S mice. LPS-treatment had no impact on microglia in the cortices but 
induced microgliosis in the spinal cord of P301S and C57BL/6 mice. LPS increased IL-
1β mRNA levels in the brains and spinal cords of C57BL/6 mice and P301S mice. LPS-
injection increased GFAP expression in the brains of C57BL/6 and P301S mice and in 















0 0 4.0 13.2 
CD11b (mRNA 
Relative Quantity) 
1.0 1.1 1.0 1.1 
IBA1-positive cells 
per mm2 
244.6 310.7 251.4 287.8 
IL-1β (mRNA 
Relative Quantity) 
1 23.4 0.8 11.8 
GFAP (mRNA 
Relative Quantity) 
1.0 2.0 1.3 2.0 
% Area containing 
GFAP +ve Signal 





0 0 22.7 37.8 
CD11b (mRNA 
Relative Quantity) 
1 1.4 1.3 1.9 
% Area containing 
IBA1 +ve Signal 
3.6 7.1 3.1 5.5 
IL-1β (mRNA 
Relative Quantity) 
1.0 74.1 2.5 46.9 
GFAP (mRNA 
Relative Quantity) 
1.0 1.0 2.3 2.9 
% Area containing 
GFAP +ve Signal 
1.5 2.2 2.6 6.0 
Table 35 – Summary table of acute impact of LPS on pathological markers. Values refer to estimated means 
of pathological markers for each group. Bold black font is used to indicate a  significant effect of LPS or genotype 
compared with C57BL/6 mice given saline (p < 0.05), except in the final column where bold black font indicates 
significance compared with saline-injected P301S mice (p < 0.05). 
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5.3.3 Chronic Pathology 
The horizontal bar task indicated an advanced decline in the P301S mice exposed to 
LPS. These mice were sacrificed at 22 weeks of age to investigate the 
neuropathological consequences at end stage. 
  No effect of LPS-injection on AT8-positive cell counts in P301S 
mice at end stage 
There were no AT8-positive cells in the motor cortex of C57BL/6 mice regardless of 
LPS exposure (Figure 31). However, AT8-positive cells were detected in the motor 
cortex of P301S mice, (65.8 cells per mm2; p<0.001; 95% CI 48.6 to 83.1) (Figure 31) and 
LPS treatment had no impact on the number of AT8-positive cells at 22 weeks of age 
(-1.8 cells per mm2; p=0.876; 95% CI -27.5 to 23.8) (Figure 31). 
There were no AT8-positive cells in lamina 9 of the spinal cord of C57BL/6 mice 
regardless of LPS exposure (Figure 31). AT8-positive cells were seen in P301S mice 
(123.8 cells per mm2; p<0.001; 95% CI 101.2 to 146.4) and LPS exposure did not 
significantly impact numbers (additional 26.3 cells per mm2; p=0.143; 95% CI -10.5 to 




Figure 31 - Chronic impact of systemic LPS on AT8-positive tau in the brain and spinal cord. A-D; 
Representative examples of AT8 stained cortical tissue collected 24h post-injection from C57BL/6 + Saline (A), 
C57BL/6 + LPS (B), P301S + Saline (C), P301S + LPS (D). E-H; Representative examples of AT8 stained spinal 
cord (lamina 9 of c5-c7) from C57BL/6 + Saline (E), C57BL/6 + LPS (F), P301S + Saline (G), P301S + LPS (H). 
Scale bar 100 μm I) AT8-positive cell counts in the motor cortex (to sub-pial depth of 150 μm) from C57BL/6 
(blue) and P301S (red) mice collected at age 22weeks following injection at 16 weeks with either saline (no pattern) 
or LPS (patterned) indicate no significant impact of LPS (mixed effects linear regression) (C57BL/6 + Saline n=3, 
C57BL/6 + LPS n=3, P301S + Saline n=7, P301S + LPS n=6). J) AT8-positive cell counts conducted in lamina 9 
of spinal cord indicate no lasting impact of LPS (C57BL/6 + Saline n=4, C57BL/6 + LPS n=4, P301S + Saline n=8, 




 LPS-injection results in cortical neuronal loss in both P301S and 
C57BL/6 mice  
NeuN-positive cell counts in the superficial layers of the cortex showed marked 
neuronal loss in P301S mice compared with C57BL/6 mice (Figure 32 and Table 36). 
LPS-injection reduced the number of NeuN-positive cells in C57BL/6 mice (Figure 32 
and Table 36) and in P301S mice (post hoc analysis: -164.1 cells per mm2; p=0.016; 95% 
CI -286.9 to -41.3). LPS had no differential impact on neuronal counts in P301S mice 
compared with C57BL/6 mice (Figure 32 and interaction term Table 36). 
Condition Cells per 
mm2  
Δ Cells 
per mm2  
p-value 95% CI 
Reference Cells per mm2 
(C57BL/6 + Saline) 
1089.3 - <0.001 982.0 1196.6 
LPS 915.6 -173.6 0.023 -320.0 -27.4 
P301S 806.1 -283.1 0.003 -452.8 -113.5 
P301S + LPS  
(interaction term) 
642.0 9.5 0.931 -219.5 238.6 
Table 36 - NeuN-positive cell counts indicate significant long term LPS-induced neuronal loss in the 
brain of C57BL/6 and P301S mice The first term represents NeuN-positive cells per mm2 for the reference group: 
C57BL/6 mice receiving saline. The following two terms test for an independent effect of genotype and intervention. 
The fourth term tests for a difference in the independent effect of LPS between genotypes.     
 No effect of LPS-injection on spinal cord NeuN-positive cell counts 
in P301S mice  
There was significant neuronal loss in the spinal cord of P301S mice compared with 
C57BL/6 mice at 22 weeks of age (Figure 32 and Table 37). LPS had no effect on NeuN 
cell counts in C57BL/6 or P301S mice (Figure 32 and Table 37). 
Condition Cells per 
mm2  
Δ Cells 
per mm2  
p-value 95% CI 
Reference Cells per mm2 
(C57BL/6 + Saline) 
93.7 - <0.001 76.0 111.3 
LPS 86.4 -7.3 0.554 -32.2 17.6 
P301S 27.7 -65.9 <0.001 -90.8 -41.0 
P301S + LPS  
(interaction term) 
24.2 3.7 0.833 -32.1 39.6 
Table 37 - NeuN-positive cell counts indicate no significant long term LPS-induced neuronal loss in the 
spinal cord of C57BL/6 or P301S mice. The first term represents NeuN-positive cells per mm2 for the reference 
group: C57BL/6 mice receiving saline. The following two terms test for an independent effect of genotype and 




Figure 32 - NeuN-positive cell counts indicate significant long term LPS-induced neuronal loss in the 
brain but not spinal cord of C57BL/6 and P301S mice. A-D; Representative examples of NeuN stained cortical 
tissue collected at 22 weeks of age from C57BL/6 + Saline (A), C57BL/6 + LPS (B), P301S + Saline (C), P301S + 
LPS (D). E-H; Representative examples of NeuN stained spinal cord (lamina 9 of c5-c7) from C57BL/6 + Saline 
(E), C57BL/6 + LPS (F), P301S + Saline (G), P301S + LPS (H). Scale bar 100 μm (A-H).  I; NeuN-positive cell 
counts in the motor cortex (to sub-pial depth of 150 μm) from C57BL/6 (blue) and P301S (red) mice injected with 
either saline (no pattern) or LPS (patterned) indicated significant neuronal loss in P301S mice compared with 
controls (mixed effects linear regression, **p<0.005). LPS impacted NeuN-positive cell counts in C57BL/6 mice, 
and P301S mice (*p<0.05) (C57BL/6 + Saline n=6, C57BL/6 + LPS n=7, P301S + Saline n=4, P301S + LPS n=5). 
J) NeuN-positive cell counts in lamina 9 of the spinal cord indicated significant neuronal loss in P301S mice 
compared with controls (*p<0.0001) but no effect of LPS NeuN-positive cell counts. (C57BL/6 + Saline n=8, 






 LPS has no long-term impacts on IBA1-positive cortical microgliosis 
Tissue collected at 22 weeks of age was stained for pan-microglial marker IBA1. As 
before, IBA1-positive cell counts in the superficial layers of the cortex indicated no 
significant difference between any of the groups (Figure 33 and Table 38). 
Condition Cells per 
mm2  
Δ Cells per 
mm2  
p-value 95% CI 
Reference Cells per mm2 
(C57BL/6 + Saline) 
181.3 - 0.000 138.4 224.2 
LPS 239.2 57.9 0.068 -4.8 120.5 
P301S 221.6 40.3 0.149 -15.9 96.6 
P301S + LPS  
(interaction term) 
213.6 -66.5 0.114 -150.7 17.6 
Table 38 - Systemic LPS has no impact on IBA1-positive microglia in the cortex at end stage The first 
term represents IBA1-positive cells per mm2 for the reference group: C57BL/6 mice receiving saline. The following 
two terms test for an independent effect of genotype and intervention. The fourth term tests for a difference in the 
independent effect of LPS between genotypes. Post hoc analysis to compare P301S + LPS with P301S + Saline: 




Figure 33 - Systemic LPS has no impact on IBA1-positive microglia in the cortex at end stage. A-D; 
Representative examples of IBA1 stained cortical tissue collected 24h post-injection from C57BL/6 + Saline (A), 
C57BL/6 + LPS (B), P301S + Saline (C), P301S + LPS (D). E-H; Close-up of microglial morphology; C57BL/6 + 
Saline (E), C57BL/6 + LPS (F), P301S + Saline (G), P301S + LPS (H). Scale bar 100 μm (A-H). I IBA1-positive 
cell counts in the motor cortex (to sub-pial depth of 150 μm) from C57BL/6 (blue) and P301S (red) mice collected 
24-hours post-injection with either saline (no pattern) or LPS (patterned) indicate that neither genotype nor LPS 
exposure significantly impacted IBA1-positive microglial cell counts in the motor cortex. (mixed effects linear 




 LPS-treatment significantly increases IBA1-positive microgliosis in 
Lamina 9 of the spinal cord of P301S mice at end stage 
IBA1-positive cell counts in lamina 9 of the spinal cord indicate significant 
microgliosis in P301S mice (Figure 34 and Table 39). LPS did not impact IBA1-positive 
cell density in C57BL/6 mice at 22 weeks (Figure 34 and Table 39). There was a 
significant increase in the number of IBA1-positive cells in the spinal cord of P301S 
mice and LPS significantly increased the number of microglial cells in P301S mice 
(additional 133.6 cells per mm2; p=0.003; 95% CI 52.7 to 214.6). The differential impact 
of LPS was also greater in P301S mice than control mice (Figure 34 and interaction 
term Table 39). 
Densitometric analysis confirmed these results. There was a disease-associated 
increase in the percentage area containing IBA1 signal in lamina 9 of P301S mice 
(Figure 34 and Table 39). LPS induced an increase in the percentage area containing 
IBA1-positive signal in C57BL/6 mice and a further increase in P301S mice (Figure 34 
and Table 39). Again, the differential effect of LPS was greater in P301S mice than 
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Figure 34 - Systemic LPS has a differential impact on IBA1-positive microglia in lamina 9 of the spinal 
cord of P301S mice.  A-D) Representative examples of IBA1 stained spinal cord (lamina 9 of c5-c7) from C57BL/6 
+ Saline (A), C57BL/6 + LPS (B), P301S + Saline (C), P301S + LPS (D). E-H) Close up of microglial morphology 
from C57BL/6 + Saline (E), C57BL/6 + LPS (F), P301S + Saline (G), P301S + LPS (H). I) IBA1-positive cell 
counts in lamina 9 of the spinal cord indicate that P301S mice have more IBA1-positive cells than controls 
(indicated by **p<0.0001) and LPS induced a further increase (indicated by *p<0.001) (C57BL/6 + Saline n=8, 
C57BL/6 + LPS n=8, P301S + Saline n=8, P301S + LPS n=7). J) Densitometric analysis indicated more IBA1 
signal in P301S mice compared with controls (mixed effects linear regression, indicated by ***p<0.0001) and LPS 





 LPS-treatment significantly increases IBA1-positive microgliosis in 
the rubrospinal tract of P301S mice at end stage  
Previous analyses have focussed on lamina 9 of the spinal cord since this area is 
enriched with AT8-positive motor neurons which degenerate and contribute to the 
hind limb pathology of P301S mice. However there was striking microgliosis in the 
rubrospinal tract at 22 weeks of age. This area contains axon fibres which descend 
from the red nucleus, combining information from the motor cortex and the 
cerebellum and synapse with interneurons and motor neurons hence this system 
establishes rudimental motor skills that are refined by further corticospinal input 
(Martinez-Lopez et al., 2015) (see Figure 3 for anatomical schematic). 
Densitometric analysis of the rubrospinal tract indicated an increase in the percentage 
area containing IBA1 signal in P301S mice (Figure 35 and Table 40). LPS exposure 
caused a significant increase in IBA1 signal in P301S mice (additional 2.6% compared 
with saline-injected P301S; p<0.001; 95% CI 1.5 to 3.8) but not C57BL/6 mice (Figure 
35). The effect of LPS was also greater in P301S mice than control mice when formally 
tested (Figure 35 and Table 40). 
 
Table 40 - Systemic LPS has a differential impact on IBA1-positive microglia in the rubrospinal tract 
of the spinal cord of P301S mice. The first term represents IBA1-positive cells per mm2 or percentage area 
containing IBA1 signal for the reference group: C57BL/6 mice receiving saline. The following two terms test for 
an independent effect of genotype and intervention. The fourth term tests for a difference in the independent effect 
of LPS between genotypes. 
 
Condition % Area 
IBA1 signal 
Δ % Area 
IBA1 signal 
p-value 95% CI 
Reference (C57BL/6 + Saline) 1.1 - <0.001 0.6 1.7 
LPS 1.9 +0.7 0.069 -0.1 1.5 
P301S 2.4 +1.3 0.002 0.5 2.1 




Figure 35 - Systemic LPS has a differential impact on IBA1-positive microglia in the rubrospinal tract 
of the spinal cord of P301S mice. A-D; Representative examples of IBA1 stained spinal cord rubrospinal tract 
(of c5-c7) from C57BL/6 + Saline (A), C57BL/6 + LPS (B), P301S + Saline (C), P301S + LPS (D). E-H) Close-up 
of microglial morphology from C57BL/6 + Saline (E), C57BL/6 + LPS (F), P301S + Saline (G), P301S + LPS (H). 
I) Densitometric analysis indicated more IBA1 signal in P301S mice compared with controls (mixed effects linear 
regression, indicated by *p<0.005) and LPS induced an increase in the area containing IBA1 signal in P301S mice 




 LPS-treatment reduced GFAP-positive cortical astrogliosis in P301S 
mice at end-stage  
As expected, by end stage there was significant disease-associated cortical astrogliosis 
in P301S mice compared to C57BL/6 mice (Figure 36 and Table 41). Acutely LPS 
exposure increased astrogliosis, however, LPS had no lasting impact on cortical 
astrogliosis in C57BL/6 mice (Figure 36 and Table 41). At 22 weeks there was an 
apparent reduction in the number of GFAP-positive cells in the cortex of LPS-injected 
P301S mice compared with saline-injected counterparts (-81.4 cells per mm2; p=0.088; 
95% CI -146.3 to 29.6) (Figure 36 and Table 41). 
Densitometric analysis of the motor cortex confirmed the disease-associated increase 
in the percentage area containing GFAP signal in P301S mice compared with C57BL/6 
mice (Figure 36 and Table 41).  Exposure to LPS had no effect on percentage area 
containing GFAP signal in control mice and again resulted in an apparent reduction 
in GFAP signal in P301S mice compared with saline-injected counterparts (Figure 36 





Figure 36 -  No chronic impact of systemic LPS on GFAP-positive reactive astrocytes in the brain. A-D; 
Representative examples of GFAP stained cortical tissue collected at 22 weeks of age from C57BL/6 + Saline (A), 
C57BL/6 + LPS (B), P301S + Saline (C), P301S + LPS (D). E-H; Scale bar 100 μm. E) GFAP-positive cell counts 
in the motor cortex (to sub-pial depth of 150 μm) from C57BL/6 (blue) and P301S (red) mice injected with either 
saline (no pattern) or LPS (patterned) indicate significant astrogliosis in P301S mice compared with controls but 
no significant long term impact of LPS (mixed effects linear regression, indicated by †p=0.088 *p<0.0001). F) 
Densitometric analysis in the same area support these results (mixed effects linear regression, indicated by 






































































































































































































































































































































































































































































































 LPS-treatment reduced GFAP-positive astrogliosis in lamina 9 of 
the spinal cord of P301S mice at end-stage  
The morphology of astrocytes in the spinal cord at end stage made it very difficult to 
count cells. Densitometric analysis of lamina 9 of the spinal cord indicated significant 
disease-associated astrogliosis in P301S mice compared with C57BL/6 mice (Figure 37 
and Table 42). LPS had no significant effect on acute astrogliosis in the spinal cord of 
control mice (Figure 37 and Table 42). Acutely LPS caused an increase in astrogliosis 
in P301S mice, however at end stage there was an apparent reduction in GFAP signal 
in the spinal cord of P301S mice as seen in the cortical tissue, although not significant 
at α=0.05 (-1.8%; p=0.254; CI 95% -5.1 to 1.5) (Figure 37). 
Condition % Area 
GFAP 
signal 
Δ % Area 
GFAP signal 
p-value 95% CI 
Reference (C57BL/6 
+ Saline) 
0.9 - 0.217 -0.6 2.5 
LPS 0.7 -0.2 0.856 -2.3 2.0 
P301S 9.9 9.0 <0.001 6.8 11.1 
P301S + LPS  
(interaction term) 
8.1 -1.6 0.289 -4.7 1.5 
Table 42 - No chronic impact of systemic LPS on GFAP-positive reactive astrocytes in the spinal cord.  
The first term represents percentage area containing GFAP signal for the reference group: C57BL/6 mice receiving 
saline. The following two terms test for an independent effect of genotype and intervention. The fourth term tests 





Figure 37 - No chronic impact of systemic LPS on GFAP-positive reactive astrocytes in the spinal cord. 
A-D; Representative examples of GFAP stained spinal cord (lamina 9 of c5-c7) from C57BL/6 + Saline (A), 
C57BL/6 + LPS (B), P301S + Saline (C), P301S + LPS (D). Scale bar 100 μm  E) Densitometric analysis of lamina 
9 of the spinal cord showed significant astrogliosis in P301S mice but no lasting effect of LPS on GFAP-positive 






5.3.4 Summary of chronic pathology 
At end stage, there was significant tau pathology and neuronal loss in the cortex and 
lamina 9 of the spinal cord of P301S mice. LPS-injection had no lasting impact on AT8-
positive tau pathology in the cortex or spinal cord. LPS-injection induced additional 
cortical neuronal loss which was equivalent in C57BL/6 and P301S mice but LPS-
injection did not impact neuronal counts in the spinal cord. There was no cortical 
microgliosis in P301S or C57BL/6 mice at end stage regardless of LPS exposure. There 
was, however, significant microgliosis in the spinal cord of P301S mice and LPS-
exposure increased that microgliosis further still. There was also significant reactive 
astrogliosis in the brain and spinal cord of P301S mice which was reduced in LPS-














0 0 65.8 63.8 
NeuN-positive cells 
per mm2 
1089.3 915.6 806.1 642.0 
IBA1-positive cells 
per mm2 
181.3 239.2 221.6 213.6 
% Area containing 
GFAP +ve Signal 





0 0 123.8 149.9 
NeuN-positive cells 
per mm2 
93.7 86.4 27.7 24.2 
% Area containing 
IBA1 +ve Signal 
1.7 3.1 3.9 7.0 
% Area containing 
GFAP +ve Signal 
0.9 0.7 9.9 8.1 
Table 43– Summary table of impact of LPS on pathological markers at end stage. Values refer to estimated 
mean measures of pathological markers for each group. Bold black font is used to indicate a  significant effect of 
LPS or genotype compared with C57BL/6 mice given saline (p < 0.05) except in the final column where bold black 
font indicates significance compared with saline-injected P301S mice (p < 0.05). Underlined font indicates a 




LPS-injection exacerbated AT8-positive tau pathology in the brain and spinal cord of 
P301S mice when assessed 24-hours post-injection (Figure 18). Although this acute 
increase in tau pathology did not persist to end stage, there was evidence of increased 
neuronal death at end stage.  
That is to say, there is already significant superficial cortical neuronal loss in P301S 
mice compared with C57BL/6 mice at end stage (22 weeks) but the data presented 
here demonstrate that a single dose of intraperitoneal LPS (500 µg/kg) at 16 weeks of 
age is sufficient to cause additional cortical neuronal loss in P301S mice, as well as 
C57BL/6 mice (Figure 32).  
Analysis of whether glial cells might contribute to this exacerbation of pathology did 
not yield conclusive results. IBA1-positive cell counts and CD11b mRNA levels 
indicated a lack of cortical microgliosis in P301S mice, regardless of age and there was 
no observed increase in cortical microgliosis following LPS-injection (Figure 19, 
Figure 20, and Figure 33). Nonetheless, there was a robust increase in IL-1β mRNA 
levels in the cortex and spinal cord of P301S mice and C57BL/6 mice 4-hours post-
LPS-injection (Figure 21 and Figure 25) which could conceivably contribute to the 
observed LPS-induced pathology.  
In the spinal cord, where there is disease-associated microgliosis, LPS acutely induced 
IBA-1 labelling in both P301S mice and C57BL/6 mice (Figure 24). These cells did not 
show exaggerated IL-1 responses to LPS in P301S mice and do not appear to be 
primed. Nonetheless, when examined at end stage there was increased disease-
associated microgliosis and further exacerbation in LPS-injected P301S mice (Figure 
34 -Figure 35). 
LPS also caused an acute increase in GFAP signal in P301S mice and C57BL/6 mice 
but in the long-term LPS-injection reduced disease-associated GFAP-positive 
astrogliosis in the brain and spinal cord (Figure 36 Figure 37).  
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Therefore, LPS has acute impacts on tau pathology and has lasting impacts on cortical 
neuronal death and spinal cord microgliosis. The contribution of microglia, astrocytes 
or IL-1β in the pathological deficits observed remain undetermined. 
5.4.1 Systemic inflammation exacerbated tau pathology in P301S mice and 
caused cortical neuronal loss in C57BL/6 and P301S mice 
In chapter 3 progressive neuronal loss and astrogliosis were demonstrated in the 
superficial layers of the cortex in the absence of apparent microgliosis. Meanwhile 
there was significant progressive microgliosis in lamina 9 of the spinal cord. The same 
disease-relevant areas were studied in this chapter to investigate the acute and long-
term impacts of systemic inflammation on these key pathological hallmarks and the 
potential interactions between systemic inflammation and disease pathology.  
LPS-injection at 16 weeks of age acutely increased AT8-positive hyperphosphorylated 
tau pathology in the motor cortex and spinal cord of P301S mice, but not C57BL/6 
mice, (Figure 18) and yet LPS-injection induced significant cortical neuronal loss in 
both P301S and C57BL/6 mice and failed to induce neuronal loss in the spinal cord of 
either. This poses interesting questions regarding the mechanisms of LPS-induced tau 
phosphorylation and neuronal loss and whether the two are related.  
It remains to be determined whether the increase in AT8-staining represents an 
increase in overall transgene expression and therefore total tau or an increase in 
phosphorylation of tau. Tau expression in the P301S mouse is driven by the Thy 1.2 
promoter. Thy 1 expression is developmentally and dynamically regulated and there 
is evidence to suggest that Thy 1 is upregulated by cytokines including IL-1β and 
TNF-α (Ishizu et al., 1997). However, Kitazawa et al. (2005) used a chronic systemic 
LPS protocol (500 μg/kg twice per week for 6 weeks) to investigate the effects of 
systemic inflammation in 3xTgAD mice which express mutant tau under the same 
Thy 1.2 promoter. They demonstrated markedly increased tau pathology following 
peripheral LPS injection but total human tau levels remained constant indicating that 
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the increased tau pathology was not due to increased transgene expression, but there 
was a 2-fold increase in AT8 and AT180 immunoreactivity in the hippocampus. From 
this work, we might infer that the increase in AT8 staining shown here in P301S mice 
is unlikely due to an increase in transgene expression since 3xTgAD and P301S mice 
share the same Thy 1.2 promoter although this still must be verified. 
How, then, did LPS increase tau phosphorylation in P301S mice and not C57BL/6 
mice? It has previously been demonstrated that intraperitoneal LPS-injection (100 
μg/kg) into young, healthy C57BL/6 mice was sufficient to induce a transient increase 
in tau hyperphosphorylation in the hippocampus (visualised by AT8 and PHF) which 
returned to baseline levels by 4-hours post LPS (Roe et al., 2011). Tau phosphorylation 
status is dependent on the balance between kinase and phosphatase activity; LPS-
injection induced the transient activation of tau kinases, GSK-3 and cyclin-dependent 
kinase-5 (CDK5) activator proteins p25 and p35 (Roe et al., 2011). Thus, transient tau 
hyperphosphorylation is a known response to systemic inflammation in wild-type 
mice and the absence of AT8-positive pathology in C57BL/6 mice 24-hours post-LPS-
injection is likely due to restoration of baseline phosphorylation status due to the 
proper balance of kinase and phosphatase reactions in C57BL/6 mice.  
It is likely that the over-expression of human P301S tau increases the propensity for 
the hyperphosphorylation of tau protein in neurons and delays, or perhaps prevents 
totally, the restoration of the normal phosphorylation status via several mechanisms: 
first, over-expression of human mutant tau protein provides abundant substrate for 
the LPS-induced kinases and in doing so shifts the reaction kinetics in favour of 
hyperphosphorylation; second, there is increased disease-associated activation of tau 
kinases, including GSK-3, in P301S mice (Allen et al., 2002); third, there is evidence 
that phosphorylation of tau occurs sequentially such that phosphorylation by CDK5 
is required for further phosphorylation by GSK-3β (Li et al., 2006), hence it is plausible 
that disease-associated tau phosphorylation prior to LPS-injection allows progressive 
accumulation of increasingly irreversible hyperphosphorylation. These factors likely 
247 
 
contribute to the tau pathology observed in LPS-injected P301S mice but not C57BL/6 
mice 24-hours post-injection.   
Alternatively, LPS induces transient hypothermia in C57BL/6 mice (Combrinck et al., 
2002) and hypothermia is associated with increased tau phosphorylation due to 
inhibition of temperature-sensitive tau phosphatase, protein phosphatase 2A (PP2A) 
(Planel et al., 2007). According to data presented in chapter 3 LPS-induced 
hypothermia might be exaggerated in P301S mice thus potentially influencing tau 
phosphorylation.  
At 22 weeks of age there was a profound disease-associated increase in AT8-positive 
cell counts in the superficial cortex and the spinal cord of saline-injected P301S mice 
compared with C57BL/6 mice (Figure 31). In contrast to the acute LPS-induced 
increase in tau pathology, there was no lasting impact of LPS on tau pathology in 
P301S mice compared with saline-injected counterparts at end stage (Figure 31). First 
and foremost, it is worth mentioning that AT8 is just one marker of pathological tau 
phosphorylated at Ser-202 and Thr-205. Early studies in the P301S mouse showed that 
human tau in the brain and spinal cord of P301S mouse at end stage is strongly 
immunoreactive for the following phosphoepitopes: AT8, AT270 (Thr181), pT212 
(Thr212), CP3 (Thr214) AT100 (Thr212 and Thr214) AT180 (Thr 231), 12E8 (Ser262 and 
Ser356), AD2 (Ser395, Ser404), PG5 (Ser 409), and AP422 (Ser 422) (Allen et al., 2002). 
More than 40 phospho-epitopes have been discovered on tau protein and they are 
phosphorylated in a hierarchical manner such that there are early and late markers of 
pathology (Augustinack et al., 2002). AT8 stained the most cells in the P301S mouse 
compared with alternative markers, and it stains soluble and insoluble tau and does 
not give information regarding the severity of tau hyperphosphorylation, 
aggregation or NFT formation. Hence it is plausible that the ubiquitous disease-
related AT8 pathology masks any impact of LPS and at this late stage in disease it is 
possible that alternative markers might better identify LPS-induced differences in 
phosphorylation status. Silver staining, thioflavin-S immunofluorescence or 
conformational antibodies Alz50 or anti-NFT antibodies ought to be used to further 
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characterise the impact of LPS on the severity of tau pathology following LPS 
injection. 
Alternatively, it is plausible that the increased cortical neuronal loss of LPS-treated 
P301S mice might account for the absence of additional AT8-positive cells at end-
stage. In agreement with previously published work there was significant disease-
associated neuronal loss in the superficial layers of the motor cortex and lamina 9 of 
the spinal cord of P301S mice at 22 weeks of age (Figure 32) and importantly, data 
presented here indicate that LPS induced additional superficial cortical neuronal loss 
in P301S mice as well as C57BL/6 mice (Figure 32). Interestingly, in lamina 9 of the 
spinal cord where LPS failed to induce significant neuronal loss of C57BL/6 or P301S 
mice there was a trend towards LPS-induced increase in tau pathology although this 
did not reach significance (p=0.143) (Figure 31). 
Due to the nature of the experiment, tissue was collected at end stage and there were 
no longitudinal data. Hence, it is unclear when neuronal loss occurred relative to the 
appearance of tau pathology, that is, whether there was acute or gradual, progressive 
neuronal loss and whether there was transient tau hyperphosphorylation which 
rapidly returned to saline-injected levels, or whether LPS-induced tau pathology 
persisted and was eventually masked by disease associated tau pathology. 
The magnitude of LPS-induced neuronal loss in C57BL/6 mice was equivalent to that 
of P301S mice suggesting that this neuronal loss was not disease-specific or 
dependent on the LPS-induced tau pathology observed exclusively in P301S mice 24-
hours post-injection. A mechanism has not been determined for LPS-induced 
neuronal loss or increased tau pathology in this instance, however, previously 
described mechanisms causing acute LPS-induced neuronal loss and LPS-induced 




Peripheral LPS administration (200 µg/kg) can induce cortical apoptosis in otherwise 
healthy male Wistar rats as demonstrated by an increased proportion of TUNEL-
positive cells from cortical tissue of LPS-injected rats (Nolan et al., 2003). This LPS-
induced apoptosis is mediated by IL-1β via IL-1 type 1 receptor (IL-1R1) signalling 
which causes downstream p38 and JNK activation, cytochrome-c translocation, 
caspase-3 activation, accumulation of reactive oxygen species (ROS) and DNA-
fragmentation (Lynch et al., 2002, Martin et al., 2002, Nolan et al., 2003, Lynch et al., 
2004, Xie et al., 2004). LPS-induced apoptosis, cytochrome c translocation and caspase 
3 activation can be reversed by IL-1β receptor inhibition and p38 inhibition (Martin 
et al., 2002, Nolan et al., 2003, Xie et al., 2004). Hence IL-1β can induce acute cortical 
neuronal loss.  
In addition, in vitro studies have shown that microglial IL-1β production can cause 
an increase in tau hyperphosphorylation (Li et al., 2003). Primary rat microglia or N9 
microglial cells were stimulated with either amyloid-β or LPS to produce IL-1α, IL-
1β and TNF-α. When co-cultured with primary rat neurons within 30 minutes 
activated microglia caused an increase in tau phosphorylation (AT8 antibody), and 
p38-MAPK phosphorylation, i.e. activation. The same effect was shown on incubation 
with IL-1β alone. Neuronal cultures were pre-treated with IL-1 receptor antagonist 
(IL-1ra), anti-IL-1β antibody, or anti-TNFα antibody prior to co-culture with activated 
microglia. Tau phosphorylation was attenuated by IL-1ra as well as anti-IL-
1β antibody but not anti-TNF-α antibody. p38-MAPK inhibition reversed the 
influence of IL-1β on tau phosphorylation (Li et al., 2003).  
Previous studies in the 3xTgAD mouse model of AD demonstrated that peripheral 
LPS-injection increased microgliosis, increased IL-1β mRNA levels and increased tau 
pathology, however no mechanistic studies were conducted to determine a causative 
link (Kitazawa et al., 2005, Sy et al., 2011).  
Studies in C57BL/6 mice showed that systemic LPS-injection induced apoptosis (4-
hours post-injection) and tau pathology (24-hours post-injection) in the dentate gyrus 
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(Cardona et al., 2006, Bhaskar et al., 2010). These effects were exacerbated in 
fractalkine deficient (Cx3cr1−/−) mice suggesting microglial involvement (Cardona et 
al., 2006, Bhaskar et al., 2010). Intraperitoneal LPS-injection (1 mg/kg) into 2-month-
old hTau mice (where the endogenous mouse tau gene is replaced by the human wild-
type tau gene) induced early tau hyperphosphorylation at TG3 (phospho-thr231) and 
AT8 epitopes 24-hours post-injection (Bhaskar et al., 2010). Fractalkine deficient hTau 
mice (hTau-Cx3cr1−/− mice) were then used to demonstrate that increased microgliosis 
in hTau-Cx3cr1−/− mice was associated with increased tau hyperphosphorylation 
(AT8, AT180 and PHF1) and increased aggregation of insoluble tau. Authors went on 
to generate Tlr4−/− and Il-1r1−/− mice which were used to demonstrate that LPS 
increases tau phosphorylation and p38-MAPK activation via the TLR4 signalling 
pathway and that IL-1 is key in mediating this effect (Bhaskar et al., 2010). Together 
these experiments indicate that LPS-induced microglial activation leads to IL-1β 
production which causes increased tau phosphorylation.  
Importantly the hTau studies focussed on the dentate gyrus (Bhaskar et al., 2010), a 
region where there is disease-associated microgliosis and where IL-1R1 expression is 
highest (Ban, 1994), whereas my studies have focussed on the superficial cortex where 
there is no apparent microgliosis and where IL-1R1 expression is minimal. However, 
the potential role of IL-1β and p38-MAPK in tau phosphorylation and neuronal loss 
is particularly interesting in the case of P301S mice because previously published 
work showed that p38-MAPK family members (MAP kinase, phospho-JNK, and 
phospho-p38) labelled tau-positive neurons in the P301S mouse (Allen et al., 2002) 
hence these neurons might be sensitive to LPS-induced increases in IL-1β.   
None of the studies investigating the effects of systemic inflammation in a pure model 
of tauopathy have directly compared the levels of LPS-induced hyperphosphorylated 
tau pathology, microglial activation or IL-1β production between models of 
tauopathy and wild-type mice. This is an important concept since studies in 
alternative models of neurodegeneration demonstrate disease-associated microglial 
priming (section 1.2.9) whereby microglia in the disease context exist in an alternative 
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state of activation, and subsequent inflammatory challenge results in the over-
production of proinflammatory cytokines, including IL-1β, with deleterious 
downstream consequences (Cunningham et al., 2007). It is important to understand 
whether the increased pathology in P301S mice is the result of an exaggerated 
neuroinflammatory response or perhaps due to increased neuronal vulnerability to 
an equivalent inflammatory environment.  
5.4.2 There is no apparent microglial priming in the brain or spinal cord of 
P301S mice, but systemic inflammation induced IL-1β expression  
The data presented here demonstrate the absence of any detectable cortical 
microgliosis. CD11b, a component of complement receptor 3, is a microglial marker 
known to be upregulated in the brainstem of P301S mice at end stage  (Bellucci et al., 
2004) and was therefore used for a gene expression assay 4-hours post-injection at 16 
weeks of age. The CD11b expression assay and IBA1-positive cell counts in the cortex 
24-hours post-injection confirmed the absence of disease-associated microgliosis in 
the cortex of P301S mice compared with C57BL/6 mice.  
There was no impact of LPS on CD11b mRNA transcript levels or IBA1-positive cell 
counts in the cortex of C57BL/6 mice or P301S mice and there were no obvious 
morphological differences between groups, although no formal morphological 
studies were undertaken (Figure 19 and Figure 20). Importantly there was no 
difference in the magnitude of LPS-induced microglial response between C57BL/6 
mice and P301S mice, as measured by either of these markers at either time point 
(Figure 19 and Figure 20). 
The apparent absence of cortical microgliosis persisted until end stage (Figure 33); 
despite the significant disease-associated neuronal loss, abundant tau pathology and 
astrogliosis in the cortex. When mice were sacrificed at 22 weeks of age, IBA1 staining 
indicated that there was still no microgliosis in this area in P301S mice compared with 
C57BL/6 mice. LPS had no impact on IBA1-positive cell counts or microglial 
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morphology in either P301S mice or C57BL/6 mice (Figure 33). These data further 
reaffirm the notion that there is, remarkably, no disease-associated microgliosis in the 
cortex of P301S mice and microglia in the cortex of P301S mice are still subject to the 
same stringent regional immune regulation as control mice. 
There is, however, known disease-associated microgliosis in the spinal cord of P301S 
mice at end stage (Bellucci et al., 2004) and this progressive microgliosis becomes 
significant in lamina 9 at 10 weeks of age (section 3.3.2.5).  
At 16 weeks of age the disease-associated increase in IBA1-positive cells detected in 
lamina 9 of the spinal cord of P301S mice did not reach significance (p=0.242) (Figure 
24). This contrasts with work in Chapter 3 which demonstrated a clear progressive 
increase in microglial counts in the spinal cord of P301S mice which became 
significant compared with controls at 10 weeks of age using the same microglial 
marker, IBA1. There are several plausible explanations which might account for this 
failure to detect microgliosis in P301S mice. 
In chapter 3 IBA1-positive cells were visualised using 3′,3′-diaminobenzidine (DAB) 
as the chromagen, whereas in chapter 5 they were visualised using 
immunofluorescence. DAB-staining depends on the oxidation of DAB into a dark 
brown or black, alcohol-insoluble reaction product. The reaction can be run until 
optimal staining is achieved, thus improving signal-to noise ratio. In chapter 5 
however IBA1 was visualised by immunofluorescence; which does not allow this type 
of optimal staining and produces more background staining.  
IBA1 cells in chapter 3 were stained using anti-IBA1 antibody (MP-290-CR05) from 
A. Menarini Diagnostics, however, the antibody expired and due to timing and cost-
effectiveness, in Chapter 5 IBA1-positive cells were stained using anti-IBA1 antibody 
(Ab5076) from AbCam. It is possible that the different results are due to problems 
with the AbCam IBA1 antibody which has since reported inconsistent results in 
mouse tissue especially at relatively mild levels of microgliosis (abcam_datasheet).  
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Alternatively, it is possible that the discrepancy is a result of variation in the tissue 
either due to the fixative or due to genuine biological variation between cohorts. 
Although statistically significant, the microgliosis demonstrated in 16-week-old 
P301S mice in chapter 3 represented only a 1.6-fold change in IBA1-positive cell 
counts compared with controls. The results in Chapter 5 represent a 1.2-fold change 
in IBA1-positive cell counts – a difference which might realistically be attributed to 
biological variation. It is worth noting that there was also relatively mild astrogliosis 
in the spinal cord of the same mice used in Chapter 5 (Figure 30), although again, 
astrogliosis in this chapter was detected by immunofluorescence and not DAB 
staining as before. 
LPS caused a subtle but significant increase in IBA1-positive signal detected in the 
spinal cord of C57BL/6 and P301S mice 24-hours post-injection (Figure 24). There was 
no difference in the magnitude of the IBA1 response between genotypes. In 
agreement with these results qPCR data indicated a significant LPS-induced increase 
in CD11b transcripts in both C57BL/6 and P301S mice and there was no difference in 
the magnitude of the response (Figure 22).  
Interestingly there were regional differences in CD11b mRNA levels; the relative 
quantity of CD11b mRNA in the spinal cord of saline-treated C57BL/6 mice is 1.5-fold 
higher than in the cortex, as might be expected since microglia are more densely 
packed in white matter than grey (Mittelbronn et al., 2001). This ratio is unchanged 
in LPS-injected C57BL/6 mice indicating an equivalent response to LPS in the brain 
and spinal cord of control mice (Table 27). Saline-injected P301S mice have 2-fold 
CD11b expression in the spinal cord compared with the brain suggesting perhaps 
some degree of microglial activation in the spinal cord at baseline and LPS-injection 
increased the relative quantity to 2.6-fold in the spinal cord compared with the brain, 
further supporting the notion that there is a differential microglial response in the 
spinal cord of P301S mice compared with the brain.  
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These data highlight a microglial response to LPS in the spinal cord which is absent 
in the cortex – whether this is due to differential exposure to systemically 
administered LPS and circulating proinflammatory mediators perhaps due to 
differences in tissue perfusion or whether it is the result of different regional 
microglial properties is unclear. These data perhaps support the theory that there are 
sub-populations of microglia which exist on a spectrum of immune-vigilance along 
the rostral-caudal axis, such that cortical microglia are subject to stringent immune-
regulation, whereas more caudal microglia are considered “immune-vigilant” by 
comparison (Kim et al., 2000, Grabert et al., 2016). There are opposing regional 
differences in the expression patterns of ITIM-containing and ITAM-associating 
immunoreceptors such that ITAM-associating receptors were found in the cerebellum 
and ITIM-containing inhibitory members were predominantly found in the cortex. In 
future studies it will be interesting to investigate the regional expression pattern of 
genes involved in restricting over-activation of microglia including 
Cx3cr1, Trem2, Cd33, Siglech and Fcgr2b, which are all usually expressed at greater 
levels in the striatum and cortex than the cerebellum (Grabert et al., 2016).  
IBA1 and CD11b are generic, widely expressed markers and do not always detect 
subtle changes in microglial sub-populations or phenotype switching, hence, a gene 
expression assay for IL-1β was conducted 4-hours post-injection. According to the 
microglial priming hypothesis, following an inflammatory stimulus, IL-1β is over-
produced by microglia which are primed by the disease context and this IL-1β over-
production is implicated in the observed exaggerated LPS-induced sickness 
behaviour (Sly et al., 2001, Cunningham et al., 2005, Perry et al., 2007, Chen et al., 
2008).  
Gene expression analysis indicated negligible IL-1β mRNA in the brains of saline-
injected C57BL/6 and P301S mice. IL-1β mRNA levels in the spinal cord of saline-
injected C57BL/6 were also negligible but IL-1β expression in the spinal cord of P301S 
mice was approximately 3.5-fold IL-1β expression in the brain (Table 30). This is in 
line with studies by Bellucci et al (2004) which failed to detect IL-1β staining in the 
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cortex of P301S mice at end stage but showed IL-1β staining in the brainstem and 
spinal cord. Following LPS-exposure there was a 3.8-fold increase in IL-1β mRNA 
levels in the spinal cord of C57BL/6 mice compared with the brain and a 4.9-fold 
increase in the spinal cord of P301S mice compared with brain tissue (Table 30) – 
again, this is in line with the hypotheses that there are microglial sub-populations 
with different immune-vigilance (Grabert et al., 2016) and that there is microglial 
activation in the spinal cord of P301S mice. 
LPS induced a robust increase in IL-1β mRNA in the cortices of C57BL/6 and P301S 
mice but there was no evidence of an exaggerated IL-1β response in P301S mice 
compared with C57BL/6 mice (Figure 21). The absence of an exaggerated LPS-
induced IL-1β response in P301S compared with C57BL/6 mice supports the notion 
that there is no disease-related microglial priming. 
In a recent review, Cunningham explains that the term “microglial priming” arose 
independently from the concept of “inflammasome priming” whereby a priming 
stimulus is required to induce expression of components and assembly of the NLRP3-
inflammasome complex and accumulation of pro-IL-1β. A secondary stimulus is 
required to activate the NLRP3-inflammasome complex resulting in cleavage of pro-
IL-1β into the active form of IL-1β (Cunningham, 2013). Despite the distinction 
between microglial priming and inflammasome priming there may well be some 
overlap. It is certainly of interest that animal models which demonstrate over-
production of IL-1β associated with microglial priming have some disease-associated 
microglial IL-1β expression prior to LPS-exposure (Sly et al., 2001, Lee et al., 2002, 
Kitazawa et al., 2005, Chen et al., 2008) whereas here I demonstrate negligible cortical 
IL-1β mRNA in saline-injected P301S mice. Post-transcriptional modifications and the 
post-translational cleavage of pro-IL-1β to IL-1β by the inflammasome complex are 
key steps in regulating IL-1β protein levels hence it remains to be seen whether the 
secreted, active IL-1β protein levels reflect mRNA levels demonstrated here.  
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Unexpectedly, not only was there no exaggerated IL-1β response but a relatively 
smaller IL-1β response in P301S mice; the LPS-induced increase in IL-1β mRNA in the 
cortex and spinal cord of P301S mice was approximately half that of C57BL/6 mice. 
There are several possible explanations for a reduced IL-1β response in P301S mice. 
Firstly, it is possibly a matter of timing; IL-1β mRNA levels were only assessed at one 
time point 4-hours post-LPS-injection. This time point was chosen based on similar 
studies showing exaggerated IL-1β expression in alternative models of 
neurodegeneration at this time point (Godbout et al., 2005, Chen et al., 2008, Henry et 
al., 2009, Sy et al., 2011, Murray et al., 2012). It is possible however that there was a 
difference in the peak of IL-1β expression in P301S mice which was not apparent at 4-
hours post-LPS. Intraperitoneal LPS (100 µg/kg) was shown by others to induce IL-
1β expression in the C57BL/6 brain (Murray et al., 2012). IL-1β mRNA transcript levels 
peaked 1-hour post-injection, and were equivalent to IL-1β mRNA in the ME7 prion 
diseased brain at this time. IL-1β transcript levels in C57BL/6 mice gradually returned 
to baseline (Murray et al., 2012) however IL-1β transcript levels were still elevated in 
the ME7 prion diseased brain compared with C57BL/6 brain at 2- and 4-hours post 
LPS injection. Both groups had returned to baseline levels by 8 hours (Murray et al., 
2012). Detailed temporal analysis of central cytokine mRNA and protein levels are 
required to better understand the impact of LPS injection on the neuropathology in 
the P301S mouse. 
In addition, there is evidence that the presence of the meninges and choroid plexus 
dramatically increase the apparent LPS-induced increase in IL-1β mRNA 
(Garabedian et al., 2000). Although effort was made to remove the meninges, mice 
were not perfused prior to extraction of fresh tissue for gene expression assays and 
hence it is plausible that the contribution of IL-1β mRNA from circulating cells in the 
blood might lead to erroneous interpretations.  
Alternatively, reduced IL-1β expression in P301S mice might indicate a different 
microglial phenotype with limited IL-1β capacity. In a study using rTg4510 mice, 
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which overexpress human mutant P301L tau under an inducible CaMKIIα promoter, 
expression of microglial markers CD45, MHCII and an “alternative activation 
marker” YM1 were assessed at 1, 5, and 9 months of age in the anterior cortex and 
hippocampus of rTg4510 mice (Lee et al., 2010). There was an age-related increase in 
CD45 expression, a small increase in MHCII expression and no change in YM-1 
expression over time. Intracerebral LPS-injection (2 μl of LPS at 5 μg/μl) dramatically 
induced CD45 and arginase-1 expression in rTg4510 mice and control mice but 
interestingly there was an exaggerated increase in YM-1-positive microgliosis in 
rTg4510 mice compared with LPS-injected controls. YM-1 is a mouse-specific 
chitinase-like protein associated with “alternative” or “M2” microglial activation (Lee 
et al., 2010). YM1 is thought to interact with, and protect extracellular matrix 
components (Jin et al., 1998) and is associated with the development of Th2 
inflammation (Lee et al., 2011).  
To date there have been no investigations of the microglial expression profile of P301S 
mice and the absence of an exaggerated IL-1β response alone is insufficient to 
characterise the phenotype of these cells. The expression data of rTg4510 mice were 
compared with that of primed microglia and there was considerable overlap between 
the consensus transcriptional signature of primed microglia and the rTg4510 dataset 
(Holtman et al., 2015). Thus, conceptually tau pathology seems capable of inducing 
microglial priming, hence gene expression assays and immunohistochemistry are 
required to determine the relative abundance of markers associated with microglial 
priming in the P301S model, including CD14, Axl, Clec7a, CD11c, Cybb and Cfs1 
(Chiu et al., 2013, Holtman et al., 2015). Several of the markers associated with 
microglial priming are involved in phagocytosis and endocytosis – it will be 
interesting to determine whether these markers are elevated in the P301S mouse with 
its mostly intracellular deposits compared with the extracellular deposits associated 
with amyloidopathies.  
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It is possible that the intracellular localisation of tau pathology in P301S mice induces 
an alternative microglial phenotype compared with the primed microglia seen in 
instances of extracellular amyloid and prion pathology.  
In innate immunology, there are intracellular and extracellular PRRs which recognise 
different PAMPs and initiate different types of immune response, as discussed in 
section 1.2.3.2  (Akira et al., 2006). Extracellular receptors tend to be associated with 
bacterial, fungal and protozoan infections and initiate an inflammatory response that 
serves to opsonize, phagocytose and destroy the pathogen (Akira et al., 2006). 
Intracellular receptors tend to be associated with viral immunity. When intracellular 
PAMPs are detected PRRs initiate complex signalling pathways which induce 
expression of type 1 interferons (IFN) (Akira et al., 2006).  
IFNs and IFN-inducible genes are upregulated in aging, in AD and in ALS (Lee et al., 
2000, Colangelo et al., 2002, Ricciarelli et al., 2004, Wang et al., 2011, Baruch et al., 
2014); a type 1 IFN signature is associated with the common gene expression 
signature of primed microglia (Holtman et al., 2015); and transcriptome analysis of 
rats overexpressing the longest isoform of wild type tau demonstrated a vast increase 
in IFN-inducible genes (Wang et al., 2010a). Importantly, type 1 IFNs can have an 
anti-inflammatory role in the CNS: they can increase anti-inflammatory cytokine 
production, such as IL-10 (Field et al., 2010); limit pro-inflammatory cytokine 
production, including TNF-α, IFN-γ and IL-12 (Castiglia et al., Teige et al., 2003, 
Makar et al., 2008); and have been shown to reduce IL-1β-induced IL-1β production 
(Schindler et al., 1990). Hence intracellular tau protein deposits might be recognised 
as non-self by intracellular receptors and might initiate a different arm of the immune 
system dominated by IFNs such that LPS-induced IL-1β expression is limited. 
Increased IFN-γ signalling is associated with increased tau pathology (Mastrangelo 
et al., 2009) hence in future it will be interesting to see if IFN signalling might 
contribute to the acute increase in tau pathology seen here.  
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Alternatively, there is evidence of inflammation-induced preconditioning associated 
with reduced inflammation. Exposure of naïve macrophages to cytokines such as 
IFN-γ, IL-12, and IL-10, alone or in combination had different effects on the response 
to subsequent LPS-exposure (Shnyra et al., 1998) and preconditioning with LPS 
resulted in neuroprotection during subsequent ischemia caused by transient middle 
cerebral artery occlusion (Rosenzweig et al., 2004); however, this was associated with 
reduced microglial activation measured by CD11b expression and since there was 
equivalent microgliosis, if not more, in the spinal cords of P301S mice compared with 
control mice, this seems an unlikely explanation for the reduced IL-1β response. 
Alternatively again, there are suggestions that microglia associated with tau 
pathology are dystrophic or senescent (Streit et al., 2009) potentially due to 
phagocytosis of pathological tau protein (Rodriguez-Callejas et al., 2016). Hence this 
attenuated IL-1β response might represent failure of microglia to respond 
appropriately due to microglial cell death. However, dystrophic microglia are 
identified based on morphological changes, including cytorrhexis and membrane 
blebbing (Streit et al., 2009) features which are not apparent 24-hours post-LPS-
injection in the P301S mouse.  
5.4.3 Systemic inflammation increased microgliosis in the spinal cord of 
P301S mice at end stage 
By 22 weeks of age, there was profound microgliosis in the spinal cord of P301S mice 
detected by IBA1 staining, in agreement with data from Chapter 3 and previously 
published work which showed MHCII and CD11b-positive microgliosis in the 
brainstem and spinal cord at end stage (Bellucci et al., 2004). The increase in IBA1-
positive cell numbers in P301S mice at 22 weeks was associated with clear 
morphological changes; cells did not exist in ramified resting morphology as seen at 
16 weeks (Figure 24) or in 22-week-old C57BL/6 mice (Figure 34E) but adopted a 
bushy morphology (Figure 34G) associated with microglial activation. In several 
instances, microglial cells also appeared to cluster around swollen dying motor 
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neurons (Figure 34H) (Allen et al., 2002). This might be indicative of phagocytosis of 
dying neurons as has been reported elsewhere (Zilka et al., 2009, Asai et al., 2015).  
During the acute phase (24-hours post-injection) there was an equivalent LPS-
induced increase in IBA1-positive microgliosis in C57BL/6 and P301S groups. 
However, at end stage there was a differential increase in microgliosis in the LPS-
treated P301S group compared with C57BL/6 mice which indicates an interaction 
between systemic inflammatory insult and disease-related pathology. Investigation 
of alternative markers of microgliosis acutely, at end stage and at intervening time 
points might be required to determine whether there was an LPS-induced phenotypic 
switch during the acute stages which was not detected using the chosen markers or 
whether there was a progressive and acquired change in microglial phenotype. 
It is plausible that the differential effect of LPS on microgliosis in the spinal cord of 
P301S mice was acquired over time, for example, the LPS-induced increase in tau 
pathology seen 24-hours post-injection may have persisted and exacerbated 
microgliosis over time. There is plenty of evidence that tau pathology results in 
microgliosis in humans and in animal models of tauopathy, as discussed in chapter 3 
(Kida et al., 1992, Paulus et al., 1993, Sheng et al., 1997, Ishizawa et al., 2001, Ikeda et 
al., 2005, Sasaki et al., 2008, Morales et al., 2013); the current data and others have 
shown that overexpression of P301S tau is sufficient to cause microgliosis in these 
mice (Bellucci et al., 2004). In addition, there is evidence that microgliosis drives tau 
pathology (Bhaskar et al., 2010, Maphis et al., 2015b) hence it is conceivable that an 
acute increase in tau pathology resulted in a self-exacerbating loop between 
microgliosis and increasing tau pathology.  
Not only was there clear disease-associated microgliosis in lamina 9 of the spinal cord 
where there is also known loss of motor neurons, but at end stage there was also 
striking microgliosis in the rubrospinal tract of P301S mice. The rubrospinal tract 
carries information which originates from the red nucleus, which integrates inputs 
from the motor cortex and the cerebellum. The tract synapses with motor neurons 
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and enables refinement of motor coordination by corticospinal inputs  (Martinez-
Lopez et al., 2015) (see Figure 3 for orientation within spinal cord). This tract is rich 
in axons and thus tau protein is abundant in this area. Disease-associated tau 
pathology is likely to result in axonal degeneration with extreme pathological 
consequences in this area. Indeed, at 22 weeks of age there was abundant microgliosis 
in the rubrospinal tract of P301S mice and significant LPS-induced changes on top of 
the disease-associated microgliosis.  
There were large bushy microglia but also smaller fragments of IBA1 staining with 
no clear cell body. The staining in the rubrospinal tract is reminiscent of the 
dystrophic (senescent) microglia apparently associated with tau pathology in Down’s 
Syndrome and AD post-mortem tissue at end stage (Streit et al., 2009, Xue et al., 2011). 
Dystrophic microglia are characterised by fragmentation or “cytorrhexis”, beading, 
blebbing and formation of spheroids (Xue et al., 2011). Confocal imaging is required 
to determine the 3-dimensional structure of microglia in this case to establish whether 
there is indeed cytorrhexis or whether the apparent fragmentation might be better 
explained by bushy processes of microglia which cross the 1-dimensional plane 
imaged here. Dystrophic microglia have not been studied in detail however they are 
associated with loss of neuroprotective functions in healthy ageing (Streit et al., 2004). 
5.4.4 Systemic inflammation caused an acute increase in GFAP signal but 
a long term decrease in GFAP signal 
In agreement with previous chapters there was disease-associated astrogliosis in the 
superficial layers of the cortex of 16-week old P301S mice by GFAP 
immunohistochemistry (Figure 28 and Table 32). In contrast, immunofluorescence 
failed to demonstrate significant astrogliosis in lamina 9 of the spinal cord of P301S 
mice, compared with control mice at 16 weeks of age (Figure 30). There are several 
plausible explanations for the failure to detect disease-associated astrogliosis at this 
time point. First, as with IBA1 staining, in chapter 3 GFAP-positive cells were 
visualised by DAB staining whereas here they were visualised using 
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immunofluorescence which brings with it the variations previously discussed. 
Second, in chapter 3 GFAP-positive cells were counted whereas in chapter 5 the 
percentage area containing GFAP signal was quantified – this method used in 
conjunction with the use of fluorescence staining rather than DAB, may introduce 
more variability in the results. Third, the discrepancies might arise from differences 
in the tissue rather than the staining or quantification methods, in which case they 
might be caused by differences in fixation or genuine biological variability. Despite 
the failure to detect disease-associated astrogliosis by immunofluorescence gene 
expression analysis of c5-c7 of the spinal cord showed an increase in the relative 
abundance of GFAP mRNA in P301S mice compared with C57BL/6 mice (Figure 29).  
Gene expression analysis indicated a 2-fold increase in cortical GFAP expression 4-
hours post-LPS and the magnitude of the LPS-induced response was equivalent in 
C57BL/6 and P301S mice (Figure 7). Immunofluorescence failed to detect a significant 
impact of LPS on GFAP-positive astrogliosis in the cortex (Figure 8). This is in line 
with detailed time course studies in the hippocampus of BALB/c mice which indicate 
that GFAP immunoreactivity does not change with systemic LPS-injection despite 
changes in the astrocyte expression profile and hence this measure alone is 
inadequate as an informant of the proinflammatory state astrocytes following 
systemic LPS (0.33 mg/kg) (Norden et al., 2016). 
In contrast, there was a large LPS-induced increase in reactive astrogliosis in the 
spinal cords of P301S mice but not C57BL/6 mice by immunohistochemistry (Figure 
30). It is of course possible that this could be a false-positive due to the peculiar 
absence of astrogliosis in the saline-treated P301S group, however, importantly the 
qPCR data, from a separate cohort of mice, confirmed the LPS-induced increase in 
GFAP expression in P301S mice but not C57BL/6 mice (Figure 29). These data thus 
indicate an impact of LPS on GFAP-positive reactive-astrogliosis in the spinal cord of 
P301S mice and not C57BL/6 mice.  
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It is unclear at this stage what caused the LPS-induced differential increase in GFAP 
expression in the spinal cord of P301S mice compared with C57BL/6 mice but not in 
the brain.  
The differential astrogliosis in the spinal cord might be microglia-mediated. Detailed 
time course studies from BALB/c mice injected intraperitoneally with LPS (0.33 
mg/kg) demonstrated sequential LPS-induced expression of cytokines and 
chemokines in microglia (2-4 hours post-LPS) followed by cytokine, chemokine and 
GFAP expression in astrocytes (peaked around 12-hours post-injection) (Norden et 
al., 2016). Evidence from the Barres lab showed that A1-astrocytes were not induced 
by LPS or IL-1β directly; instead the A1-reactive astrocyte profile was induced by 
microglia-derived IL-1α, TNF-α and complement component C1q, (Liddelow et al., 
2017). LPS induction of A1-astrocytes required microglial activation. It is plausible 
that the differential increase in GFAP-positive reactive astrogliosis in LPS-injected 
P301S mice is microglia-dependent and reflects an exaggerated inflammatory 
environment in P301S mice compared with control mice which is not detected with 
the chosen microglial markers. 
On the contrary, a study in the ME7 prion disease model demonstrated “astrocyte 
priming”; there was disease-associated astrogliosis in the brains of ME7 mice, 
visualised by GFAP staining, and subsequent inflammatory insult with intracerebral 
IL-1β or TNF-α altered the expression profile of astrocytes. There was an exaggerated 
astrocyte response in ME7 mice compared with control mice characterised by 
increased NFκB activation due to nuclear localisation of p65 and increased expression 
of chemokines (CCL2, CXCL1, RANTES, CXCL10) and markers of reactive 
astrogliosis (PTX3 and STEAP4) (Hennessy et al., 2015). Astrocyte activation was 
assessed 2-hours post intracerebral cytokine injection hence these astrocytic 
responses were unlikely to be microglia-dependent.  
Recently published work identified a host of astrocytic genes which are differentially 
regulated when astrocytes are co-cultured with neurons rather than grown in mono-
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culture (Hasel et al., 2017). There were nine neuronally-regulated astrocyte genes 
which were assessed in P301S spinal cord tissue. There was a reduced expression of 
astrocyte-specific genes involved in glutamate and GABA transport (Metabotropic 
Glutamate Receptor 3, GABA Transporter 3) and in metabolism in 20-week-old P301S 
mice compared with age-matched control mice (Hasel et al., 2017). This is of interest 
since LPS-administration is known to induce hypoglycaemia (del Rey et al., 1987, 
Oguri et al., 2002) and in this context altered astrocyte metabolism might be 
deleterious.  
Far more significant than the amount of GFAP in the brain or spinal cord is the 
functional output of those GFAP-positive cells. As discussed in the introduction, 
astrocytes are abundant cells which play an essential role in maintaining brain 
homeostasis; they provide structural, metabolic and trophic support to neurons and 
remove waste products, they participate in the tripartite synapse where they recycle 
neurotransmitters, regulate synaptogenesis, synaptic pruning and participate in 
synaptic transmission and they maintain the BBB and regulate blood flow (Martinez-
Hernandez et al., 1977, Zhou et al., 1994, Friedman et al., 1998, Hirase, 2005, Stevens 
et al., 2007, Fuller et al., 2010).  
GFAP is a generic marker of reactive astrocytes and does not distinguish between 
different profiles of these cells. GeneChip expression profiling of astrocytes 
demonstrated that reactive gliosis is dependent on the transient expression of 
networks of genes and those networks are dependent on the stimulus.  Astrocytes 
isolated following i.p. LPS-injection (5 mg/kg) expressed proteins involved in the 
antigen presentation pathway and complement pathway initiation, as well as 
cytokine and chemokine production – hence LPS-induced astrocytes adopt a 
damaging, proinflammatory phenotype whereas astrocytes isolated following 
ischemia (induced by middle cerebral artery occlusion (MCAO)) express 
neurotrophic factors and cytokines, and thrombospondins which help to rebuild lost 
synapses therefore seem to be neuroprotective (Zamanian et al., 2012). These two 
phenotypes were later referred to as “A1” and “A2” phenotypes respectively 
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(Liddelow et al., 2017). This terminology refers to the now out-dated “M1 vs. M2” 
microglial/macrophage phenotypes (Martinez et al., 2014) and while it is inevitably 
an over-simplification, it will prove to be a necessary step in shifting the field away 
from thinking of only reactive, GFAP-positive astrogliosis towards thinking about 
different types of astrogliosis (neuroprotective vs deleterious astrogliosis) and 
ultimately towards a more refined understanding the spectrum of astrocyte profiles.  
A1-reactive-astrocytes lose their neuroprotective functions and are neurotoxic 
(Liddelow et al., 2017) hence in future experiments, it will be interesting to use a 
transcriptomic approach to determine the baseline profile of astrocytes in the P301S 
model compared with controls and in addition to investigate whether systemic LPS 
has a differential impact on the astrocyte expression profile in P301S mice compared 
with C57BL/6 mice. 
At 22 weeks of age there was robust disease-associated GFAP-positive astrogliosis in 
the superficial layers of the cortex and lamina 9 of the spinal cord of P301S mice 
(Figure 36 and Figure 37) in agreement with data shown in chapter 3 and previously 
published data (Allen et al., 2002, Hampton et al., 2010). 
LPS-injection at 16 weeks of age had no lasting impact on astrogliosis in the brain or 
spinal cord of C57BL/6 mice, yet unexpectedly LPS caused a reduction in GFAP signal 
in P301S mice at 22 weeks of age compared with saline-injected counterparts (Figure 
36 and Figure 37). Reduced astrogliosis has previously been associated with increased 
neuronal loss and increased disease severity (Broe et al., 2004). Given the role of 
astrocytes in maintaining homeostasis it is possible that loss of astrocytes might lead 
to loss of neuroprotective function.  
Without a pan-astrocyte marker such as Aldh1l1 it is unclear whether this apparent 
decrease in astrogliosis at end stage results from down-regulation of GFAP 




There is evidence from in vitro studies that treatment of astrocyte cultures with LPS-
activated microglial conditioned medium stimulates astrocyte proliferation but 
decreases GFAP protein and mRNA levels (Röhl et al., 2007). This effect has been 
shown by treatment of astrocyte cultures with proinflammatory cytokines such as IL-
1β and TNF-α (Selmaj et al., 1991, Oh et al., 1993, Murphy et al., 1995). Studies in CSF-
1 deficient op/op mice showed that deficits in microgliosis increased GFAP 
expression in astrocytes in response to trauma (Bruccoleri et al., 2000). Swiss Webster 
mice expressing eGFP in astrocytes under the pan-astrocyte Aldh1l1 promoter 
exposed to i.p. LPS (5 mg/kg) showed an acute increase in GFAP 24-hours post-LPS 
which returned to baseline 30-days post-injection. There was no corresponding loss 
of e-GFP expression indicating that there was a down-regulation of GFAP rather than 
astrocyte cell death on resolution of inflammation (Zamanian et al., 2012). It is 
plausible that the acute inflammatory insult at 16 weeks might cause long-term down-
regulation of GFAP in P301S mice which persists until 22 weeks of age. 
LPS-induced microgliosis can also cause astrocyte cell death. Several in vitro studies 
have shown that inflammatory mediators IL-1β and nitric oxide, which are often 
produced by microglia and astrocytes following LPS-injection, can induce apoptosis 
in astrocytes in culture (Hu et al., 1996, Ehrlich et al., 1999, Suk et al., 2002). Hence it 
is possible that the exacerbated microgliosis with associated increase in 
proinflammatory cytokine production in the spinal cord of LPS-treated P301S mice at 
end stage might either cause a decrease in GFAP expression in astrocytes or 
apoptosis. However, this cannot explain the loss of astrogliosis in the cortex where 
there was no microgliosis even at end stage.  
At end stage, there was disease-associated astrogliosis and microgliosis in the spinal 
cord of P301S mice. LPS induced a further increase in microgliosis in lamina 9 and in 
the rubrospinal tract of P301S mice compared with saline-injected counterparts, but a 




Despite these LPS-induced glial changes, there was no impact of LPS on the NeuN-
positive cell counts conducted in Lamina 9 of the spinal cord. This might have been 
because at such a late stage in disease motor neuron loss is so severe (~75% loss) there 
is a floor effect and any LPS-induced neuronal loss is masked by disease-associated 
neuron loss.  
We have seen previously that the over-expression of human mutant tau protein is 
sufficient to cause astrogliosis with altered astrocyte gene expression (Hampton et al., 
2010, Hasel et al., 2017) and microgliosis (Bellucci et al., 2004) hence it is possible that 
the exacerbated tau pathology in LPS-injected mice caused the acute increase in 
reactive astrogliosis and long term increase in microgliosis in P301S mice and not the 
other way around. 
5.5 Conclusions  
In conclusion, peripheral LPS-injection (500 μg/kg) at 16 weeks of age was sufficient 
to acutely increase AT8-positive tau pathology in P301S mice but not C57BL/6 mice 
and cause equivalent cortical neuronal loss in both genotypes, apparent at end stage. 
There was no evidence of microglial priming in P301S mice. LPS-injection induced an 
increase in IL-1β mRNA levels in the cortex and spinal cord of P301S and C57BL/6 
mice 4-hours post-injection, which although reduced in P301S mice, might have been 
sufficient to induce the observed tau pathology in neurons which express human 
mutant tau protein and have activated kinases, including p38 and JNK (Allen et al., 
2002). IL-1β might also have induced neuronal loss in P301S mice and C57BL/6 mice. 
Mechanistic studies with IL-1 receptor antagonists and downstream kinase inhibitors 
are required to confirm or deny the potential involvement of IL-1β in the observed 
pathological changes. 
Interestingly, LPS-injection at 16-weeks-of-age advanced the chronic decline in 
horizontal bar performance (between 16-22 weeks of age) in P301S mice. The precise 
neurocircuitry involved in this declining performance is unknown, however, LPS-
injection failed to induce additional neuronal loss in lamina 9 of the spinal cord of 
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P301S mice. Neuronal loss in this area might not be the correct biological correlate for 
motor dysfunction: tau protein is known to influence synaptic changes and axonal 
degeneration. LPS caused a long-term increase in microgliosis in lamina 9 and in the 
rubrospinal (Rb) tract. The Rb tract carries information from the motor cortex and 
cerebellum to interneurons and motor neurons (Martinez-Lopez et al., 2015) hence 
exaggerated microgliosis in this area might indicate axonal degeneration associated 
with worse horizontal bar performance. LPS also reduced GFAP-positive astrogliosis 
in the cortex and spinal cord which might be associated with loss of neuroprotective 
function.  
In future, it will be interesting to investigate the impact of systemic inflammation on 
axonal degeneration and synaptic changes in areas relevant for sickness behaviours 




6 Chapter 6 - Discussion 
The overarching aim of this study was to explore the effect of systemic inflammation 
on disease progression in a mouse model of tauopathy neurodegeneration, with both 
pathological and non-invasive, behavioural outcomes.  
It had previously been demonstrated that over-expression of human mutant P301S 
tau protein under the Thy 1.2 promoter was sufficient to cause regional neuronal loss, 
astrogliosis and microgliosis (Allen et al., 2002, Bellucci et al., 2004, Hampton et al., 
2010). Here I built on that knowledge and determined a detailed time course for these 
pathological markers. I showed that there was progressive superficial cortical 
neuronal loss which occurred between 10-12 weeks of age, there was progressive 
astrogliosis in the same area and in the cervical spinal cord, significant already at 8 
weeks of age. Importantly I demonstrated that disease-associated microgliosis was 
regional; there was progressive microgliosis in lamina 9 of the spinal cord but 
microgliosis was absent in the cortex even at very late stages of disease.  
The lack of microgliosis in the cortex despite the neuronal loss and astrogliosis in the 
same area was surprising. A recent study isolated microglia from different regions of 
the brain for transcriptomic studies and demonstrated that there are regional sub-
populations of microglia which exist on a spectrum of immune vigilance (Grabert et 
al., 2016). It would be fascinating to apply these transcriptomic techniques to 
microglia isolated from the cortex and spinal cord of C57BL/6 and P301S mice in order 
to investigate the regional differences in microglial activation in tauopathy dementia. 
Given the relatively limited microglial activation and the failure to demonstrate 
microglial priming it is now essential to perform a more detailed analysis of the 
microglial phenotype in this model and to compare it to transcriptomics performed 
in other tau pathology models (Holtman et al., 2015).  
In addition, this study identified the horizontal bar task as a reliable tool with which 
to reproducibly and non-invasively monitor disease progression. Together with 
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pathological read-outs, this task provided essential information for identifying when 
neurological function begins to become vulnerable, thus identifying potential tipping 
points at which acute inflammatory insults might alter the trajectory of disease. The 
precise neurocircuitry which is required for good horizontal bar performance and 
which is impaired during the chronic decline phase remains to be determined. Tau is 
known to cause synaptic changes, axonal degeneration and neuronal cell death hence 
precisely how that neurocircuitry is impaired also requires further study. 
The horizontal bar task is a measure of motor strength and coordination. Attempts to 
identify an appropriate assay of cognitive decline which reflected the progressive 
nature of the disease failed. In the case of burrowing it was impossible to determine 
whether the chronic decline phase was due to motor or cognitive impairments and in 
the case of T-maze alternation, at 22 weeks of age P301S mice were still able to attain 
80% successful alternation so working memory deficits are not occurring even 
relatively late in disease. 
This dominant hind limb phenotype, is in line with previously published data, and 
pathological data from Chapter 3 demonstrating worse tau pathology and 
microgliosis in the spinal cord than in the cortex or hippocampus (Allen et al., 2002, 
Bellucci et al., 2004). The hind limb paralysis is one of the major limitations of this and 
other tau models, as it means mice must be humanely sacrificed before pathology in 
the forebrain has had a chance to fully develop. However, as discussed in Chapter 3 
this regional pathology should not be dismissed as merely an artefact of Thy 1.2 
driven expression of mutant tau protein since tau is expressed at two-fold 
endogenous mouse tau levels in the brain and spinal cord (Allen et al., 2002) hence 
the variations in pathology might reflect true and important regional vulnerability to 
tau pathology. Although tau expression levels are equivalent in the brain and spinal 
cord, it is also worth considering whether there are different types of tau pathologies 
in different regions, perhaps due to regional or cell-specific expression of kinase and 
phosphatase enzymes.  
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Initially we set out to model aspects of delirium caused by systemic inflammation 
superimposed onto dementia. Clinical studies show that in someone with pre-
existing dementia, acute systemic inflammation (for example, in the context of a 
peripheral infection)  frequently results in delirium (Cunningham et al., 2013). 
Additionally, delirium and systemic inflammatory illness are associated with 
increased risk of dementia, and can exacerbate or accelerate pre-existing dementia 
(Rockwood et al., 1999, Engelhart et al., 2004, Yaffe et al., 2004, Perry et al., 2007, 
Tobinick, 2008, Fong et al., 2009). Failure to detect cognitive decline in this model 
limits its usefulness as a tool for modelling dementia or indeed delirium 
superimposed onto dementia. However, there is no a priori reason to believe that the 
disease exacerbation has to be cognitive. The prediction is that systemic inflammation 
will exacerbate impaired function in tasks that become impaired in the underlying 
disease and that the inflammatory stress unmasks this circuit vulnerability and the 
data presented here are consistent with that hypothesis.  
In this case the vulnerable circuitry in the P301S model is predominantly involved in 
motor coordination, thus, the horizontal bar task offers an excellent tool for tracking 
the progression of disease pathology in P301S mice and detecting inflammation 
induced acute impairments in the same functions. Using this task, I demonstrated 
that a single dose of LPS (500 μg/kg) early in disease was sufficient to induce 
exaggerated acute impairments of motor strength and coordination in P301S tau mice 
compared with LPS-injected control mice. P301S mice injected at 16 weeks of age were 
more impaired and took longer to recover from the systemic inflammatory insult 
compared with mice injected with the same dose of LPS at 10 weeks of age. This 
indicates that the disease severity determines the level of vulnerability to the effects 
of a secondary stressor.  
In P301S mice injected at 16 weeks of age systemic inflammation was sufficient to 
increase the rate of the chronic decline in horizontal bar performance which is thought 
to be associated with neurodegeneration. It remains to be determined whether there 
is a change in the rate of neurodegeneration or whether injury causes acute damage 
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to the brain and then the disease continues at the same rate, but reaches the threshold 
for a measurable functional deficit sooner.  
In this study, the systemic inflammatory insult was modelled by LPS – a chemical 
moiety found on gram negative bacteria, however studies in alternative animal 
models of neurodegeneration and ageing demonstrate that other secondary 
inflammatory insults such as poly I:C or mouse hepatitis virus, both viral mimetics, 
osteoarthritis and obesity can influence disease pathology (Sriram et al., 2002, Field 
et al., 2010, Kyrkanides et al., 2011, Sy et al., 2011). There is also evidence that 
psychosocial stress can exacerbate tau pathology, neurodegeneration and chronic 
decline in alternative models of tauopathy (Carroll et al., 2011).  
Here I also showed that as the disease severity of P301S mice progresses, the animals 
become more vulnerable both acutely and in the long-term. If this is true of patients 
with on-going tau pathology the clinical consequences could be very significant.  
6.1 Potential mechanisms 
In order to better understand the pathological consequences of LPS-injection, brain 
and spinal cord tissue were collected acutely after LPS-injection and at end stage and 
the same pathological hallmarks were assessed.  
Previous studies investigating the impact of systemic inflammation on models of 
ageing or neurodegeneration have demonstrated microglial priming whereby the 
microglia are activated or disinhibited by some aspect of the diseased or aged brain 
and a subsequent inflammatory insult stimulates an exaggerated inflammatory 
response with deleterious effects (discussed in detail in section 1.2.9), however in 
P301S mice there was no evidence of microglial priming.  
The superficial cortex and spinal cord are relevant areas for investigating regional 
differences between the microglia, asking whether microglia are primed by the 
disease pathology and whether they are differentially responsive to systemic 
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inflammation. However, these regions are largely irrelevant neurocircuitry when it 
comes to identifying biological substrates of the exaggerated sickness response seen 
in chapter 4 and the focus has been on these areas as a result of prior knowledge 
regarding disease pathology in the P301S tau model.  
The focus has been on CD11b and IBA1 as they are classical markers of microglial 
populations and IL-1β because it has been the classical descriptor of further activation 
associated with primed microglia. Taken together the evidence presented here fails 
to demonstrate the presence of microglial priming with the archetypal exaggerated 
IL-1β response. LPS-treatment induced equivalent microgliosis in P301S and C57BL/6 
mice and LPS-induced IL-1β mRNA levels were relatively reduced in P301S mice 
compared with C57BL/6 mice. In future studies, it would be interesting to confirm 
these results with the transcriptomic studies previously mentioned and perhaps 
identify an alternative microglial profile. Although binary classifications of microglial 
phenotype are still referred to in the literature, known as “classically activated, M1” 
or “alternatively activated, M2”, it is becoming clear that there are very many 
microglial activation phenotypes (Ransohoff, 2016), influenced by ageing, regional 
heterogeneity, and the timing, dose, duration and type of pathology they are exposed 
to. The microglial phenotype in the current model certainly merits full analysis.  
In the absence of microglial priming, it remains to be understood what drives the 
exaggerated acute response to LPS in P301S mice compared with control mice. 
Despite the reduced IL-1β response, peripheral LPS-injection at 16 weeks of age was 
sufficient to increase AT8-positive tau pathology in the motor cortex and the spinal 
cord of P301S mice but not C57BL/6 mice at 24-hours post-injection which might 
indicate that over-expression of tau by neurons renders them more vulnerable to 
equivalent neuroinflammation.  
It is unclear at this stage whether the LPS-induced increase in acute AT8 staining 
represents an increase in transgene expression or tau phosphorylation. To resolve 
this, the most obvious next step would be to collect further tissue 24-hours post-
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injection, in order to run Western blots to determine whether there is a change in the 
amount of total tau protein as well as investigating the impact of LPS on other 
phospho-tau epitopes.  
Neurons in P301S mice are likely to be sensitised to the effects of LPS-induced IL-1β 
production since they contain tau pathology as well as elevated levels of activated 
p38 and JNK (Allen et al., 2002). Mechanistic studies using IL-1 receptor agonists and 
specific kinase inhibitors are required to determine whether this is indeed the 
mechanism of neuronal loss and increased tau pathology in LPS-injected P301S mice 
as has been suggested in alternative models of tauopathy (Kitazawa et al., 2005, 
Bhaskar et al., 2010).  
Indeed research showed that endogenous mouse tau mediated the neurotoxic effects 
of LPS in Cx3cr1−/− mice (Maphis et al., 2015a). In Cx3cr1−/− mice AT8-positive tau 
pathology co-localised with markers of neuronal death including cleaved caspase 
(CC3) but when Cx3cr1−/− mice were crossed with tau deficient mice to generate 
Cx3cr1−/−/Mapt−/− mice; tau deficiency was neuroprotective and following LPS-
injection there were fewer CC3-positive cells and fewer NeuN-positive-TUNEL-
positive cells in Cx3cr1−/−/Mapt−/− mice compared with Cx3cr1−/− mice (Maphis et al., 
2015a).  
It would be interesting to conduct similar studies to these in a knock-in mutant tau 
mouse model (Gilley et al., 2012) where mutant tau levels are equivalent to normal 
endogenous mouse tau levels in order to determine whether the LPS-induced 
increase in phospho-tau observed in P301S mice is in fact an artefact of over-
expression of tau, that is there is LPS-induced tau phosphorylation compared with 
C57BL/6 mice because of increased substrate availability, or whether mutation 
induced tau pathology might also be sufficient to yield similar results. 
Peripheral LPS is known to induce transient pathology in the hippocampus, where 
IL-1β receptor type 1 expression is greatest (Cunningham et al., 1992, Parnet et al., 
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1994) and Roe et al. (2011) demonstrated a transient LPS-induced increase in tau 
pathology in the dentate gyrus and CA3 of the hippocampus of C57BL/6 mice which 
returned to baseline by 24-hours post-injection. Given that there is evidence of tau 
pathology in the hippocampus of P301S mice as early as 2.5 months of age (Xu et al., 
2014) it might be interesting to investigate the possibility of a differential response in 
this area since it is relevant for sickness behaviours as well as disease pathology and 
thus a differential response in this area might account for the exaggerated sickness 
behaviour. 
Astrocytes can also have beneficial or detrimental roles in a pathological context 
(Zamanian et al., 2012). LPS-injection caused an acute increase in GFAP signal in the 
spinal cord of P301S mice and not C57BL/6 and a decrease in GFAP signal in P301S 
mice at end stage hence it would be interesting to first use Aldh1l1 stain to determine 
whether the increase in GFAP signal is due to upregulation or proliferation. In the 
absence of microglial priming and given the known disease-associated astrogliosis in 
the cortex of P301S mice it would be interesting to conduct further transcriptomic 
studies akin to those of Zamanian et al. (2012) to investigate the beneficial or 
detrimental role of astrocytes in the P301S mouse following LPS-injection.  
It is possible that the major change in microglia is not a pro-inflammatory switch but 
rather a loss of support functions, as has been demonstrated in alternative models 
associated with neurodegeneration (Holtman et al., 2015). LPS-induced inflammation 
impairs hippocampal neurogenesis in the sub-granular zone of rodents and is 
thought to do so via microglial activation; suppression of neuroinflammation using 
minocycline or indomethacin treatment restored this neurogenesis (Ekdahl et al., 
2003, Monje et al., 2003). This discovery was followed by the observation that LPS is 
associated with reduced production of neurotrophins – BDNF, NGF and NT-3 – in 
the frontal cortex (Guan et al., 2006) which are involved in neurogenesis during 
development but also neuroprotection during adulthood (Tandon et al., 1999, 
Yanamoto et al., 2004), and which are reduced in dementia (Phillips et al., 1991), hence 
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LPS might not only induce neuronal death directly but might also reduce 
neuroprotection.  
This study is the first of its kind to show that systemic inflammation, modelled by 
LPS has an exaggerated acute impact on motor control in a mouse model of tauopathy 
dementia and can affect the long-term trajectory of chronic decline associated with 
neurodegeneration, and importantly that these outcomes are not necessarily 
dependent on microglial status. 
6.2 Implications of these results 
The notion that systemic inflammation advances the onset of decline of 
neurodegeneration and can exacerbate disease-associated pathology might provide 
us with exciting therapeutic targets out-with the CNS, which might significantly 
delay the onset of dementia.  
There is a possibility of acute interventions in high risk populations; if it becomes 
clear in clinical research that an inflammatory insult is sufficient to exacerbate 
neurodegeneration, for example in the context of an acute infection or hip fracture, 
this provides a rationale for trials of anti-inflammatory agents used at the time of the 
insult.  
Researchers who showed that systemic inflammatory events and specifically 
increased TNF-α plasma levels predict increased rate of cognitive decline went on to 
test the effectiveness of Etanercept, an anti-TNF treatment, at preventing cognitive 
decline in a randomised, placebo-controlled clinical trial. Although the trial was too 
small to draw conclusions on efficacy, Etanercept was well tolerated and trends 
indicated cognitive benefits (Butchart et al., 2015). There are similar, promising trials 
underway to determine whether minocycline is superior to placebo in affecting the 
rate of decline in cognitive and functional outcomes, measured by standardised 
cognitive testing and Bristol Activities of Daily Living Scale over a 2-year period in 
patients with very early Alzheimer’s Disease (Howard, 2017).   
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There might be opportunities to influence the risk of dementia and rate of cognitive 
decline via important lifestyle changes. There is a known inflammatory component 
to numerous preventable medical conditions including hypertension, 
hypercholesterolaemia and obesity (Dunn et al., 2005) and there are suggestions that 
prevention and treatment of vascular and chronic conditions and attention to 
optimum health early in life might reduce the incidence of dementia and improve 
cognitive health later in life (Wu et al., 2016).  
The impact of treatments like this could be enormous. It is estimated that if we could 
delay the onset of Alzheimer’s disease by five years, then over the following 15 years 
there would be 425,000 fewer people with dementia and accumulated savings of 
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